,variant,EvidenceLevel,ClinicalSignificance,Disease,entrez_id,TherapyRegimen,Gene
0,P124S,D,Resistance,Melanoma,5604.0,Selumetinib,MAP2K1
1,Q56P,D,Resistance,Melanoma,5604.0,Selumetinib,MAP2K1
2,Q61,B,Resistance,Melanoma,4893.0,Vemurafenib,NRAS
3,D842V,B,Resistance,Gastrointestinal Stromal Tumor,5156.0,Imatinib,PDGFRA
4,D842V,B,Resistance,Gastrointestinal Stromal Tumor,5156.0,Imatinib,PDGFRA
5,S214C,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,369.0,Sorafenib,ARAF
6,R882,B,Sensitivity/Response,Acute Myeloid Leukemia,1788.0,Idarubicin,DNMT3A
7,V617F,B,Sensitivity/Response,Polycythemia Vera,3717.0,,JAK2
8,V617F,D,Sensitivity/Response,Polycythemia Vera,3717.0,Fedratinib,JAK2
9,G13D,C,Sensitivity/Response,Melanoma,4893.0,Tanespimycin,NRAS
10,Q61L,C,Sensitivity/Response,Melanoma,4893.0,Temozolomide,NRAS
11,Q61R,C,Sensitivity/Response,Melanoma,4893.0,Temozolomide,NRAS
12,F1174L,D,Resistance,Inflammatory Myofibroblastic Tumor,238.0,Crizotinib,ALK
13,F1174L,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
14,L576P,D,Resistance,Melanoma,3815.0,Nilotinib+Imatinib+Sorafenib,KIT
15,G12/G13,B,Resistance,Lung Non-small Cell Carcinoma,3845.0,Gefitinib+Erlotinib,KRAS
16,Q61,B,Resistance,Colorectal Cancer,4893.0,Cetuximab+Chemotherapy,NRAS
17,F1174L,D,Sensitivity/Response,Neuroblastoma,238.0,Alectinib,ALK
18,F1174L,D,Sensitivity/Response,Neuroblastoma,238.0,Crizotinib,ALK
19,R1275Q,D,Sensitivity/Response,Neuroblastoma,238.0,TAE684,ALK
20,S214C,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,369.0,Sorafenib,ARAF
21,S214C,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,369.0,Trametinib,ARAF
22,L576P,D,Sensitivity/Response,Melanoma,3815.0,Dasatinib,KIT
23,D842I,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,5156.0,Crenolanib,PDGFRA
24,D842V,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,5156.0,Crenolanib,PDGFRA
25,D842Y,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,5156.0,Crenolanib,PDGFRA
26,I843DEL,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,5156.0,Crenolanib,PDGFRA
27,D842_I843delinsVM,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,5156.0,Crenolanib,PDGFRA
28,R1275Q,D,Resistance,Neuroblastoma,238.0,TAE684,ALK
29,Exon 11 Mutation,B,Sensitivity/Response,Melanoma,3815.0,Imatinib,KIT
30,V600E and V600M,C,Sensitivity/Response,Melanoma,673.0,Dabrafenib,BRAF
31,C634W,D,Resistance,Thyroid Gland Medullary Carcinoma,5979.0,Motesanib,RET
32,M918T,D,Resistance,Thyroid Gland Medullary Carcinoma,5979.0,Motesanib,RET
33,M918T,D,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,5979.0,JAK2 Inhibitor AZD1480,RET
34,V600,B,Resistance,Colorectal Cancer,673.0,Panitumumab,BRAF
35,V600E,D,Sensitivity/Response,Colorectal Cancer,673.0,Panitumumab+Sorafenib,BRAF
36,V600E,D,Resistance,Melanoma,673.0,Vemurafenib,BRAF
37,V600E,C,Resistance,Lung Non-small Cell Carcinoma,673.0,Dabrafenib,BRAF
38,V600E and Amplification,E,Resistance,Colorectal Cancer,673.0,Selumetinib,BRAF
39,V600,B,Sensitivity/Response,Melanoma,673.0,Dabrafenib+Trametinib,BRAF
40,V600D,B,Sensitivity/Response,Melanoma,673.0,Dabrafenib,BRAF
41,V600E,B,Sensitivity/Response,Melanoma,673.0,Trametinib+Dabrafenib,BRAF
42,V600E,D,Sensitivity/Response,Colorectal Cancer,673.0,Pictilisib Bismesylate+PLX4720,BRAF
43,V600E,D,Sensitivity/Response,Colorectal Cancer,673.0,PLX4720+Nutlin-3,BRAF
44,V600E,D,Sensitivity/Response,Colorectal Cancer,673.0,Bevacizumab+Capecitabine+Vemurafenib,BRAF
45,V600E,D,Sensitivity/Response,Colorectal Cancer,673.0,Vemurafenib,BRAF
46,F1174L,D,Resistance,Neuroblastoma,238.0,Crizotinib,ALK
47,V600E,B,Resistance,Colorectal Cancer,673.0,Cetuximab,BRAF
48,ITD,B,Resistance,Acute Myeloid Leukemia,2322.0,Tretinoin,FLT3
49,ITD,D,Resistance,Acute Myeloid Leukemia,2322.0,Daunorubicin,FLT3
50,ITD,D,Resistance,Acute Myeloid Leukemia,2322.0,SU5614,FLT3
51,G12/G13,B,Resistance,Colorectal Cancer,3845.0,Chemotherapy+Cetuximab,KRAS
52,G12/G13,D,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
53,G12V,D,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
54,EXON 12 MUTATION,B,Resistance,Acute Myeloid Leukemia,4869.0,Tretinoin,NPM1
55,Exon 21 Mutation,B,Resistance,Colorectal Cancer,5290.0,Chemotherapy+Cetuximab,PIK3CA
56,EXON 7 MUTATION,B,Resistance,Acute Myeloid Leukemia,7490.0,Daunorubicin+Cytarabine,WT1
57,EML4-ALK L1196M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Alectinib,ALK
58,F1174L,D,Sensitivity/Response,Neuroblastoma,238.0,TAE684,ALK
59,R1275Q,D,Sensitivity/Response,Neuroblastoma,238.0,Crizotinib,ALK
60,FGFR3-BAIAP2L1,D,Sensitivity/Response,Bladder Carcinoma,2261.0,PD173074,FGFR3
61,G13D,D,Sensitivity/Response,Colorectal Cancer,3845.0,Cetuximab,KRAS
62,EXON 12 MUTATION,B,Sensitivity/Response,Acute Myeloid Leukemia,4869.0,Tretinoin,NPM1
63,EXON 12 MUTATION,B,Sensitivity/Response,Acute Myeloid Leukemia,4869.0,Daunorubicin,NPM1
64,EXON 12 MUTATION,B,Sensitivity/Response,Acute Myeloid Leukemia,4869.0,Valproic Acid,NPM1
65,EXON 12 MUTATION,D,Sensitivity/Response,Acute Myeloid Leukemia,4869.0,Tretinoin+NSC348884,NPM1
66,EXON 12 MUTATION,E,Sensitivity/Response,Acute Myeloid Leukemia,4869.0,Anti-CD33+Anti-CD123,NPM1
67,EXON 12 MUTATION,E,Sensitivity/Response,Acute Myeloid Leukemia,4869.0,Anti-CD33,NPM1
68,W288FS,D,Sensitivity/Response,Acute Myeloid Leukemia,4869.0,NSC348884,NPM1
69,W288FS,E,Sensitivity/Response,Acute Myeloid Leukemia,4869.0,Daunorubicin+Cytarabine+Etoposide,NPM1
70,FRAMESHIFT TRUNCATION,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,7248.0,Sirolimus,TSC1
71,Loss-of-function,B,Sensitivity/Response,Bladder Carcinoma,7248.0,Everolimus,TSC1
72,Loss-of-function,B,Sensitivity/Response,Ovarian Cancer,672.0,Olaparib,BRCA1
73,Loss-of-function,B,Sensitivity/Response,Ovarian Cancer,675.0,Olaparib,BRCA2
74,L858R,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib+Erlotinib,EGFR
75,BCR-ABL,D,Resistance,Acute Myeloid Leukemia,25.0,Imatinib,ABL1
76,BCR-ABL E255K,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
77,BCR-ABL T315I,B,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
78,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
79,EML4-ALK C1156Y,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
80,EML4-ALK L1196M,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
81,T790M,A,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
82,T790M,B,Resistance,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
83,T790M,B,Resistance,Lung Non-small Cell Carcinoma,1956.0,Dacomitinib,EGFR
84,L755S,D,Resistance,Breast Cancer,2064.0,Lapatinib,ERBB2
85,L536Q,D,Resistance,Breast Cancer,2099.0,Hormone Therapy,ESR1
86,D538G,D,Resistance,Breast Cancer,2099.0,Hormone Therapy,ESR1
87,Y537C,D,Resistance,Breast Cancer,2099.0,Hormone Therapy,ESR1
88,Y537N,D,Resistance,Breast Cancer,2099.0,Hormone Therapy,ESR1
89,Y537S,D,Resistance,Breast Cancer,2099.0,Hormone Therapy,ESR1
90,TKD MUTATION,B,Resistance,Acute Myeloid Leukemia,2322.0,Sorafenib,FLT3
91,TKD MUTATION,B,Resistance,Acute Myeloid Leukemia,2322.0,Sorafenib,FLT3
92,V654A,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
93,Exon 2 Mutation,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
94,G12A,B,Resistance,Lung Adenocarcinoma,3845.0,Gefitinib+Erlotinib,KRAS
95,E542K,B,Resistance,Colorectal Cancer,5290.0,Cetuximab+Panitumumab,PIK3CA
96,BCR-ABL,A,Sensitivity/Response,Acute Myeloid Leukemia,25.0,Imatinib,ABL1
97,BCR-ABL,A,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
98,BCR-ABL,A,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib+Nilotinib,ABL1
99,EML4-ALK,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
100,LOSS,D,Sensitivity/Response,T-cell Lymphoblastic Leukemia/lymphoma,896.0,Palbociclib,CCND3
101,EXPRESSION,D,Sensitivity/Response,Estrogen-receptor Positive Breast Cancer,1019.0,Alpelisib,CDK4
102,G253C,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,4921.0,Dasatinib,DDR2
103,G505S,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,4921.0,Dasatinib,DDR2
104,G774V,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,4921.0,Dasatinib,DDR2
105,I638F,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,4921.0,Dasatinib,DDR2
106,L239R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,4921.0,Dasatinib,DDR2
107,L63V,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,4921.0,Dasatinib,DDR2
108,S768R,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,4921.0,Erlotinib+Dasatinib,DDR2
109,Exon 19 Deletion,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
110,G719S,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
111,L858R,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib+Gefitinib,EGFR
112,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
113,T790M,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Pemetrexed+Erlotinib,EGFR
114,T790M,E,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Staurosporine,EGFR
115,D769H,D,Sensitivity/Response,Breast Cancer,2064.0,Lapatinib+Neratinib,ERBB2
116,D769Y,D,Sensitivity/Response,Breast Cancer,2064.0,Neratinib,ERBB2
117,L755_T759del,D,Sensitivity/Response,Breast Cancer,2064.0,Neratinib,ERBB2
118,G309A,D,Sensitivity/Response,Breast Cancer,2064.0,Neratinib,ERBB2
119,L755S,D,Sensitivity/Response,Breast Cancer,2064.0,Neratinib,ERBB2
120,L755W,D,Sensitivity/Response,Breast Cancer,2064.0,Neratinib,ERBB2
121,P780INS,D,Sensitivity/Response,Breast Cancer,2064.0,Neratinib,ERBB2
122,R678Q,D,Sensitivity/Response,Breast Cancer,2064.0,Neratinib+Lapatinib,ERBB2
123,R896C,D,Sensitivity/Response,Breast Cancer,2064.0,Neratinib,ERBB2
124,V777L,D,Sensitivity/Response,Breast Cancer,2064.0,Neratinib,ERBB2
125,V842I,D,Sensitivity/Response,Breast Cancer,2064.0,Neratinib,ERBB2
126,L536Q,D,Sensitivity/Response,Breast Cancer,2099.0,Fulvestrant+Tamoxifen,ESR1
127,D538G,D,Sensitivity/Response,Breast Cancer,2099.0,Fulvestrant+Tamoxifen,ESR1
128,Y537C,D,Sensitivity/Response,Breast Cancer,2099.0,Tamoxifen+Fulvestrant,ESR1
129,Y537N,D,Sensitivity/Response,Breast Cancer,2099.0,Tamoxifen+Fulvestrant,ESR1
130,Y537S,D,Sensitivity/Response,Breast Cancer,2099.0,Fulvestrant+Tamoxifen,ESR1
131,FGFR2-MGEA5,C,Sensitivity/Response,Cholangiocarcinoma,2263.0,Ponatinib,FGFR2
132,FGFR2-TACC3,C,Sensitivity/Response,Cholangiocarcinoma,2263.0,Ponatinib+Pazopanib,FGFR2
133,ITD,B,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Lestaurtinib,FLT3
134,ITD,B,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sorafenib,FLT3
135,ITD,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Tyrphostin AG 1296,FLT3
136,EXPRESSION,D,Sensitivity/Response,Lung Adenocarcinoma,2624.0,Fasudil+Bortezomib,GATA2
137,Internal Duplication,C,Sensitivity/Response,Malignant Anus Melanoma,3815.0,Imatinib,KIT
138,L576P,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,3815.0,Dasatinib+Imatinib+Nilotinib,KIT
139,V654A,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
140,G12D,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,3845.0,Dactolisib+Selumetinib,KRAS
141,G13D,B,Sensitivity/Response,Colorectal Cancer,3845.0,Cetuximab,KRAS
142,Promoter Methylation,A,Sensitivity/Response,Glioblastoma,4255.0,Temozolomide,MGMT
143,Promoter Methylation,B,Sensitivity/Response,Glioblastoma,4255.0,Carmustine,MGMT
144,Promoter Methylation,E,Sensitivity/Response,Glioblastoma,4255.0,O6-Benzylguanine,MGMT
145,E542K,D,Sensitivity/Response,Breast Cancer,5290.0,PI3K-alpha Inhibitor MEN1611,PIK3CA
146,E542K,D,Sensitivity/Response,Breast Cancer,5290.0,Sirolimus,PIK3CA
147,H1047R,D,Sensitivity/Response,Breast Cancer,5290.0,PI3K-alpha Inhibitor MEN1611,PIK3CA
148,PML-RARA,B,Sensitivity/Response,Acute Promyelocytic Leukemia,5371.0,Tretinoin,PML
149,R233*,D,Sensitivity/Response,Breast Cancer,5728.0,MTOR Inhibitor,PTEN
150,R175H,D,Sensitivity/Response,Breast Cancer,7157.0,Doxorubicin,TP53
151,FRAMESHIFT TRUNCATION,B,Sensitivity/Response,Invasive Bladder Transitional Cell Carcinoma,7248.0,Everolimus,TSC1
152,BCR-ABL,A,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
153,EXPRESSION,B,Sensitivity/Response,Estrogen-receptor Positive Breast Cancer,1019.0,Palbociclib,CDK4
154,E545K,C,Resistance,Colorectal Cancer,5290.0,Panitumumab+Cetuximab,PIK3CA
155,H1047R,C,Resistance,Colorectal Cancer,5290.0,Panitumumab+Cetuximab,PIK3CA
156,R249,B,Sensitivity/Response,Breast Cancer,7157.0,Doxorubicin,TP53
157,MEF2D-CSF1R,D,Sensitivity/Response,Acute Lymphoblastic Leukemia,1436.0,GW-2580+Imatinib,CSF1R
158,Mutation,B,Resistance,Acute Myeloid Leukemia,861.0,Cytarabine,RUNX1
159,Exon 19 Deletion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib+Erlotinib,EGFR
160,Overexpression,D,Sensitivity/Response,Prostate Cancer,3481.0,Docetaxel+Cabazitaxel+Linsitinib,IGF2
161,C481S,B,Resistance,Chronic Lymphocytic Leukemia,695.0,Ibrutinib,BTK
162,Q79K,D,Resistance,Melanoma,207.0,Vemurafenib,AKT1
163,EML4-ALK and Amplification,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
164,ALK Fusion G1202R,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
165,EML4-ALK L1196M,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
166,EML4-ALK S1206Y,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
167,EML4-ALK T1151INST,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
168,MUTATION,D,Sensitivity/Response,Colon Carcinoma,324.0,JW55,APC
169,MUTATION,D,Sensitivity/Response,Colorectal Cancer,324.0,G007-LK,APC
170,F877L,D,Resistance,Prostate Cancer,367.0,Apalutamide+Enzalutamide,AR
171,W742,D,Resistance,Prostate Carcinoma,367.0,Bicalutamide,AR
172,Mutation,D,Sensitivity/Response,Glioblastoma,472.0,Temozolomide,ATM
173,Mutation,D,Sensitivity/Response,Melanoma,472.0,Temozolomide,ATM
174,Underexpression,D,Sensitivity/Response,Cancer,472.0,NU7441+KU-0060648,ATM
175,Mutation,D,Sensitivity/Response,Hematologic Cancer,472.0,Olaparib,ATM
176,AMPLIFICATION,E,Sensitivity/Response,Esophagus Adenocarcinoma,6790.0,Alisertib+Cisplatin,AURKA
177,Overexpression,D,Resistance,Cervical Adenocarcinoma,6790.0,Paclitaxel,AURKA
178,V560DEL,C,Sensitivity/Response,Thymic Carcinoma,3815.0,Imatinib,KIT
179,Loss,B,Resistance,Colorectal Cancer,5728.0,Cetuximab,PTEN
180,Loss,D,Sensitivity/Response,Prostate Cancer,5728.0,Temsirolimus,PTEN
181,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Trastuzumab,ERBB2
182,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Trastuzumab,ERBB2
183,G12/G13,B,Resistance,Pancreatic Adenocarcinoma,3845.0,Trametinib+Gemcitabine,KRAS
184,LOSS-OF-FUNCTION,D,Sensitivity/Response,Ovarian Serous Carcinoma,51755.0,Olaparib,CDK12
185,R367Q,D,Resistance,T-cell Acute Lymphoblastic Leukemia,22978.0,Mercaptopurine+Thioguanine,NT5C2
186,K359Q,D,Resistance,T-cell Acute Lymphoblastic Leukemia,22978.0,Mercaptopurine+Thioguanine,NT5C2
187,D407A,D,Resistance,T-cell Acute Lymphoblastic Leukemia,22978.0,Mercaptopurine+Thioguanine,NT5C2
188,BCR-ABL F317L,B,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
189,BCR-ABL F317L,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Ponatinib,ABL1
190,BCR-ABL F317L,B,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Ponatinib,ABL1
191,T790M,D,Resistance,Lung Cancer,1956.0,Gefitinib+Multikinase Inhibitor AEE788,EGFR
192,Loss,B,Resistance,Bladder Carcinoma,5728.0,Everolimus,PTEN
193,Loss,B,Resistance,Breast Cancer,5728.0,Trastuzumab,PTEN
194,T790M,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Rociletinib,EGFR
195,S2289*,C,Sensitivity/Response,Prostate Cancer,472.0,Olaparib,ATM
196,N2875H,C,Sensitivity/Response,Prostate Cancer,472.0,Olaparib,ATM
197,Y177fs,C,Resistance,Peritoneal Mesothelioma,4771.0,Carboplatin+Cisplatin,NF2
198,Loss-of-function,B,Sensitivity/Response,Prostate Cancer,675.0,Olaparib,BRCA2
199,D842V,D,Resistance,Gastrointestinal Stromal Tumor,5156.0,Imatinib,PDGFRA
200,V561A,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,5156.0,Imatinib,PDGFRA
201,Exon 11 Mutation,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
202,R194W,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,7515.0,Gemcitabine+Vinorelbine+Docetaxel,XRCC1
203,DELETION,D,Sensitivity/Response,Ovarian Carcinoma,2950.0,Carboplatin+Cisplatin+Paclitaxel,
204,AMPLIFICATION,D,Resistance,Colon Cancer,79444.0,Cisplatin,
205,Exon 4 Deletion,D,Resistance,Epithelial Ovarian Cancer,1956.0,Cisplatin,EGFR
206,3' UTR MUTATION,B,Resistance,Ovarian Cancer,1956.0,Paclitaxel+Carboplatin,EGFR
207,RS61764370,B,Resistance,Epithelial Ovarian Cancer,3845.0,Paclitaxel+Carboplatin,KRAS
208,A222V,B,Sensitivity/Response,Stomach Cancer,4524.0,Fluorouracil,
209,I105V,B,Sensitivity/Response,Colorectal Cancer,2950.0,FOLFOX Regimen,
210,Q399R,B,Sensitivity/Response,Cervical Cancer,7515.0,Cisplatin+Carboplatin,XRCC1
211,S893T,B,Sensitivity/Response,Ovarian Cancer,5243.0,Paclitaxel,
212,I1145I,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,5243.0,Carboplatin+Cisplatin,
213,K751Q,B,Resistance,Osteosarcoma,2068.0,Cisplatin,ERCC2
214,K751Q,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,2068.0,Paclitaxel+Carboplatin,ERCC2
215,5' TANDEM REPEAT,B,Resistance,Colorectal Cancer,7298.0,Irinotecan+Fluorouracil,TYMS
216,EXON 12-22 DELETION,D,Resistance,Ovarian Cancer,53353.0,Doxorubicin,LRP1B
217,Amplification,D,Sensitivity/Response,Lung Squamous Cell Carcinoma,2260.0,PD173074,FGFR1
218,Expression,D,Sensitivity/Response,Lung Cancer,2260.0,Ponatinib,FGFR1
219,Amplification,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,2260.0,PD173074,FGFR1
220,REARRANGEMENT,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,6098.0,Crizotinib,ROS1
221,Amplification,C,Sensitivity/Response,Gastric Adenocarcinoma,4233.0,Onartuzumab,MET
222,Overexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,EGFR
223,p16 Expression,B,Resistance,Head And Neck Squamous Cell Carcinoma,1029.0,Panitumumab,CDKN2A
224,KIF5B-RET,C,Sensitivity/Response,Lung Adenocarcinoma,5979.0,Vandetanib,RET
225,G13D,C,Resistance,Colorectal Cancer,3265.0,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,HRAS
226,MUTATION,D,Sensitivity/Response,Cancer,3265.0,MTOR Kinase Inhibitor AZD8055+Everolimus+Mirdametinib+Binimetinib+Selumetinib,HRAS
227,Expression,B,Sensitivity/Response,Melanoma,29126.0,Nivolumab+Pembrolizumab,CD274
228,MUTATION,C,Sensitivity/Response,Bladder Carcinoma,2475.0,Everolimus+Pazopanib,MTOR
229,EXPRESSION,B,Sensitivity/Response,Breast Cancer,208.0,Trastuzumab,AKT2
230,E17K,D,Sensitivity/Response,Melanoma,207.0,Uprosertib,AKT1
231,Loss,D,Sensitivity/Response,Melanoma,5728.0,Uprosertib,PTEN
232,E17K,C,Sensitivity/Response,Breast Cancer,207.0,Capivasertib,AKT1
233,E545K,D,Sensitivity/Response,Breast Cancer,5290.0,Pictilisib+Akt Inhibitor MK2206,PIK3CA
234,Loss,D,Sensitivity/Response,Breast Cancer,5728.0,PI3Kbeta Inhibitor AZD8186,PTEN
235,H1968Y,D,Sensitivity/Response,Melanoma,2475.0,Capivasertib+PI3K/BET Inhibitor LY294002,MTOR
236,Loss,B,Sensitivity/Response,Cancer,5728.0,Buparlisib+Carboplatin+Paclitaxel,PTEN
237,K159fs,C,Sensitivity/Response,Breast Cancer,4771.0,Temsirolimus,NF2
238,Loss,D,Resistance,Breast Cancer,5728.0,Alpelisib,PTEN
239,S492R,C,Resistance,Colorectal Cancer,1956.0,Cetuximab,EGFR
240,MUTATION,B,Resistance,Colorectal Cancer,55294.0,Cetuximab+Panitumumab,FBXW7
241,MUTATION,B,Resistance,Colorectal Cancer,4089.0,Panitumumab+Cetuximab,SMAD4
242,UNDEREXPRESSION,D,Resistance,Head And Neck Squamous Cell Carcinoma,4089.0,Cetuximab,SMAD4
243,H1968Y,D,Sensitivity/Response,Melanoma,2475.0,Capivasertib,MTOR
244,P2213S,D,Sensitivity/Response,Melanoma,2475.0,Capivasertib+PI3K/BET Inhibitor LY294002,MTOR
245,AGK-BRAF,C,Sensitivity/Response,Melanoma,673.0,Sorafenib,BRAF
246,AGK-BRAF,D,Resistance,Melanoma,673.0,Vemurafenib,BRAF
247,PAPSS1-BRAF,D,Resistance,Melanoma,673.0,Vemurafenib,BRAF
248,PAPSS1-BRAF,D,Sensitivity/Response,Melanoma,673.0,Trametinib,BRAF
249,TRIM24-BRAF,D,Sensitivity/Response,Melanoma,673.0,Trametinib,BRAF
250,L597R,C,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
251,Overexpression,B,Resistance,Colorectal Cancer,2065.0,Cetuximab,ERBB3
252,OVEREXPRESSION,B,Sensitivity/Response,Colorectal Cancer,4907.0,Cetuximab,
253,R132C,D,Sensitivity/Response,Acute Myeloid Leukemia,3417.0,GSK321,IDH1
254,Amplification,D,Resistance,Lung Non-small Cell Carcinoma,4233.0,Gefitinib,MET
255,OVEREXPRESSION,D,Resistance,Breast Cancer,4615.0,Paclitaxel,MYD88
256,Amplification,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,4233.0,Crizotinib,MET
257,EXON 14 SKIPPING MUTATION,D,Sensitivity/Response,Cancer,4233.0,Crizotinib,MET
258,Overexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,EGFR
259,D842V,B,Resistance,Gastrointestinal Stromal Tumor,5156.0,Imatinib,PDGFRA
260,P471L,C,Sensitivity/Response,Merkel Cell Carcinoma,5290.0,Idelalisib,PIK3CA
261,Overexpression,D,Sensitivity/Response,Breast Cancer,5979.0,Vandetanib,RET
262,MUTATION,D,Sensitivity/Response,Lung Adenocarcinoma,6016.0,Pictilisib+Selumetinib,RIT1
263,Expression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,29126.0,Nivolumab+Pembrolizumab,CD274
264,Amplification,D,Sensitivity/Response,Neuroblastoma,4613.0,FACT Complex-targeting Curaxin CBL0137,MYCN
265,D473H,C,Resistance,Medulloblastoma,6608.0,Vismodegib,SMO
266,Mutation,B,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
267,Mutation,D,Sensitivity/Response,Basal Cell Carcinoma,6608.0,PSI+Arsenic Trioxide,SMO
268,MUTATION,B,Sensitivity/Response,Medulloblastoma,5727.0,Sonidegib,PTCH1
269,LOH,B,Sensitivity/Response,Medulloblastoma,5727.0,Vismodegib,PTCH1
270,UNDEREXPRESSION,D,Sensitivity/Response,Prostate Cancer,6794.0,SB202190,STK11
271,OVEREXPRESSION,D,Resistance,Ovarian Cancer,6850.0,Paclitaxel,SYK
272,p16 Expression,B,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,1029.0,Panitumumab,CDKN2A
273,D473H,D,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
274,Amplification,C,Sensitivity/Response,Epithelial Ovarian Cancer,5290.0,Pictilisib,PIK3CA
275,V600E,C,Sensitivity/Response,Melanoma,673.0,Pictilisib,BRAF
276,Amplification,D,Sensitivity/Response,Breast Cancer,2064.0,AKTi-1/2,ERBB2
277,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Neratinib,ERBB2
278,T790M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Rociletinib,EGFR
279,EML4-ALK L1152R,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
280,EML4-ALK G1269A,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
281,EML4-ALK G1269A,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
282,EML4-ALK and Amplification,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
283,EML4-ALK and Amplification,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
284,AUTOCRINE ACTIVATION,D,Resistance,Lung Non-small Cell Carcinoma,1956.0,Crizotinib,EGFR
285,AUTOCRINE ACTIVATION,B,Resistance,Lung Non-small Cell Carcinoma,1956.0,Crizotinib,EGFR
286,MUTATION,D,Sensitivity/Response,Melanoma,2066.0,Lapatinib,ERBB4
287,Mutation,D,Sensitivity/Response,Colorectal Cancer,5290.0,Cabozantinib,PIK3CA
288,VIII,B,Sensitivity/Response,Glioblastoma,1956.0,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,EGFR
289,VIII,C,Sensitivity/Response,Glioblastoma,1956.0,Afatinib,EGFR
290,Expression,B,Sensitivity/Response,Glioblastoma,5728.0,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,PTEN
291,Expression,D,Sensitivity/Response,Glioblastoma,5728.0,Dacomitinib,PTEN
292,Expression,D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,3084.0,Lapatinib,NRG1
293,Expression,D,Resistance,Colorectal Cancer,3084.0,Cetuximab,NRG1
294,Expression,D,Sensitivity/Response,Ovarian Cancer,3084.0,Seribantumab,NRG1
295,Expression,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,3084.0,Gemcitabine+Paclitaxel+Cisplatin+Carboplatin,NRG1
296,Expression,D,Resistance,Lung Non-small Cell Carcinoma,374.0,Crizotinib,
297,Expression,B,Resistance,Lung Non-small Cell Carcinoma,374.0,Crizotinib,
298,G724S,D,Sensitivity/Response,Colorectal Cancer,1956.0,Cetuximab,EGFR
299,G719S,D,Sensitivity/Response,Colorectal Cancer,1956.0,Cetuximab,EGFR
300,Expression,B,Sensitivity/Response,Colorectal Cancer,374.0,Cetuximab,
301,EXPRESSION,B,Sensitivity/Response,Colorectal Cancer,2069.0,Cetuximab,
302,EXPRESSION,B,Sensitivity/Response,Colorectal Cancer,1943.0,,
303,E322K,C,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,5594.0,Erlotinib,MAPK1
304,AMPLIFICATION,D,Resistance,Lung Non-small Cell Carcinoma,5594.0,WZ4002,MAPK1
305,A146V,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,3845.0,Abemaciclib,KRAS
306,G12V,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,3845.0,Palbociclib,KRAS
307,Mutation,B,Sensitivity/Response,Papillary Renal Cell Carcinoma,4233.0,Foretinib,MET
308,EXON 14 SKIPPING MUTATION,C,Sensitivity/Response,Lung Adenocarcinoma,4233.0,Crizotinib,MET
309,Expression,D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,2260.0,Infigratinib,FGFR1
310,Expression,D,Sensitivity/Response,Gastric Adenocarcinoma,2260.0,Infigratinib,FGFR1
311,Expression,D,Sensitivity/Response,Bladder Carcinoma,2260.0,PD173074+Dovitinib,FGFR1
312,Expression,D,Sensitivity/Response,Bladder Carcinoma,2260.0,,FGFR1
313,Overexpression,D,Sensitivity/Response,Bladder Carcinoma,2261.0,Tyrosine Kinase Inhibitor SU5402+PD173074+Dovitinib,FGFR3
314,EXPRESSION,D,Resistance,Cancer,23624.0,Olaparib,CBLC
315,MUTATION,D,Sensitivity/Response,Head And Neck Carcinoma,5789.0,JSI-124,PTPRD
316,EXPRESSION,B,Sensitivity/Response,Prostate Cancer,1667.0,Docetaxel,
317,AMPLIFICATION,D,Sensitivity/Response,Colorectal Cancer,4851.0,NOTCH1 Antibody (PF-06293622),NOTCH1
318,Expression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,3084.0,Patritumab,NRG1
319,RS3910384,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,7465.0,Platinum Compound+Gemcitabine,WEE1
320,RS11623866,B,Resistance,Ovarian Cancer,2342.0,Lonafarnib,
321,PROMOTER HYPERMETHYLATION,D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,11122.0,Stattic+JSI-124,PTPRT
322,Decreased Peri-therapeutic Expression,B,Sensitivity/Response,Colorectal Cancer,7422.0,Fluorouracil+Irinotecan+Levoleucovorin+Bevacizumab,VEGFA
323,EXPRESSION,D,Sensitivity/Response,Ovarian Cancer,1786.0,Decitabine,DNMT1
324,Mutation,D,Sensitivity/Response,Ovarian Cancer,3845.0,Decitabine,KRAS
325,EXPRESSION,B,Sensitivity/Response,Lung Cancer,27250.0,Paclitaxel,
326,RS16906252,B,Sensitivity/Response,Glioblastoma,4255.0,Temozolomide,MGMT
327,EXPRESSION,B,Sensitivity/Response,Breast Cancer,7033.0,Aminoglutethimide+Tamoxifen,
328,NUCLEAR EXPRESSION,B,Resistance,Colorectal Cancer,22943.0,Oxaliplatin+Fluorouracil+Irinotecan+Levoleucovorin,DKK1.00
329,CD44s Expression,D,Sensitivity/Response,Cancer,960.0,RG7356,
330,EXPRESSION,D,Resistance,Head And Neck Squamous Cell Carcinoma,1950.0,Cetuximab,
331,EXPRESSION,B,Resistance,Malignant Pleural Mesothelioma,4193.0,Pemetrexed+Cisplatin,MDM2
332,EXPRESSION,B,Resistance,Renal Cell Carcinoma,3162.0,Sunitinib+Sorafenib,
333,Overexpression,D,Sensitivity/Response,Ewing Sarcoma Of Bone,841.0,Conatumumab,CASP8
334,Overexpression,B,Resistance,Lung Non-small Cell Carcinoma,7298.0,Pemetrexed,TYMS
335,OVEREXPRESSION,D,Resistance,Lung Non-small Cell Carcinoma,55872.0,Gefitinib,
336,Amplification,C,Sensitivity/Response,Lung Adenocarcinoma,4233.0,Crizotinib,MET
337,UNDEREXPRESSION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,6597.0,Vinorelbine+Cisplatin,SMARCA4
338,EML4-ALK C1156Y,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib+Ceritinib+Luminespib,ALK
339,EML4-ALK C1156Y,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Lorlatinib,ALK
340,EML4::ALK C1156Y-L1198F,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Lorlatinib,ALK
341,EML4::ALK C1156Y-L1198F,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
342,Loss-of-function,C,Sensitivity/Response,Prostate Cancer,672.0,Olaparib,BRCA1
343,Expression,B,Resistance,Head And Neck Squamous Cell Carcinoma,374.0,Cetuximab+Docetaxel,
344,Expression,B,Resistance,Head And Neck Squamous Cell Carcinoma,374.0,,
345,VIII,B,Resistance,Head And Neck Squamous Cell Carcinoma,1956.0,Docetaxel+Cetuximab,EGFR
346,Mutation,B,Sensitivity/Response,Gastric Adenocarcinoma,7157.0,Chemotherapy,TP53
347,Mutation,D,Sensitivity/Response,Breast Cancer,7157.0,Doxorubicin,TP53
348,EXPRESSION,B,Resistance,Colorectal Cancer,1026.0,Fluorouracil,CDKN1A
349,EXPRESSION,B,Resistance,Colorectal Cancer,214.0,Fluorouracil,
350,Amplification,B,Sensitivity/Response,Colorectal Cancer,1956.0,Cetuximab+Panitumumab,EGFR
351,EXPRESSION,B,Resistance,Endometrial Carcinoma,3925.0,Paclitaxel,
352,Overexpression,B,Resistance,Estrogen-receptor Positive Breast Cancer,595.0,Tamoxifen,CCND1
353,AMPLIFICATION,B,Resistance,Breast Cancer,51773.0,Tamoxifen,
354,OVEREXPRESSION,D,Sensitivity/Response,Breast Cancer,367.0,Dactolisib,AR
355,CYTOPLASMIC MISLOCALIZATION,D,Resistance,Breast Cancer,1027.0,Lapatinib,CDKN1B
356,Expression,D,Sensitivity/Response,Cancer,3084.0,Anti-ErbB3 Monoclonal Antibody AV-203,NRG1
357,V7 EXPRESSION,B,Resistance,Prostate Cancer,367.0,Enzalutamide+Abiraterone,AR
358,Loss,B,Resistance,Gastric Adenocarcinoma,5728.0,Trastuzumab+Lapatinib,PTEN
359,EXPRESSION,D,Sensitivity/Response,Pancreatic Ductal Adenocarcinoma,2065.0,9F7-F11+Pertuzumab,ERBB3
360,EXPRESSION,D,Resistance,Colorectal Cancer,7361.0,Ganetespib,
361,NUCLEAR TRANSLOCATION,D,Resistance,Breast Cancer,2066.0,Trastuzumab,ERBB4
362,EXPRESSION,D,Resistance,Breast Cancer,2066.0,Trastuzumab,ERBB4
363,EXPRESSION,D,Resistance,Breast Cancer,2066.0,Lapatinib,ERBB4
364,EXPRESSION,D,Sensitivity/Response,Colorectal Cancer,91607.0,7-Ethyl-10-Hydroxycamptothecin,SLFN11
365,Overexpression,B,Resistance,Lung Non-small Cell Carcinoma,6790.0,Cisplatin,AURKA
366,RS61764370,B,Resistance,Head And Neck Squamous Cell Carcinoma,3845.0,Cisplatin,KRAS
367,P29S,D,Resistance,Melanoma,5879.0,Dabrafenib+Vemurafenib,RAC1
368,NUCLEAR EXPRESSION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,332.0,Taxane Compound+Platinum Compound,
369,Wildtype,B,Sensitivity/Response,Colorectal Cancer,7157.0,Cetuximab+Oxaliplatin+Capecitabine,TP53
370,LOSS,D,Sensitivity/Response,Endometrial Cancer,4361.0,Talazoparib,MRE11
371,LOSS,C,Sensitivity/Response,Prostate Cancer,4361.0,,MRE11
372,Underexpression,D,Sensitivity/Response,Gastric Adenocarcinoma,472.0,Olaparib,ATM
373,L858R,B,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Afatinib,EGFR
374,Exon 19 Deletion,B,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Afatinib,EGFR
375,Exon 19 Deletion,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
376,Exon 19 Deletion,B,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Afatinib,EGFR
377,L858R,B,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Afatinib,EGFR
378,Exon 19 Deletion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
379,L858R,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
380,Amplification,D,Sensitivity/Response,Uterine Corpus Endometrial Carcinoma,2064.0,Afatinib,ERBB2
381,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Lapatinib+Trastuzumab+Afatinib,ERBB2
382,AMPLIFICATION,B,Sensitivity/Response,Colorectal Cancer,7150.0,Irinotecan,TOP1.00
383,EXPRESSION,B,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,1027.0,Fluorouracil+Cisplatin,CDKN1B
384,Amplification,C,Sensitivity/Response,Lung Squamous Cell Carcinoma,4233.0,Crizotinib,MET
385,EXPRESSION,B,Resistance,Breast Cancer,10551.0,Tamoxifen,
386,Expression,D,Sensitivity/Response,Colorectal Cancer,2260.0,Infigratinib,FGFR1
387,PROMOTER HYPERMETHYLATION,D,Sensitivity/Response,Cancer,93100.0,GNE-617,
388,Exon 18 Overexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Bevacizumab+Erlotinib,EGFR
389,Expression,D,Resistance,Mantle Cell Lymphoma,6935.0,Doxorubicin+Cytarabine+Gemcitabine,ZEB1
390,Expression,D,Sensitivity/Response,Mantle Cell Lymphoma,6935.0,Salinomycin+Doxorubicin,ZEB1
391,OVEREXPRESSION,D,Resistance,Breast Cancer,7076.0,Fulvestrant,
392,OVEREXPRESSION,D,Sensitivity/Response,Colorectal Cancer,11156.0,Cetuximab,
393,Amplification,B,Resistance,Lung Adenocarcinoma,7298.0,Pemetrexed,TYMS
394,EXPRESSION,D,Resistance,Lung Non-small Cell Carcinoma,3480.0,Gefitinib,IGF1R
395,EXPRESSION,B,Resistance,Colorectal Cancer,2050.0,Bevacizumab,EPHB4
396,Wildtype,B,Sensitivity/Response,Esophageal Carcinoma,7157.0,Chemotherapy,TP53
397,Underexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,7298.0,Pemetrexed,TYMS
398,Underexpression,C,Sensitivity/Response,Prostate Cancer,7298.0,Pemetrexed,TYMS
399,EXPRESSION,B,Sensitivity/Response,Breast Cancer,7153.0,Doxorubicin,
400,EXPRESSION,B,Sensitivity/Response,Ovarian Cancer,7150.0,Carboplatin+Cyclophosphamide+Topotecan,TOP1.00
401,Amplification,B,Sensitivity/Response,Colorectal Cancer,1956.0,Cetuximab,EGFR
402,EXPRESSION,B,Sensitivity/Response,Colorectal Cancer,7150.0,Irinotecan,TOP1.00
403,T172 PHOSPHORYLATION,E,Sensitivity/Response,Cancer,5563.0,ACLY SiRNA,
404,EXPRESSION,B,Sensitivity/Response,Colorectal Cancer,3309.0,Fluorouracil,
405,Mutation,B,Resistance,Colorectal Cancer,5290.0,Anti-EGFR Monoclonal Antibody,PIK3CA
406,PHOSPHORYLATION,D,Sensitivity/Response,Gastric Adenocarcinoma,1978.0,Everolimus,
407,MUTATION,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib+Pictilisib,KIT
408,EXPRESSION,D,Resistance,Cancer,10381.0,Paclitaxel,
409,EXPRESSION,B,Sensitivity/Response,Breast Cancer,10381.0,Taxane Compound,
410,Overexpression,B,Resistance,Lung Non-small Cell Carcinoma,7298.0,Pemetrexed,TYMS
411,Y1092 PHOSPHORYLATION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib+Erlotinib,EGFR
412,NUCLEAR EXPRESSION,B,Sensitivity/Response,Sarcoma,3480.0,IGF1R Monoclonal Antibody,IGF1R
413,EXPRESSION,D,Resistance,Prostate Cancer,8837.0,Bicalutamide,
414,EXPRESSION,B,Resistance,Hepatocellular Carcinoma,8842.0,Sorafenib,
415,OVEREXPRESSION,B,Resistance,Breast Cancer,7076.0,Paclitaxel,
416,EXPRESSION,B,Sensitivity/Response,Breast Cancer,50943.0,Epirubicin,
417,Overexpression,B,Resistance,Gastric Adenocarcinoma,7298.0,Raltitrexed,TYMS
418,PHOSPHORYLATION,D,Sensitivity/Response,Gastric Adenocarcinoma,6194.0,Everolimus,
419,OVEREXPRESSION,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,3716.0,Enzastaurin,JAK1
420,PHOSPHORYLATION,D,Resistance,Colorectal Cancer,1978.0,MTOR Kinase Inhibitor PP242+Dactolisib+WYE354,
421,Expression,D,Sensitivity/Response,Malignant Mesothelioma,672.0,Vinorelbine,BRCA1
422,EXPRESSION,D,Sensitivity/Response,Cancer,1848.0,Trametinib,
423,Mutation,D,Sensitivity/Response,Cancer,3845.0,Trametinib,KRAS
424,Mutation,D,Sensitivity/Response,Cancer,673.0,Trametinib,BRAF
425,G12D,C,Sensitivity/Response,Pancreatic Carcinoma,3845.0,Akt Inhibitor MK2206,KRAS
426,Loss,C,Sensitivity/Response,Pancreatic Carcinoma,5728.0,Akt Inhibitor MK2206,PTEN
427,EXPRESSION,D,Sensitivity/Response,Pancreatic Ductal Adenocarcinoma,3315.0,Gemcitabine,
428,EXPRESSION,D,Resistance,Lung Cancer,1728.0,Amrubicin,
429,P187S,D,Sensitivity/Response,Lung Cancer,1728.0,Amrubicin,
430,Underexpression,B,Sensitivity/Response,Ovarian Cancer,672.0,Platinum Compound+Taxane Compound,BRCA1
431,Mutation,D,Sensitivity/Response,Colorectal Cancer,3845.0,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor+Immunomodulatory Oligonucleotide,KRAS
432,Overexpression,D,Resistance,Lung Non-small Cell Carcinoma,5243.0,Paclitaxel,
433,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Pemetrexed,ALK
434,EXPRESSION,B,Resistance,Gastric Adenocarcinoma,1786.0,Cisplatin,DNMT1
435,Mutation,D,Sensitivity/Response,Colorectal Cancer,3845.0,Dasatinib+Cetuximab,KRAS
436,Amplification,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,EGFR
437,EXPRESSION,B,Resistance,Gastric Adenocarcinoma,7852.0,Docetaxel,CXCR4
438,EXPRESSION,D,Resistance,Bile Duct Adenocarcinoma,28986.0,Gemcitabine,
439,AMPLIFICATION,D,Resistance,Breast Cancer,8714.0,Paclitaxel+Monomethyl Auristatin E,
440,Overexpression,D,Resistance,Lung Non-small Cell Carcinoma,89845.0,Paclitaxel,
441,AMPLIFICATION,D,Resistance,Ovarian Cancer,440.0,Asparaginase,
442,Overexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
443,Expression,B,Sensitivity/Response,Breast Cancer,5728.0,Trastuzumab,PTEN
444,EXPRESSION,D,Resistance,Colon Cancer,5460.0,Oxaliplatin,POU5F1
445,Kinase Domain Mutation,C,Sensitivity/Response,Lung Adenocarcinoma,2064.0,Afatinib,ERBB2
446,Y772_A775DUP,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,2064.0,Afatinib+Sirolimus,ERBB2
447,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Afatinib,ERBB2
448,Amplification,D,Sensitivity/Response,Pancreatic Adenocarcinoma,2064.0,Afatinib,ERBB2
449,T790M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Osimertinib,EGFR
450,C797S,B,Resistance,Lung Non-small Cell Carcinoma,1956.0,Osimertinib,EGFR
451,T790M,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Osimertinib,EGFR
452,T790M,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Osimertinib,EGFR
453,T790M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Rociletinib+Osimertinib,EGFR
454,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
455,Exon 19 Deletion,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
456,VIII,B,Sensitivity/Response,Glioblastoma,1956.0,Rindopepimut,EGFR
457,SERUM LEVELS,B,Sensitivity/Response,Breast Cancer,2064.0,Lapatinib,ERBB2
458,Fusion,D,Sensitivity/Response,Colorectal Cancer,4914.0,Larotrectinib,NTRK1
459,R132H,D,Sensitivity/Response,Oligodendroglioma,3417.0,AGI-5198,IDH1
460,Exon 19 Deletion,B,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Afatinib,EGFR
461,L858R,B,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Afatinib,EGFR
462,Exon 19 Deletion,B,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Afatinib,EGFR
463,EXPRESSION,B,Sensitivity/Response,Skin Melanoma,3122.0,Nivolumab+Pembrolizumab+Atezolizumab,
464,L265P,B,Sensitivity/Response,Waldenstroem's Macroglobulinemia,4615.0,Ibrutinib,MYD88
465,Mutation,D,Sensitivity/Response,Colorectal Cancer,3845.0,B-Raf/VEGFR-2 Inhibitor RAF265+Selumetinib,KRAS
466,Mutation,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,3845.0,B-Raf/VEGFR-2 Inhibitor RAF265+Selumetinib,KRAS
467,Mutation,D,Sensitivity/Response,Colorectal Cancer,3845.0,Trametinib+Afatinib,KRAS
468,Mutation,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,3845.0,Trametinib+Afatinib,KRAS
469,Exon 2 Mutation,A,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
470,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,3845.0,Selumetinib+Docetaxel,KRAS
471,V600,C,Resistance,Melanoma,673.0,Refametinib,BRAF
472,Q61K,D,Sensitivity/Response,Neuroblastoma,4893.0,Everolimus+Binimetinib,NRAS
473,Mutation,D,Sensitivity/Response,Pancreatic Adenocarcinoma,3845.0,PI3Kbeta Inhibitor AZD8186+SCH772984,KRAS
474,Mutation,D,Sensitivity/Response,Colorectal Cancer,3845.0,Selumetinib+Teprotumumab,KRAS
475,V600E,D,Sensitivity/Response,Melanoma,673.0,Dactolisib+Selumetinib,BRAF
476,Amplification,D,Sensitivity/Response,Breast Cancer,2064.0,Lapatinib+Trastuzumab,ERBB2
477,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Trastuzumab+Lapatinib,ERBB2
478,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Lapatinib+Trastuzumab,ERBB2
479,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Afatinib,ERBB2
480,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Afatinib,ERBB2
481,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Afatinib+Trastuzumab,ERBB2
482,FRAMESHIFT MUTATION,B,Sensitivity/Response,Prostate Cancer,4361.0,Olaparib,MRE11
483,VIII,D,Sensitivity/Response,Brain Glioma,1956.0,Nimotuzumab,EGFR
484,Fusion,D,Sensitivity/Response,Lung Adenocarcinoma,4914.0,Lestaurtinib+Crizotinib+Larotrectinib,NTRK1
485,Expression,B,Sensitivity/Response,Colorectal Cancer,374.0,Panitumumab,
486,EXPRESSION,B,Sensitivity/Response,Colorectal Cancer,2069.0,Panitumumab,
487,Amplification,B,Sensitivity/Response,Gastric Adenocarcinoma,2064.0,Trastuzumab,ERBB2
488,Amplification,B,Sensitivity/Response,Gastric Adenocarcinoma,2064.0,Lapatinib,ERBB2
489,EXPRESSION,C,Sensitivity/Response,Endometrial Cancer,3815.0,Imatinib,KIT
490,EXPRESSION,C,Sensitivity/Response,Endometrial Cancer,3815.0,Imatinib,KIT
491,REARRANGEMENT,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,6098.0,Crizotinib,ROS1
492,LOSS,D,Sensitivity/Response,Renal Carcinoma,7428.0,Temsirolimus,VHL
493,D835,D,Resistance,Acute Myeloid Leukemia,2322.0,Ponatinib+Quizartinib,FLT3
494,D835,D,Resistance,Acute Myeloid Leukemia,2322.0,SU5614,FLT3
495,D835,B,Resistance,Acute Myeloid Leukemia,2322.0,Quizartinib+Sorafenib,FLT3
496,D835,B,Resistance,Acute Myeloid Leukemia,2322.0,Sorafenib,FLT3
497,ITD,B,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sorafenib,FLT3
498,Kinase Domain Mutation,C,Sensitivity/Response,Lung Adenocarcinoma,2064.0,Trastuzumab,ERBB2
499,Amplification,C,Sensitivity/Response,Lung Small Cell Carcinoma,2064.0,Trastuzumab+Irinotecan,ERBB2
500,Y772_A775DUP,C,Sensitivity/Response,Lung Adenocarcinoma,2064.0,Afatinib,ERBB2
501,Y772_A775DUP,D,Sensitivity/Response,Lung Carcinoma,2064.0,Afatinib+Sirolimus,ERBB2
502,Y772_A775DUP,D,Sensitivity/Response,Lung Carcinoma,2064.0,Afatinib,ERBB2
503,P780INS,C,Sensitivity/Response,Lung Adenocarcinoma,2064.0,Dacomitinib,ERBB2
504,Amplification,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,2064.0,Trastuzumab Emtansine,ERBB2
505,Mutation,D,Sensitivity/Response,Colorectal Cancer,1956.0,Futuximab/Modotuximab Mixture,EGFR
506,G465R,C,Sensitivity/Response,Colorectal Cancer,1956.0,Futuximab/Modotuximab Mixture,EGFR
507,G465R,C,Resistance,Colorectal Cancer,1956.0,Cetuximab+Panitumumab,EGFR
508,RS461155,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,2114.0,Paclitaxel+Cisplatin,
509,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Pertuzumab+Docetaxel+Trastuzumab,ERBB2
510,S492R,C,Sensitivity/Response,Colorectal Cancer,1956.0,Panitumumab,EGFR
511,S492R,D,Sensitivity/Response,Colorectal Cancer,1956.0,Futuximab/Modotuximab Mixture+Panitumumab,EGFR
512,S492R,D,Resistance,Colorectal Cancer,1956.0,Cetuximab,EGFR
513,R451C,D,Sensitivity/Response,Colorectal Cancer,1956.0,Panitumumab+Cetuximab+Futuximab/Modotuximab Mixture,EGFR
514,K467T,D,Sensitivity/Response,Colorectal Cancer,1956.0,Panitumumab+Futuximab/Modotuximab Mixture,EGFR
515,K467T,D,Resistance,Colorectal Cancer,1956.0,Cetuximab,EGFR
516,P753S,C,Sensitivity/Response,Skin Squamous Cell Carcinoma,1956.0,Sirolimus+Cetuximab,EGFR
517,PML-RARA,A,Sensitivity/Response,Acute Promyelocytic Leukemia,5371.0,Arsenic Trioxide+Tretinoin,PML
518,B2 DOMAIN MUTATION,B,Resistance,Acute Promyelocytic Leukemia,5371.0,Tretinoin,PML
519,PML-RARA A216V,C,Resistance,Acute Promyelocytic Leukemia,5371.0,Tretinoin,PML
520,PML-RARA L218P,C,Resistance,Acute Promyelocytic Leukemia,5371.0,Tretinoin,PML
521,EXON 14 MUTATION and AMPLIFICATION,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,4233.0,Crizotinib,MET
522,Amplification,C,Sensitivity/Response,Endometrial Serous Adenocarcinoma,2064.0,Trastuzumab,ERBB2
523,D473H,D,Sensitivity/Response,Medulloblastoma,6608.0,Patidegib,SMO
524,CD74-ROS1 G2032R,C,Resistance,Lung Adenocarcinoma,6098.0,Crizotinib,ROS1
525,CD74-ROS1 G2032R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,6098.0,Cabozantinib,ROS1
526,N-TERMINAL FRAME SHIFT,D,Sensitivity/Response,Acute Myeloid Leukemia,1050.0,OICR-9429,CEBPA
527,ZNF198-FGFR1,C,Sensitivity/Response,Myeloproliferative Neoplasm,2260.0,Midostaurin,FGFR1
528,Amplification,D,Resistance,Breast Cancer,2260.0,Afimoxifene,FGFR1
529,A1065T,D,Sensitivity/Response,Angiosarcoma,3791.0,Sunitinib+Sorafenib,KDR
530,D717V,D,Sensitivity/Response,Angiosarcoma,3791.0,Sorafenib+Sunitinib,KDR
531,Q1178*,C,Sensitivity/Response,Thyroid Gland Carcinoma,7249.0,Everolimus,TSC2
532,F2108L,C,Resistance,Thyroid Gland Carcinoma,2475.0,Everolimus,MTOR
533,ITD,B,Resistance,Acute Promyelocytic Leukemia,2322.0,Anthracycline Antineoplastic Antibiotic+Tretinoin,FLT3
534,Amplification,A,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Neratinib+Trastuzumab,ERBB2
535,Underexpression,D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,8854.0,Tretinoin,
536,UNDEREXPRESSION,D,Sensitivity/Response,Pancreatic Ductal Adenocarcinoma,57650.0,Gemcitabine,
537,EML4-ALK,C,Resistance,Lung Acinar Adenocarcinoma,238.0,Erlotinib,ALK
538,Amplification,A,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Trastuzumab,ERBB2
539,Y772_A775DUP,C,Sensitivity/Response,Lung Adenocarcinoma,2064.0,Trastuzumab Emtansine,ERBB2
540,VIII,B,Sensitivity/Response,Glioblastoma,1956.0,Erlotinib+Gefitinib,EGFR
541,Expression,B,Sensitivity/Response,Glioblastoma,5728.0,Erlotinib+Gefitinib,PTEN
542,Q22*,C,Resistance,Colon Mucinous Adenocarcinoma,3845.0,Panitumumab,KRAS
543,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Capecitabine+Lapatinib,ERBB2
544,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Trastuzumab+Capecitabine,ERBB2
545,P904L,E,Sensitivity/Response,Myelodysplastic Syndrome,1788.0,Decitabine+5-Fluoro-2-Deoxycytidine+Guadecitabine+Azacitidine,DNMT3A
546,OVEREXPRESSION,D,Resistance,Uveal Melanoma,55510.0,Selumetinib+Trametinib+Mirdametinib,
547,RS3733542,B,Sensitivity/Response,Acute Myeloid Leukemia,3815.0,Selumetinib,KIT
548,ITD,B,Resistance,Acute Myeloid Leukemia,2322.0,Selumetinib,FLT3
549,OVEREXPRESSION,D,Sensitivity/Response,Melanoma,29110.0,AZ909+Selumetinib,
550,Mutation,B,Resistance,Colorectal Cancer,3845.0,Bevacizumab+Chemotherapy,KRAS
551,Mutation,D,Sensitivity/Response,Cancer,3845.0,G-573+MEK Inhibitor GDC-0623,KRAS
552,V600E,D,Sensitivity/Response,Cancer,673.0,Cobimetinib,BRAF
553,G12C,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,3845.0,Selumetinib+Docetaxel,KRAS
554,G12V,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,3845.0,Docetaxel+Selumetinib,KRAS
555,LOSS,D,Resistance,Lung Non-small Cell Carcinoma,6794.0,Selumetinib+Docetaxel,STK11
556,Mutation,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,7157.0,Selumetinib+Docetaxel,TP53
557,Mutation,D,Resistance,Lung Non-small Cell Carcinoma,7157.0,Docetaxel,TP53
558,Wildtype,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,7157.0,Adjuvant Chemotherapy,TP53
559,OVEREXPRESSION,C,Resistance,Lung Non-small Cell Carcinoma,84868.0,PD1 Inhibitor,
560,OVEREXPRESSION,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,84868.0,Anti-TIM-3 Monoclonal Antibody+PD1 Inhibitor,
561,Overexpression,D,Sensitivity/Response,Cancer,2065.0,Selumetinib+Afatinib,ERBB3
562,Overexpression,D,Resistance,Cancer,2065.0,"HER2 Inhibitor CP-724,714+Selumetinib+Gefitinib",ERBB3
563,p16 Expression,B,Resistance,Head And Neck Squamous Cell Carcinoma,1029.0,Afatinib,CDKN2A
564,SERUM LEVELS,B,Sensitivity/Response,Inflammatory Breast Carcinoma,4313.0,Bevacizumab,
565,SERUM LEVELS,B,Resistance,Inflammatory Breast Carcinoma,4318.0,Bevacizumab,
566,SERUM LEVELS,B,Sensitivity/Response,Brain Glioma,4313.0,Bevacizumab,
567,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Trastuzumab Emtansine,ERBB2
568,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Trastuzumab Emtansine,ERBB2
569,NUCLEAR EXPRESSION,D,Sensitivity/Response,Gastric Adenocarcinoma,10808.0,Cisplatin+Fluorouracil,
570,T17 DELETION,B,Sensitivity/Response,Colorectal Cancer,10808.0,Oxaliplatin+Fluorouracil,
571,Expression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,29126.0,Nivolumab+Pembrolizumab+Avelumab+Atezolizumab,CD274
572,Deleterious Mutation,B,Sensitivity/Response,Sarcoma,7157.0,Pazopanib,TP53
573,E545K,D,Resistance,Lung Adenocarcinoma,5290.0,Gefitinib,PIK3CA
574,Expression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,29126.0,Atezolizumab,CD274
575,G12C,D,Sensitivity/Response,Cancer,3845.0,ARS-853+Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,KRAS
576,V842I,D,Sensitivity/Response,Colon Cancer,2064.0,Trastuzumab+Lapatinib+Neratinib,ERBB2
577,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Ceritinib,ALK
578,L755S,D,Sensitivity/Response,Colon Cancer,2064.0,Lapatinib+Neratinib+Trastuzumab,ERBB2
579,V777L,D,Sensitivity/Response,Colon Cancer,2064.0,Trastuzumab+Lapatinib+Neratinib,ERBB2
580,L866M,D,Sensitivity/Response,Colon Cancer,2064.0,Trastuzumab+Neratinib+Lapatinib,ERBB2
581,S310F/Y,D,Sensitivity/Response,Colon Cancer,2064.0,Neratinib+Trastuzumab+Lapatinib,ERBB2
582,G13D,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
583,G13D,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
584,Mutation,D,Resistance,Colorectal Cancer,3845.0,Ixazomib,KRAS
585,Mutation,D,Sensitivity/Response,Cancer,3845.0,AZD5438,KRAS
586,EXON 14 SKIPPING MUTATION,C,Sensitivity/Response,Lung Adenocarcinoma,4233.0,Crizotinib,MET
587,EXON 14 SKIPPING MUTATION,C,Sensitivity/Response,Lung Adenocarcinoma,4233.0,Capmatinib,MET
588,Fusion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
589,EML4-ALK,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,WHI-P154,ALK
590,EML4::ALK e20-e20,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
591,EML4::ALK e2-e20,E,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
592,R961W,C,Sensitivity/Response,Colorectal Adenocarcinoma,3791.0,Regorafenib,KDR
593,EML4::ALK e6-e20,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,"2,4-pyrimidinediamine",ALK
594,EML4::ALK e6-e20,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
595,EML4::ALK e6-e20,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,TAE684,ALK
596,EML4::ALK e20-e20,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
597,Fusion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
598,Fusion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
599,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
600,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
601,Fusion,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Retaspimycin Hydrochloride,ALK
602,EML4-ALK,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Crizotinib+Retaspimycin Hydrochloride,ALK
603,EML4::ALK e20-e20,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Alvespimycin+Crizotinib,ALK
604,EML4-ALK,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Alvespimycin+Crizotinib,ALK
605,EML4-ALK,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
606,Exon 2 Mutation,B,Resistance,Colorectal Cancer,3845.0,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,KRAS
607,P47S,E,Resistance,Cancer,7157.0,Cisplatin,TP53
608,MUTATION,D,Sensitivity/Response,Uveal Melanoma,2776.0,JQ1,GNAQ
609,MUTATION,D,Sensitivity/Response,Uveal Melanoma,2767.0,JQ1,GNA11
610,K706FS*19,C,Sensitivity/Response,Glioblastoma,5395.0,Nivolumab,PMS2
611,G12C,B,Resistance,Colorectal Cancer,3845.0,Gefitinib+Erlotinib,KRAS
612,Exon 2 Mutation,B,Resistance,Pancreatic Cancer,3845.0,Gemcitabine+Erlotinib,KRAS
613,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,3845.0,Trametinib,KRAS
614,Exon 9 Mutation,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
615,MUTATION,B,Sensitivity/Response,Melanoma,3815.0,Imatinib,KIT
616,Exon 9 Mutation,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
617,Exon 11 Mutation,C,Sensitivity/Response,Melanoma,3815.0,Sunitinib,KIT
618,Mutation,B,Sensitivity/Response,Skin Melanoma,4893.0,Trametinib+Docetaxel,NRAS
619,Q61,B,Sensitivity/Response,Skin Melanoma,4893.0,Binimetinib,NRAS
620,MUTATION,C,Sensitivity/Response,Uveal Melanoma,2767.0,Trametinib,GNA11
621,MUTATION,B,Sensitivity/Response,Uveal Melanoma,2776.0,Trametinib,GNAQ
622,Mutation,D,Sensitivity/Response,Cancer,4893.0,Metformin+Trametinib,NRAS
623,Deletion,B,Sensitivity/Response,Prostate Cancer,5728.0,Everolimus,PTEN
624,Q209,C,Sensitivity/Response,Uveal Melanoma,2776.0,Refametinib,GNAQ
625,Mutation,D,Sensitivity/Response,Uveal Melanoma,8314.0,Trichostatin A+Vorinostat+Valproic Acid+Panobinostat,BAP1
626,Mutation,E,Sensitivity/Response,Malignant Mesothelioma,8314.0,MC1568+Mocetinostat+Vorinostat,BAP1
627,Mutation,D,Sensitivity/Response,Endometrial Cancer,2263.0,Ponatinib,FGFR2
628,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Ceritinib,ALK
629,NPM-ALK,D,Sensitivity/Response,Anaplastic Large Cell Lymphoma,238.0,Crizotinib,ALK
630,Fusion,C,Sensitivity/Response,Anaplastic Large Cell Lymphoma,238.0,Crizotinib,ALK
631,NPM-ALK,B,Sensitivity/Response,Anaplastic Large Cell Lymphoma,238.0,Crizotinib,ALK
632,Fusion,C,Sensitivity/Response,Anaplastic Large Cell Lymphoma,238.0,Crizotinib,ALK
633,Fusion,B,Sensitivity/Response,Inflammatory Myofibroblastic Tumor,238.0,Crizotinib,ALK
634,RANBP2-ALK,C,Sensitivity/Response,Inflammatory Myofibroblastic Tumor,238.0,Crizotinib,ALK
635,EML4::ALK e20-e20,C,Sensitivity/Response,Cancer,238.0,Crizotinib,ALK
636,N546K,E,Sensitivity/Response,Ewing Sarcoma Of Bone,2260.0,Ponatinib,FGFR1
637,Amplification,D,Sensitivity/Response,Ewing Sarcoma Of Bone,2260.0,Ponatinib,FGFR1
638,REARRANGEMENT,C,Sensitivity/Response,Lung Adenocarcinoma,6098.0,Ceritinib,ROS1
639,CD74-ROS1 G2032R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,6098.0,Foretinib+Cabozantinib,ROS1
640,CD74-ROS1 G2032R,D,Resistance,Lung Non-small Cell Carcinoma,6098.0,Ceritinib+Crizotinib+AZD3463+Brigatinib,ROS1
641,CD74-ROS1 G2032R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,6098.0,Lorlatinib,ROS1
642,CD74-ROS1 L2026M,D,Resistance,Lung Non-small Cell Carcinoma,6098.0,Crizotinib,ROS1
643,CD74-ROS1 L2026M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,6098.0,Lorlatinib,ROS1
644,CD74-ROS1 G2032R,C,Resistance,Lung Non-small Cell Carcinoma,6098.0,Crizotinib,ROS1
645,CD74-ROS1 G2032R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,6098.0,Foretinib,ROS1
646,CD74-ROS1 L2155S,D,Resistance,Lung Non-small Cell Carcinoma,6098.0,Foretinib+Crizotinib+TAE684,ROS1
647,CD74-ROS1 L2026M,D,Resistance,Lung Non-small Cell Carcinoma,6098.0,Crizotinib,ROS1
648,CD74-ROS1 L2026M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,6098.0,Foretinib,ROS1
649,CD74-ROS1 G2101A,D,Resistance,Lung Non-small Cell Carcinoma,6098.0,Crizotinib,ROS1
650,CD74-ROS1 G2101A,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,6098.0,Foretinib,ROS1
651,CLTC-ALK,D,Sensitivity/Response,Diffuse Large B-cell Lymphoma,238.0,TAE684,ALK
652,Fusion,C,Sensitivity/Response,Diffuse Large B-cell Lymphoma,238.0,Crizotinib,ALK
653,CLTC-ALK,C,Sensitivity/Response,Diffuse Large B-cell Lymphoma,238.0,Crizotinib,ALK
654,EML4::ALK e2-e20,E,Sensitivity/Response,Renal Cell Carcinoma,238.0,,ALK
655,DEL 485-490,D,Sensitivity/Response,Cancer,673.0,Pan-RAF Inhibitor LY3009120,BRAF
656,NPM-ALK,D,Sensitivity/Response,Cancer,238.0,Crizotinib,ALK
657,R1275Q,C,Sensitivity/Response,Neuroblastoma,238.0,Crizotinib,ALK
658,R1275Q,C,Sensitivity/Response,Neuroblastoma,238.0,Crizotinib,ALK
659,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Alectinib,ALK
660,Fusion,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Alectinib,ALK
661,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Alectinib,ALK
662,DELETION POLYMORPHISM,B,Resistance,Chronic Myeloid Leukemia,10018.0,Imatinib,BCL2L11
663,DELETION POLYMORPHISM,B,Resistance,Lung Non-small Cell Carcinoma,10018.0,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,BCL2L11
664,Fusion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Alectinib,ALK
665,ALK Fusion I1171,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Alectinib,ALK
666,ALK Fusion I1171,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Ceritinib,ALK
667,ALK Fusion I1171,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,TAE684,ALK
668,EML4-ALK  V1180L,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Alectinib,ALK
669,ALK Fusion I1171,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
670,EML4-ALK  V1180L,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
671,EML4-ALK  V1180L,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Ceritinib,ALK
672,EML4-ALK  V1180L,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,TAE684,ALK
673,EML4-ALK  V1180L,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Brigatinib,ALK
674,OVEREXPRESSION,D,Resistance,Pancreatic Cancer,23411.0,Niacinamide,
675,TKD MUTATION,B,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Midostaurin,FLT3
676,Mutation,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,Everolimus,PIK3CA
677,Loss,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5728.0,Everolimus,PTEN
678,REARRANGEMENT,E,Sensitivity/Response,Colorectal Adenocarcinoma,6098.0,Crizotinib,ROS1
679,Biallelic Inactivation,C,Sensitivity/Response,Pancreatic Cancer,79728.0,Mitomycin,PALB2
680,LOSS-OF-FUNCTION,D,Sensitivity/Response,Pancreatic Cancer,2176.0,Melphalan+Gemcitabine+Mitomycin+Cisplatin+Chlorambucil,FANCC
681,Loss-of-function,D,Sensitivity/Response,Pancreatic Cancer,675.0,Mitomycin,BRCA2
682,I843DEL,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,5156.0,Imatinib,PDGFRA
683,EBF1-PDGFRB,C,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,5159.0,Imatinib,PDGFRB
684,SNP,B,Resistance,Prostate Cancer,6783.0,Abiraterone Acetate,
685,METHYLATION,B,Resistance,Stomach Carcinoma,4292.0,Oxaliplatin,MLH1
686,T227M,B,Adverse Response,Renal Cell Carcinoma,2322.0,Sunitinib,FLT3
687,S2215Y,D,Sensitivity/Response,Endometrial Adenocarcinoma,2475.0,Sirolimus,MTOR
688,C1483Y,D,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,2475.0,Sirolimus,MTOR
689,E1799K,D,Sensitivity/Response,Clear Cell Renal Cell Carcinoma,2475.0,Sirolimus,MTOR
690,N550K,D,Sensitivity/Response,Endometrial Cancer,2263.0,PD173074,FGFR2
691,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Brigatinib,ALK
692,OVEREXPRESSION,D,Resistance,Pancreatic Adenocarcinoma,5925.0,Doxorubicin+Gemcitabine+Fluorouracil+Mitomycin,RB1
693,RS557806,B,Sensitivity/Response,Colorectal Cancer,23645.0,FOLFIRI Regimen+Bevacizumab,
694,Exon 2 Mutation,B,Sensitivity/Response,Colorectal Cancer,3845.0,Irinotecan+Selumetinib,KRAS
695,F1174L,D,Sensitivity/Response,Neuroblastoma,238.0,AZD3463,ALK
696,F1174L,D,Sensitivity/Response,Neuroblastoma,238.0,Lorlatinib,ALK
697,F1245C,D,Sensitivity/Response,Neuroblastoma,238.0,Lorlatinib,ALK
698,R1275Q,D,Sensitivity/Response,Neuroblastoma,238.0,Lorlatinib,ALK
699,EML4-ALK,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Lorlatinib,ALK
700,F1245C,C,Resistance,Neuroblastoma,238.0,Crizotinib,ALK
701,Fusion,E,Sensitivity/Response,Colorectal Adenocarcinoma,238.0,Crizotinib,ALK
702,Fusion,E,Sensitivity/Response,Breast Cancer,238.0,Crizotinib,ALK
703,Exon 4-11 Deletion,D,Sensitivity/Response,Neuroblastoma,238.0,Brigatinib,ALK
704,ALK Fusion F1245C,D,Resistance,Cancer,238.0,Crizotinib,ALK
705,ALK Fusion F1245C,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Ceritinib,ALK
706,ALK Fusion F1245C,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
707,EML4::ALK e6-e20,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Ceritinib,ALK
708,EML4-ALK L1196M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Ceritinib,ALK
709,ALK Fusion G1269A,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Ceritinib,ALK
710,EML4-ALK S1206Y,D,Sensitivity/Response,Cancer,238.0,Ceritinib,ALK
711,ALK Fusion I1171,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Ceritinib,ALK
712,ALK Fusion G1202R,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Ceritinib,ALK
713,EML4-ALK C1156Y,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
714,EML4-ALK T1151INST,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Alectinib,ALK
715,EML4-ALK T1151INST,D,Resistance,Lung Non-small Cell Carcinoma,238.0,TAE684,ALK
716,EML4-ALK T1151INST,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Tanespimycin,ALK
717,ALK Fusion G1202R,D,Resistance,Cancer,238.0,Alectinib,ALK
718,ALK Fusion G1202R,D,Resistance,Cancer,238.0,Brigatinib,ALK
719,ALK Fusion G1202R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Tanespimycin,ALK
720,ALK Fusion G1269A,D,Sensitivity/Response,Cancer,238.0,Brigatinib,ALK
721,ALK Fusion G1269A,D,Resistance,Cancer,238.0,Alectinib,ALK
722,ALK Fusion G1269A,D,Sensitivity/Response,Cancer,238.0,Ceritinib,ALK
723,NPM-ALK,D,Sensitivity/Response,Cancer,238.0,Crizotinib,ALK
724,ALK Fusion G1202R,C,Resistance,Lung Adenocarcinoma,238.0,Crizotinib,ALK
725,Mutation,D,Sensitivity/Response,Head And Neck Cancer,5290.0,Dactolisib,PIK3CA
726,H1047R,D,Sensitivity/Response,Head And Neck Cancer,5290.0,Dactolisib,PIK3CA
727,H1047R,D,Sensitivity/Response,Head And Neck Cancer,5290.0,Dactolisib,PIK3CA
728,H1047R,D,Sensitivity/Response,Head And Neck Cancer,5290.0,Dactolisib+Cetuximab,PIK3CA
729,M918T,B,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,5979.0,Sorafenib,RET
730,AMPLIFICATION,B,Sensitivity/Response,Liposarcoma,1019.0,Palbociclib,CDK4
731,ALK Fusion I1171,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Alectinib,ALK
732,ALK Fusion I1171,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Ceritinib,ALK
733,Mutation,A,Sensitivity/Response,Cancer,672.0,Olaparib,BRCA1
734,Mutation,A,Sensitivity/Response,Cancer,675.0,Olaparib,BRCA2
735,Loss,D,Sensitivity/Response,Skin Melanoma,1029.0,Alvocidib,CDKN2A
736,Loss,D,Sensitivity/Response,Renal Cell Carcinoma,1029.0,Palbociclib,CDKN2A
737,LOSS,D,Sensitivity/Response,Renal Cell Carcinoma,1030.0,Palbociclib,CDKN2B
738,Loss,D,Sensitivity/Response,Skin Melanoma,1029.0,Palbociclib,CDKN2A
739,R24C,D,Sensitivity/Response,Skin Melanoma,1019.0,Palbociclib,CDK4
740,Loss,D,Sensitivity/Response,Ovarian Cancer,1029.0,Palbociclib,CDKN2A
741,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Pictilisib,ERBB2
742,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,A66,ERBB2
743,Loss,D,Resistance,Her2-receptor Positive Breast Cancer,5728.0,Trastuzumab,PTEN
744,Mutation,B,Resistance,Her2-receptor Positive Breast Cancer,5290.0,Trastuzumab,PIK3CA
745,Loss,B,Resistance,Her2-receptor Positive Breast Cancer,5728.0,Trastuzumab,PTEN
746,BCR-ABL T315I,B,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Ponatinib,ABL1
747,T790M,B,Resistance,Lung Adenocarcinoma,1956.0,Gefitinib+Erlotinib,EGFR
748,Amplification,C,Resistance,Lung Adenocarcinoma,4233.0,Gefitinib+Erlotinib,MET
749,Amplification,C,Resistance,Lung Adenocarcinoma,2064.0,Erlotinib+Gefitinib,ERBB2
750,S768I,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
751,S768I,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Gefitinib,EGFR
752,C797S,C,Resistance,Lung Adenocarcinoma,1956.0,Osimertinib,EGFR
753,T790M,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Osimertinib,EGFR
754,V600E,B,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
755,V600K,B,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
756,V600K,C,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
757,H1047R,D,Sensitivity/Response,Head And Neck Cancer,5290.0,Alpelisib,PIK3CA
758,Mutation,D,Sensitivity/Response,Cancer,5290.0,Alpelisib,PIK3CA
759,Amplification,D,Sensitivity/Response,Stomach Carcinoma,5290.0,Alpelisib,PIK3CA
760,V600,B,Sensitivity/Response,Melanoma,673.0,Dabrafenib,BRAF
761,V600E,D,Sensitivity/Response,Colorectal Cancer,673.0,Vemurafenib+Cetuximab+Gefitinib,BRAF
762,V600E,A,Sensitivity/Response,Skin Melanoma,673.0,Vemurafenib,BRAF
763,V600E,B,Sensitivity/Response,Skin Melanoma,673.0,Vemurafenib,BRAF
764,V600,A,Sensitivity/Response,Skin Melanoma,673.0,Trametinib+Dabrafenib,BRAF
765,V600E,C,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,673.0,Vemurafenib,BRAF
766,V600,B,Sensitivity/Response,Colorectal Cancer,673.0,Trametinib+Dabrafenib,BRAF
767,TRIM24-BRAF,D,Resistance,Skin Melanoma,673.0,Vemurafenib,BRAF
768,K700E,D,Sensitivity/Response,Breast Cancer,23451.0,Spliceostatin A,SF3B1
769,K666N,D,Sensitivity/Response,Breast Cancer,23451.0,Spliceostatin A,SF3B1
770,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
771,V600E,B,Sensitivity/Response,Melanoma,673.0,Cobimetinib+Vemurafenib,BRAF
772,V600,B,Sensitivity/Response,Melanoma,673.0,Vemurafenib+Cobimetinib,BRAF
773,M541L,C,Sensitivity/Response,Chronic Leukemia,3815.0,Imatinib,KIT
774,Exon 9 Mutation,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
775,V600E,D,Sensitivity/Response,Colorectal Cancer,673.0,Dactolisib+GDC-0879,BRAF
776,Mutation,D,Sensitivity/Response,Melanoma,4893.0,Omipalisib+Trametinib,NRAS
777,V600E,C,Sensitivity/Response,Gastrointestinal Neuroendocrine Tumor,673.0,Dabrafenib+Vemurafenib+Trametinib,BRAF
778,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Trastuzumab Emtansine,ERBB2
779,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Docetaxel+Pertuzumab+Trastuzumab,ERBB2
780,E2014K and E2419K,C,Sensitivity/Response,Transitional Cell Carcinoma,2475.0,Everolimus+Pazopanib,MTOR
781,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Lapatinib+Trastuzumab,ERBB2
782,AMPLIFICATION,C,Sensitivity/Response,Lung Adenocarcinoma,253260.0,Sapanisertib+Onatasertib,RICTOR
783,FIP1L1-PDGFRA,B,Sensitivity/Response,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",5156.0,Imatinib,PDGFRA
784,REARRANGEMENT,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,6098.0,Crizotinib,ROS1
785,REARRANGEMENT,C,Sensitivity/Response,Bronchiolo-alveolar Adenocarcinoma,6098.0,Crizotinib,ROS1
786,TFG-ROS1,C,Sensitivity/Response,Inflammatory Myofibroblastic Tumor,6098.0,Crizotinib,ROS1
787,FIP1L1-PDGFRA,A,Sensitivity/Response,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",5156.0,Imatinib,PDGFRA
788,FIP1L1-PDGFRA T674I,C,Resistance,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",5156.0,Imatinib,PDGFRA
789,H1047R,D,Sensitivity/Response,Lung Adenocarcinoma,5290.0,Dactolisib,PIK3CA
790,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Pilaralisib+Trastuzumab,ERBB2
791,OVEREXPRESSION,B,Resistance,Her2-receptor Positive Breast Cancer,332.0,Trastuzumab,
792,E545K,D,Resistance,Her2-receptor Positive Breast Cancer,5290.0,Trastuzumab,PIK3CA
793,D594A,E,Sensitivity/Response,Skin Melanoma,673.0,Sorafenib+Mitogen-Activated Protein Kinase Kinase Inhibitor,BRAF
794,Loss,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5728.0,Trastuzumab+PI3K/BET Inhibitor LY294002,PTEN
795,D594V,E,Sensitivity/Response,Skin Melanoma,673.0,Sorafenib+Trametinib,BRAF
796,K483M,E,Sensitivity/Response,Skin Melanoma,673.0,Mitogen-Activated Protein Kinase Kinase Inhibitor+Sorafenib,BRAF
797,L597R,D,Sensitivity/Response,Skin Melanoma,673.0,Vemurafenib+Trametinib,BRAF
798,L597S,D,Sensitivity/Response,Skin Melanoma,673.0,Vemurafenib+Trametinib,BRAF
799,L597S,C,Sensitivity/Response,Skin Melanoma,673.0,MEK Inhibitor TAK-733,BRAF
800,L597Q,D,Sensitivity/Response,Skin Melanoma,673.0,Trametinib+Vemurafenib,BRAF
801,K601E,D,Sensitivity/Response,Skin Melanoma,673.0,Vemurafenib+Trametinib,BRAF
802,L597V,C,Sensitivity/Response,Skin Melanoma,673.0,Trametinib,BRAF
803,Amplification,D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,5290.0,Taselisib,PIK3CA
804,H1047R,D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,5290.0,Taselisib,PIK3CA
805,Amplification,B,Resistance,Mucosal Melanoma,3815.0,Imatinib,KIT
806,Mutation,D,Resistance,Head And Neck Squamous Cell Carcinoma,5728.0,Taselisib,PTEN
807,Mutation,D,Resistance,Skin Melanoma,4763.0,Vemurafenib,NF1
808,Mutation,D,Sensitivity/Response,Skin Melanoma,4763.0,Sirolimus+Mirdametinib,NF1
809,Mutation,C,Resistance,Skin Melanoma,4763.0,Vemurafenib,NF1
810,Mutation,D,Sensitivity/Response,Skin Melanoma,4763.0,AZ628+VTX-11e,NF1
811,Mutation,B,Sensitivity/Response,Skin Melanoma,4893.0,Binimetinib,NRAS
812,Q61,C,Sensitivity/Response,Skin Melanoma,4893.0,Selumetinib,NRAS
813,Q61K,D,Resistance,Skin Melanoma,4893.0,Vemurafenib,NRAS
814,Q61K,D,Sensitivity/Response,Skin Melanoma,4893.0,Selumetinib,NRAS
815,Mutation,D,Sensitivity/Response,Skin Melanoma,4893.0,Amuvatinib,NRAS
816,Mutation,B,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib+Sonidegib,SMO
817,Mutation,B,Sensitivity/Response,Chronic Lymphocytic Leukemia,7157.0,Alemtuzumab,TP53
818,EXON 9 FRAMESHIFT,B,Sensitivity/Response,Myeloproliferative Neoplasm,811.0,Peginterferon Alfa-2a,CALR
819,HIP1-ALK I1171N,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib+Alectinib,ALK
820,EML4-ALK I1171S,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Alectinib+Crizotinib,ALK
821,Mutation,D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,5290.0,Radiation Therapy+Taselisib,PIK3CA
822,Mutation,D,Sensitivity/Response,Cancer,5728.0,Ipatasertib,PTEN
823,Loss,D,Resistance,Ovarian Cancer,5728.0,Cisplatin,PTEN
824,Loss,B,Resistance,Stomach Carcinoma,5728.0,Chemotherapy,PTEN
825,Y646,D,Sensitivity/Response,Skin Melanoma,2146.0,GSK126,EZH2
826,Amplification,B,Sensitivity/Response,Skin Melanoma,595.0,Carboplatin+Paclitaxel+Sorafenib,CCND1
827,AMPLIFICATION,B,Sensitivity/Response,Skin Melanoma,5894.0,Carboplatin+Paclitaxel+Sorafenib,RAF1
828,Amplification,B,Sensitivity/Response,Skin Melanoma,3845.0,Carboplatin+Docetaxel+Sorafenib,KRAS
829,Fusion,A,Sensitivity/Response,Myeloproliferative Neoplasm,5159.0,Imatinib,PDGFRB
830,Amplification,A,Sensitivity/Response,Gastric Adenocarcinoma,2064.0,Trastuzumab,ERBB2
831,Loss,D,Sensitivity/Response,Stomach Cancer,5728.0,Docetaxel+Capivasertib,PTEN
832,Mutation,D,Sensitivity/Response,Stomach Cancer,5290.0,Capivasertib,PIK3CA
833,Loss,D,Sensitivity/Response,Cancer,5728.0,Capivasertib,PTEN
834,Mutation,D,Sensitivity/Response,Cancer,5290.0,Capivasertib,PIK3CA
835,Mutation,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,Capivasertib,PIK3CA
836,H1047R,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,Trastuzumab+Capivasertib,PIK3CA
837,H1047R,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,Capivasertib+Lapatinib,PIK3CA
838,Mutation,D,Sensitivity/Response,Melanoma,4893.0,Binimetinib,NRAS
839,Expression,B,Sensitivity/Response,Cancer,29126.0,Nivolumab,CD274
840,Overexpression,C,Sensitivity/Response,Papillary Adenocarcinoma,5979.0,Sunitinib,RET
841,PML-RARA,C,Sensitivity/Response,Acute Promyelocytic Leukemia,5371.0,Tretinoin,PML
842,CTLA4-CD28,C,Sensitivity/Response,Sezary's Disease,1493.0,Ipilimumab,CTLA4
843,MUTATION,B,Resistance,Prostate Cancer,367.0,Flutamide+Cyproterone Acetate+Bicalutamide+Nilutamide,AR
844,Mutation,D,Sensitivity/Response,Prostate Cancer,5728.0,Alpelisib+Enzalutamide+PI3Kbeta Inhibitor AZD8186,PTEN
845,LOSS-OF-FUNCTION,D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,4851.0,Porcupine Inhibitor WNT974,NOTCH1
846,OVEREXPRESSION,B,Resistance,Estrogen-receptor Positive Breast Cancer,1021.0,Fulvestrant,CDK6
847,OVEREXPRESSION,D,Sensitivity/Response,Estrogen-receptor Positive Breast Cancer,1021.0,Palbociclib+Fulvestrant,CDK6
848,Overexpression,C,Sensitivity/Response,B-cell Adult Acute Lymphocytic Leukemia,2322.0,Sunitinib,FLT3
849,Mutation,B,Sensitivity/Response,Ovarian Carcinoma,672.0,Platinum Compound,BRCA1
850,Mutation,B,Sensitivity/Response,Ovarian Carcinoma,675.0,Platinum Compound,BRCA2
851,Mutation,B,Sensitivity/Response,Ovarian Carcinoma,672.0,Platinum Compound,BRCA1
852,Mutation,B,Sensitivity/Response,Ovarian Carcinoma,675.0,Platinum Compound,BRCA2
853,Q209P,C,Resistance,Skin Melanoma,2776.0,Vemurafenib,GNAQ
854,V317FS,D,Sensitivity/Response,Skin Melanoma,5728.0,Akt Inhibitor MK2206+MEK Inhibitor CI-1040,PTEN
855,LOSS-OF-FUNCTION,D,Resistance,Breast Cancer,5925.0,Palbociclib,RB1
856,Q209P,D,Resistance,Skin Melanoma,2776.0,PLX4720,GNAQ
857,Overexpression,B,Sensitivity/Response,Breast Cancer,2099.0,Letrozole+Palbociclib,ESR1
858,F2108L,D,Resistance,Breast Cancer,2475.0,Sirolimus,MTOR
859,M2327I,D,Resistance,Breast Cancer,2475.0,MTOR Kinase Inhibitor AZD8055,MTOR
860,M2327I,D,Resistance,Breast Cancer,2475.0,Sirolimus,MTOR
861,A2034V,D,Resistance,Breast Cancer,2475.0,Sirolimus,MTOR
862,E542K,C,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,5290.0,Apitolisib,PIK3CA
863,E545K,C,Sensitivity/Response,Cancer,5290.0,Apitolisib,PIK3CA
864,ITD,C,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sorafenib,FLT3
865,D835H,C,Resistance,Acute Myeloid Leukemia,2322.0,Sorafenib,FLT3
866,D835H/Y,D,Resistance,Acute Myeloid Leukemia,2322.0,Sorafenib,FLT3
867,Loss,D,Sensitivity/Response,Glioblastoma,1029.0,Palbociclib,CDKN2A
868,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Palbociclib+Trastuzumab,ERBB2
869,Amplification,D,Sensitivity/Response,Breast Cancer,595.0,Palbociclib,CCND1
870,Overexpression,D,Sensitivity/Response,Mantle Cell Lymphoma,595.0,Palbociclib,CCND1
871,Amplification,C,Sensitivity/Response,Glioblastoma,4233.0,Crizotinib,MET
872,Amplification,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,4233.0,Crizotinib,MET
873,Q503*,C,Resistance,Skin Melanoma,3716.0,Pembrolizumab,JAK1
874,c.1641+1dup,C,Resistance,Skin Melanoma,3717.0,Pembrolizumab,JAK2
875,S14FS,C,Resistance,Skin Melanoma,567.0,Pembrolizumab,B2M
876,PPFIBP2-BRAF,C,Sensitivity/Response,Skin Melanoma,673.0,Trametinib,BRAF
877,KIAA1549-BRAF,C,Sensitivity/Response,Skin Melanoma,673.0,Trametinib,BRAF
878,Expression,B,Sensitivity/Response,Colorectal Cancer,1956.0,Cetuximab,EGFR
879,OVEREXPRESSION,B,Sensitivity/Response,Colorectal Cancer,5743.0,Aspirin,
880,V600,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,673.0,Vemurafenib,BRAF
881,V600,B,Sensitivity/Response,Langerhans-cell Histiocytosis,673.0,Vemurafenib,BRAF
882,V600,B,Resistance,Colorectal Cancer,673.0,Vemurafenib,BRAF
883,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
884,V600E,B,Sensitivity/Response,Hairy Cell Leukemia,673.0,Vemurafenib,BRAF
885,G12D,C,Resistance,Hairy Cell Leukemia,3845.0,Vemurafenib,KRAS
886,Overexpression,B,Resistance,Skin Melanoma,4233.0,Vemurafenib,MET
887,Overexpression,E,Sensitivity/Response,Uveal Melanoma,4233.0,Crizotinib,MET
888,Overexpression,D,Sensitivity/Response,Uveal Melanoma,4233.0,Crizotinib,MET
889,Mutation,B,Sensitivity/Response,Acute Myeloid Leukemia,1788.0,Decitabine,DNMT3A
890,Amplification,C,Sensitivity/Response,Colorectal Cancer,4233.0,Crizotinib+Vemurafenib,MET
891,V600E,C,Sensitivity/Response,Colorectal Cancer,673.0,Panitumumab+Vemurafenib,BRAF
892,V600E,B,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,673.0,Vemurafenib,BRAF
893,T790M,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Osimertinib,EGFR
894,LOSS-OF-FUNCTION,D,Resistance,Glioblastoma,5925.0,Palbociclib,RB1
895,EXPRESSION,D,Sensitivity/Response,Sarcoma,5887.0,Vorinostat,RAD23B
896,Mutation,D,Sensitivity/Response,Breast Cancer,5290.0,Ribociclib+Phosphatidylinositide 3-Kinase Inhibitor,PIK3CA
897,CCDC6-RET,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,5979.0,Nintedanib,RET
898,C121S,C,Resistance,Melanoma,5604.0,Vemurafenib,MAP2K1
899,S249C,C,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,Pazopanib,FGFR3
900,Amplification,B,Sensitivity/Response,Breast Cancer,2260.0,Dovitinib,FGFR1
901,Amplification,B,Sensitivity/Response,Breast Cancer,2263.0,Dovitinib,FGFR2
902,AMPLIFICATION,B,Sensitivity/Response,Breast Cancer,2248.0,Dovitinib,FGF3
903,Mutation,D,Sensitivity/Response,Breast Cancer,5290.0,Phosphatidylinositide 3-Kinase Inhibitor+Palbociclib,PIK3CA
904,R200W (c.598C>T),C,Sensitivity/Response,Chuvash Polycythemia,7428.0,Ruxolitinib,VHL
905,PHOSPHORYLATION,B,Resistance,Breast Cancer,5925.0,Alpelisib,RB1
906,Mutation,D,Sensitivity/Response,Breast Cancer,5290.0,Everolimus+MTOR Kinase Inhibitor PP242,PIK3CA
907,MUTATION,D,Sensitivity/Response,Breast Cancer,5295.0,MTOR Kinase Inhibitor PP242,PIK3R1
908,Amplification,D,Sensitivity/Response,Breast Cancer,2064.0,MTOR Kinase Inhibitor PP242,ERBB2
909,Loss,D,Sensitivity/Response,Endometrial Cancer,5728.0,Temsirolimus,PTEN
910,Mutation,D,Sensitivity/Response,Endometrial Cancer,5290.0,Pictilisib,PIK3CA
911,D194E,C,Sensitivity/Response,Pancreatic Cancer,6794.0,Everolimus,STK11
912,LOSS,D,Sensitivity/Response,Peutz-Jeghers Syndrome,6794.0,Sirolimus,STK11
913,LOSS,D,Sensitivity/Response,Peutz-Jeghers Syndrome,6794.0,Sirolimus,STK11
914,Amplification,C,Sensitivity/Response,Lung Adenocarcinoma,208.0,Vandetanib+Everolimus,AKT2
915,KIF5B-RET,C,Sensitivity/Response,Lung Adenocarcinoma,5979.0,Vandetanib+Everolimus,RET
916,H1047R,C,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,Fulvestrant+Everolimus,PIK3CA
917,Expression,C,Resistance,Her2-receptor Positive Breast Cancer,5728.0,Fulvestrant+Everolimus,PTEN
918,H1047R,D,Sensitivity/Response,Thyroid Gland Cancer,5290.0,Perifosine+Temsirolimus,PIK3CA
919,E542K,D,Sensitivity/Response,Thyroid Gland Cancer,5290.0,Perifosine+Temsirolimus,PIK3CA
920,R130*,D,Sensitivity/Response,Thyroid Gland Cancer,5728.0,Temsirolimus+Perifosine,PTEN
921,LOSS-OF-FUNCTION,E,Sensitivity/Response,Renal Cell Carcinoma,55294.0,Everolimus,FBXW7
922,Amplification,D,Resistance,Estrogen-receptor Positive Breast Cancer,898.0,Palbociclib,CCNE1
923,M695FS*26,D,Resistance,Estrogen-receptor Positive Breast Cancer,5925.0,Palbociclib,RB1
924,MUTATION,B,Sensitivity/Response,Cancer,55294.0,MTOR Inhibitor,FBXW7
925,LOSS-OF-FUNCTION,D,Sensitivity/Response,Cancer,55294.0,Sirolimus,FBXW7
926,OVEREXPRESSION,C,Sensitivity/Response,Colorectal Adenocarcinoma,3725.0,Irbesartan,JUN
927,OVEREXPRESSION,C,Sensitivity/Response,Colon Adenocarcinoma,2353.0,Irbesartan,
928,L265P,D,Sensitivity/Response,Waldenstroem's Macroglobulinemia,4615.0,IRAK-1/4 Inhibitor+IMG-2005-5,MYD88
929,Mutation,B,Sensitivity/Response,Hepatocellular Carcinoma,3845.0,Refametinib+Sorafenib,KRAS
930,Deletion,B,Resistance,Colorectal Cancer,4089.0,Fluorouracil,SMAD4
931,Underexpression,B,Sensitivity/Response,Malignant Astrocytoma,546.0,PCV Regimen+Temozolomide,ATRX
932,Overexpression,B,Resistance,Ovarian Serous Carcinoma,6790.0,Platinum Compound,AURKA
933,EXON 14 SKIPPING MUTATION,C,Sensitivity/Response,Lung Adenocarcinoma,4233.0,Crizotinib,MET
934,D1228N,C,Resistance,Lung Non-small Cell Carcinoma,4233.0,Crizotinib,MET
935,EXPRESSION,B,Sensitivity/Response,Esophagus Squamous Cell Carcinoma,6790.0,Fluorouracil+Cisplatin+Radiation Therapy,AURKA
936,EXPRESSION,D,Resistance,Prostate Cancer,2621.0,Docetaxel,
937,UNDEREXPRESSION,D,Resistance,Melanoma,10735.0,Vemurafenib,STAG2
938,UNDEREXPRESSION,D,Resistance,Melanoma,10734.0,Vemurafenib,
939,Q56_V60del,C,Sensitivity/Response,Ovarian Serous Carcinoma,5604.0,Selumetinib,MAP2K1
940,BRAF-CUL1,C,Sensitivity/Response,Ovarian Serous Carcinoma,673.0,Mitogen-Activated Protein Kinase Kinase Inhibitor,BRAF
941,ZKSCAN1-BRAF,C,Sensitivity/Response,Melanoma,673.0,Trametinib,BRAF
942,KIAA1549-BRAF,C,Sensitivity/Response,Spindle Cell Sarcoma,673.0,Bevacizumab+Temsirolimus+Sorafenib,BRAF
943,L858R,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
944,Exon 19 Deletion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
945,T790M,B,Resistance,Lung Non-small Cell Carcinoma,1956.0,Gefitinib+Erlotinib,EGFR
946,L505H,D,Resistance,Melanoma,673.0,Vemurafenib,BRAF
947,L505H,B,Resistance,Melanoma,673.0,Vemurafenib,BRAF
948,E545K,C,Resistance,Lung Adenocarcinoma,5290.0,Gefitinib+Erlotinib,PIK3CA
949,Mutation,B,Sensitivity/Response,Ovarian Cancer,672.0,Cediranib+Olaparib,BRCA1
950,Mutation,B,Sensitivity/Response,Ovarian Cancer,675.0,Cediranib+Olaparib,BRCA2
951,Mutation,B,Sensitivity/Response,Triple-receptor Negative Breast Cancer,672.0,Cisplatin+Carboplatin,BRCA1
952,Mutation,B,Sensitivity/Response,Triple-receptor Negative Breast Cancer,675.0,Carboplatin+Cisplatin,BRCA2
953,Amplification,B,Resistance,Colorectal Cancer,2064.0,Cetuximab,ERBB2
954,Amplification,B,Resistance,Colorectal Cancer,2064.0,Cetuximab,ERBB2
955,Amplification,B,Resistance,Colorectal Cancer,2064.0,Cetuximab+Panitumumab,ERBB2
956,Amplification,B,Sensitivity/Response,Colorectal Cancer,2064.0,Trastuzumab+Lapatinib,ERBB2
957,REARRANGEMENT,C,Sensitivity/Response,Lung Adenocarcinoma,6098.0,Crizotinib,ROS1
958,Fusion,C,Sensitivity/Response,Lung Adenocarcinoma,238.0,Crizotinib,ALK
959,Amplification,C,Sensitivity/Response,Lung Adenocarcinoma,4233.0,Crizotinib,MET
960,Amplification,C,Sensitivity/Response,Scrotum Paget's Disease,2064.0,Trastuzumab,ERBB2
961,Mutation,C,Sensitivity/Response,Bladder Carcinoma,2064.0,Platinum Compound,ERBB2
962,V600E,C,Sensitivity/Response,Multiple Myeloma,673.0,Vemurafenib,BRAF
963,V600E,C,Sensitivity/Response,Multiple Myeloma,673.0,Vemurafenib,BRAF
964,Mutation,D,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
965,Mutation,D,Resistance,Colorectal Cancer,4893.0,Cetuximab,NRAS
966,Mutation,D,Resistance,Colorectal Cancer,673.0,Cetuximab,BRAF
967,Mutation,D,Resistance,Colorectal Cancer,5290.0,Cetuximab,PIK3CA
968,EXPRESSION,D,Sensitivity/Response,Multiple Myeloma,4610.0,I-BET151+JQ1,MYCL
969,EXPRESSION,D,Sensitivity/Response,Glioblastoma,3082.0,MET Tyrosine Kinase Inhibitor SGX523,HGF
970,Expression,B,Sensitivity/Response,Colorectal Cancer,1956.0,Panitumumab,EGFR
971,Expression,B,Sensitivity/Response,Colorectal Cancer,1956.0,Cetuximab,EGFR
972,LOSS,D,Resistance,Melanoma,6663.0,Vemurafenib,SOX10
973,EXPRESSION,D,Resistance,Acute Myeloid Leukemia,2247.0,Quizartinib,
974,Amplification,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,4233.0,Crizotinib,MET
975,Amplification,C,Sensitivity/Response,Cancer,4233.0,Crizotinib,MET
976,E384*,C,Sensitivity/Response,Cholangiocarcinoma,54206.0,Erlotinib,ERRFI1
977,D816V,B,Sensitivity/Response,Systemic Mastocytosis,3815.0,Midostaurin,KIT
978,S463P,D,Resistance,Estrogen-receptor Positive Breast Cancer,2099.0,Aromatase Inhibitor,ESR1
979,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
980,Overexpression,D,Resistance,Breast Cancer,6446.0,Alpelisib,SGK1
981,Overexpression,B,Resistance,Breast Cancer,6446.0,Alpelisib,SGK1
982,Overexpression,D,Sensitivity/Response,Breast Cancer,6446.0,SGK1-Inh+Alpelisib,SGK1
983,Expression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,29126.0,Pembrolizumab,CD274
984,Overexpression,D,Sensitivity/Response,Ovarian Cancer,898.0,CDK Inhibitor SNS-032,CCNE1
985,Amplification,D,Sensitivity/Response,Ovarian Serous Cystadenocarcinoma,898.0,Akt Inhibitor MK2206+Dinaciclib,CCNE1
986,G719S,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib+Gefitinib,EGFR
987,G596C,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,673.0,Dabrafenib+Trametinib,BRAF
988,UNDEREXPRESSION,D,Sensitivity/Response,Synovial Sarcoma,6598.0,Tazemetostat,SMARCB1
989,DELETION,D,Sensitivity/Response,Rhabdoid Cancer,6598.0,Tazemetostat,SMARCB1
990,Loss,D,Sensitivity/Response,Thyroid Gland Carcinoma,4771.0,Selumetinib,NF2
991,Loss,D,Sensitivity/Response,Malignant Peripheral Nerve Sheath Tumor,4763.0,JQ1 Compound,NF1
992,V104M,B,Sensitivity/Response,Transitional Cell Carcinoma,2065.0,Afatinib,ERBB3
993,R103G,B,Sensitivity/Response,Transitional Cell Carcinoma,2065.0,Afatinib,ERBB3
994,G284R,B,Sensitivity/Response,Transitional Cell Carcinoma,2065.0,Afatinib,ERBB3
995,V600E,B,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
996,V600,B,Sensitivity/Response,Melanoma,673.0,Trametinib,BRAF
997,A222V,B,Sensitivity/Response,Rectum Cancer,4524.0,Fluorouracil,
998,D761Y,C,Resistance,Lung Non-small Cell Carcinoma,1956.0,Gefitinib+Erlotinib,EGFR
999,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Trastuzumab Emtansine,ERBB2
1000,Loss,C,Sensitivity/Response,Her2-receptor Negative Breast Cancer,1029.0,Palbociclib+Letrozole,CDKN2A
1001,MUTATION,C,Resistance,Multiple Myeloma,51185.0,Pomalidomide+Lenalidomide,CRBN
1002,Amplification,D,Sensitivity/Response,Estrogen-receptor Positive Breast Cancer,2260.0,Ponatinib,FGFR1
1003,C481S,B,Resistance,Chronic Lymphocytic Leukemia,695.0,Ibrutinib,BTK
1004,Amplification,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,5156.0,Sunitinib,PDGFRA
1005,Mutation,B,Sensitivity/Response,Ovarian Cancer,672.0,Olaparib,BRCA1
1006,Mutation,B,Sensitivity/Response,Ovarian Cancer,675.0,Olaparib,BRCA2
1007,FIP1L1-PDGFRA,C,Sensitivity/Response,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",5156.0,Imatinib,PDGFRA
1008,Mutation,B,Resistance,Triple-receptor Negative Breast Cancer,672.0,Olaparib,BRCA1
1009,FIP1L1-PDGFRA,D,Sensitivity/Response,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",5156.0,Ponatinib,PDGFRA
1010,FIP1L1-PDGFRA T674I,D,Sensitivity/Response,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",5156.0,Ponatinib,PDGFRA
1011,G719,B,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
1012,BRD4-NUTM1,D,Sensitivity/Response,NUT Midline Carcinoma,23476.0,JQ1,BRD4
1013,S720,C,Resistance,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
1014,K757R,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
1015,E746G,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
1016,Exon 20 Insertion,C,Resistance,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
1017,UGT1A1*28,A,Adverse Response,Cancer,54658.0,Belinostat,
1018,UGT1A1*60,B,Adverse Response,Cancer,54658.0,Belinostat,
1019,V769_770insASV,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
1020,DPYD*2A HOMOZYGOSITY,A,Adverse Response,Cancer,1806.0,Tegafur+Capecitabine+Fluorouracil,
1021,DPYD*13 HOMOZYGOSITY,A,Adverse Response,Cancer,1806.0,Capecitabine+Fluorouracil+Tegafur,
1022,RS67376798 HOMOZYGOSITY,A,Adverse Response,Cancer,1806.0,Capecitabine+Tegafur+Fluorouracil,
1023,Exon 20 Insertion,B,Resistance,Lung Adenocarcinoma,1956.0,Afatinib,EGFR
1024,TNKS2-PDGFRA,C,Sensitivity/Response,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",5156.0,Imatinib,PDGFRA
1025,RS4149056,B,Adverse Response,Cancer,10599.0,Methotrexate,
1026,N130D,B,Adverse Response,Cancer,10599.0,Methotrexate,
1027,RS34743033,B,Adverse Response,Cancer,7298.0,Methotrexate,TYMS
1028,V855A,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,2065.0,Afatinib+Pertuzumab,ERBB3
1029,FGFR2-BICC1,D,Sensitivity/Response,Cholangiocarcinoma,2263.0,PD173074+Infigratinib,FGFR2
1030,FGFR2-AHCYL1,D,Sensitivity/Response,Cholangiocarcinoma,2263.0,Infigratinib+PD173074,FGFR2
1031,V253I,C,Sensitivity/Response,Ewing Sarcoma Of Bone,5789.0,Cixutumumab+Teprotumumab,PTPRD
1032,Overexpression,D,Resistance,Pancreatic Cancer,6240.0,Gemcitabine,RRM1
1033,OVEREXPRESSION,D,Resistance,Pancreatic Cancer,6241.0,Gemcitabine,RRM2
1034,MUTATION,C,Sensitivity/Response,Glioblastoma,5426.0,Pembrolizumab,POLE
1035,MUTATION,C,Sensitivity/Response,Endometrial Cancer,5426.0,Pembrolizumab,POLE
1036,T790M,B,Resistance,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1037,D1228V,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,4233.0,Cabozantinib,MET
1038,D1228V,C,Resistance,Lung Non-small Cell Carcinoma,4233.0,Savolitinib,MET
1039,MUTATION,B,Sensitivity/Response,Lung Small Cell Carcinoma,5925.0,Chemotherapy,RB1
1040,T790M,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Osimertinib,EGFR
1041,SQSTM1-NTRK1,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,4914.0,Entrectinib,NTRK1
1042,ETV6-NTRK3,C,Sensitivity/Response,Mammary Analogue Secretory Carcinoma,4916.0,Entrectinib,NTRK3
1043,ETV6-NTRK3 G623R,C,Resistance,Mammary Analogue Secretory Carcinoma,4916.0,Entrectinib,NTRK3
1044,LOSS,C,Sensitivity/Response,Transitional Cell Carcinoma,4436.0,Anti-PD-1 Monoclonal Antibody MEDI0680+Durvalumab,MSH2
1045,LOSS,C,Sensitivity/Response,Transitional Cell Carcinoma,2956.0,Anti-PD-1 Monoclonal Antibody MEDI0680+Durvalumab,MSH6
1046,Loss,D,Sensitivity/Response,Ewing Sarcoma,1029.0,Palbociclib+Linsitinib,CDKN2A
1047,LOSS,D,Sensitivity/Response,Ewing Sarcoma,1030.0,Palbociclib+Linsitinib,CDKN2B
1048,Loss,D,Sensitivity/Response,Dermatofibrosarcoma Protuberans,1029.0,Palbociclib,CDKN2A
1049,Y772_A775DUP,C,Sensitivity/Response,Lung Adenocarcinoma,2064.0,Afatinib,ERBB2
1050,G776L,C,Sensitivity/Response,Lung Adenocarcinoma,2064.0,Afatinib,ERBB2
1051,G778_P780DUP,C,Sensitivity/Response,Lung Adenocarcinoma,2064.0,Afatinib,ERBB2
1052,G778_P780DUP,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,2064.0,Dacomitinib,ERBB2
1053,M774DELINSWLV,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,2064.0,Dacomitinib,ERBB2
1054,Loss-of-function,D,Sensitivity/Response,Angiosarcoma,5787.0,Sunitinib+Vatalanib,PTPRB
1055,Mutation,B,Sensitivity/Response,Ovarian Cancer,672.0,Rucaparib,BRCA1
1056,G12D,C,Sensitivity/Response,Colorectal Cancer,3845.0,Therapeutic Tumor Infiltrating Lymphocytes,KRAS
1057,COPY-NEUTRAL LOSS OF HETEROZYGOSITY,C,Resistance,Colorectal Cancer,3107.0,Therapeutic Tumor Infiltrating Lymphocytes,HLA-C
1058,S703I,D,Sensitivity/Response,Hepatocellular Carcinoma,3716.0,Ruxolitinib,JAK1
1059,V600E,B,Sensitivity/Response,Colorectal Cancer,673.0,Irinotecan+Vemurafenib+Cetuximab,BRAF
1060,C121S,C,Resistance,Colorectal Cancer,5604.0,Cetuximab+Vemurafenib+Irinotecan,MAP2K1
1061,K57T,C,Resistance,Colorectal Cancer,5604.0,Vemurafenib+Cetuximab+Irinotecan,MAP2K1
1062,S490T,C,Resistance,Colorectal Cancer,369.0,Vemurafenib+Cetuximab+Irinotecan,ARAF
1063,R201C,C,Resistance,Colorectal Cancer,2778.0,Irinotecan+Vemurafenib+Cetuximab,GNAS
1064,Mutation,D,Sensitivity/Response,Mantle Cell Lymphoma,472.0,Olaparib,ATM
1065,Amplification,B,Sensitivity/Response,Lung Squamous Cell Carcinoma,2260.0,Infigratinib,FGFR1
1066,Mutation,B,Sensitivity/Response,Bladder Carcinoma,2261.0,Infigratinib,FGFR3
1067,Mutation,C,Sensitivity/Response,Cholangiocarcinoma,2263.0,Infigratinib,FGFR2
1068,Fusion,C,Sensitivity/Response,Cholangiocarcinoma,2263.0,Infigratinib,FGFR2
1069,AMPLIFICATION,D,Sensitivity/Response,Gastric Adenocarcinoma,253260.0,Vistusertib,RICTOR
1070,AMPLIFICATION,D,Sensitivity/Response,Lung Small Cell Carcinoma,253260.0,Sapanisertib+Vistusertib+MTOR Kinase Inhibitor AZD8055,RICTOR
1071,FGFR2-BICC1,C,Sensitivity/Response,Transitional Cell Carcinoma,2263.0,Erdafitinib,FGFR2
1072,Fusion,B,Sensitivity/Response,Cancer,2263.0,Erdafitinib,FGFR2
1073,FGFR3-TACC3,B,Sensitivity/Response,Cancer,2261.0,Erdafitinib,FGFR3
1074,FGFR2-BICC1,C,Sensitivity/Response,Endometrial Cancer,2263.0,Erdafitinib,FGFR2
1075,OVEREXPRESSION,D,Resistance,Breast Cancer,10000.0,Akt Inhibitor MK2206,AKT3
1076,OVEREXPRESSION,E,Sensitivity/Response,Triple-receptor Negative Breast Cancer,10000.0,Pan-AKT Kinase Inhibitor GSK690693,AKT3
1077,Loss-of-function,D,Sensitivity/Response,Breast Cancer,672.0,Pidnarulex+Quarfloxin,BRCA1
1078,Loss-of-function,D,Sensitivity/Response,Breast Cancer,675.0,Pidnarulex+Quarfloxin,BRCA2
1079,Alternative Transcript (ATI),C,Sensitivity/Response,Skin Melanoma,238.0,Crizotinib,ALK
1080,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1081,G469R,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,673.0,Sorafenib,BRAF
1082,G469V,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,673.0,Sorafenib,BRAF
1083,MUTATION,D,Sensitivity/Response,Uveal Melanoma,2767.0,Mirdametinib+Sotrastaurin Acetate,GNA11
1084,MUTATION,D,Sensitivity/Response,Uveal Melanoma,2776.0,Sotrastaurin Acetate+Mirdametinib,GNAQ
1085,LOSS,D,Sensitivity/Response,Head And Neck Cancer,4683.0,GPI-15427,NBN
1086,Q61L,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,3265.0,Everolimus+Selumetinib,HRAS
1087,Loss,D,Sensitivity/Response,Neuroblastoma,4763.0,Binimetinib,NF1
1088,Loss,D,Resistance,Melanoma,4763.0,Dabrafenib,NF1
1089,Mutation,B,Sensitivity/Response,Plexiform Neurofibroma,4763.0,Selumetinib,NF1
1090,EXPRESSION,D,Resistance,Estrogen-receptor Positive Breast Cancer,6790.0,Tamoxifen,AURKA
1091,Mutation,C,Sensitivity/Response,Prostate Cancer,472.0,Olaparib,ATM
1092,D419del,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1093,Biallelic Inactivation,C,Sensitivity/Response,Prostate Cancer,79728.0,Olaparib,PALB2
1094,DELETION,D,Sensitivity/Response,Rhabdoid Cancer,6598.0,Panobinostat,SMARCB1
1095,DELETION,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1387.0,C646,CREBBP
1096,AMPLIFICATION,C,Sensitivity/Response,Hepatocellular Carcinoma,2248.0,Sorafenib,FGF3
1097,Expression,D,Resistance,Breast Cancer,3084.0,Lapatinib,NRG1
1098,OVEREXPRESSION,B,Sensitivity/Response,Tenosynovial Giant Cell Tumor,1435.0,Pexidartinib,CSF1
1099,Overexpression,D,Resistance,Glioblastoma,6098.0,Gefitinib,ROS1
1100,Amplification,D,Resistance,Colorectal Cancer,4233.0,Anti-EGFR Monoclonal Antibody,MET
1101,P577S,D,Sensitivity/Response,Melanoma,5156.0,Imatinib+Crenolanib,PDGFRA
1102,R841K,D,Sensitivity/Response,Melanoma,5156.0,Crenolanib+Imatinib,PDGFRA
1103,H845Y,D,Sensitivity/Response,Melanoma,5156.0,Imatinib+Crenolanib,PDGFRA
1104,G853D,D,Sensitivity/Response,Melanoma,5156.0,Crenolanib+Imatinib,PDGFRA
1105,OVEREXPRESSION,D,Resistance,Melanoma,4286.0,PLX4720+Selumetinib,MITF
1106,Amplification,D,Sensitivity/Response,Colorectal Cancer,4233.0,Cetuximab+Crizotinib,MET
1107,Underexpression,D,Sensitivity/Response,Breast Cancer,4507.0,Pyrimidine Antagonist,MTAP
1108,UNDEREXPRESSION,D,Resistance,Ovarian Cancer,137492.0,Cetuximab,
1109,OVEREXPRESSION,D,Resistance,Esophageal Cancer,10413.0,Docetaxel+Fluorouracil,YAP1
1110,OVEREXPRESSION,D,Sensitivity/Response,Esophageal Cancer,10413.0,Verteporfin,YAP1
1111,Expression,B,Sensitivity/Response,Chordoma,1956.0,Lapatinib,EGFR
1112,T316A,C,Resistance,Chronic Lymphocytic Leukemia,695.0,Ibrutinib,BTK
1113,T862A,D,Sensitivity/Response,Stomach Carcinoma,2064.0,Lapatinib,ERBB2
1114,V773A,D,Sensitivity/Response,Breast Cancer,2064.0,Lapatinib,ERBB2
1115,N857S,D,Sensitivity/Response,Breast Cancer,2064.0,Lapatinib,ERBB2
1116,H878Y,D,Sensitivity/Response,Hepatocellular Carcinoma,2064.0,Lapatinib,ERBB2
1117,Amplification,B,Sensitivity/Response,Stomach Carcinoma,2263.0,FGFR Inhibitor AZD4547,FGFR2
1118,Amplification,C,Sensitivity/Response,Breast Cancer,2260.0,FGFR Inhibitor AZD4547,FGFR1
1119,Overexpression,C,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,2064.0,Lapatinib,ERBB2
1120,Amplification,B,Resistance,Colorectal Cancer,2064.0,Cetuximab,ERBB2
1121,c.393T>C,B,Resistance,Lung Non-small Cell Carcinoma,2778.0,Erlotinib+Gefitinib,GNAS
1122,G12D,D,Sensitivity/Response,Colorectal Cancer,4893.0,Dactolisib,NRAS
1123,G12D,C,Sensitivity/Response,Colorectal Cancer,4893.0,Dactolisib,NRAS
1124,G12V,D,Sensitivity/Response,Colorectal Cancer,3845.0,Selumetinib+Dactolisib,KRAS
1125,G12D,C,Resistance,Colorectal Cancer,4893.0,Cetuximab+Irinotecan,NRAS
1126,G12D,C,Sensitivity/Response,Colorectal Cancer,4893.0,Selumetinib,NRAS
1127,G12/G13,B,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1128,G12A,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1129,G12A,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1130,G12A,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1131,G12A,B,Resistance,Lung Cancer,3845.0,Gefitinib,KRAS
1132,G12A,B,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1133,G12A,B,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1134,G12A,B,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1135,G12A,D,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1136,G12A,D,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1137,G12A,D,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1138,R132L,B,Sensitivity/Response,Brain Glioma,3417.0,Temozolomide,IDH1
1139,R132L,B,Sensitivity/Response,Brain Glioma,3417.0,Temozolomide,IDH1
1140,R132L,B,Sensitivity/Response,Brain Glioma,3417.0,Temozolomide,IDH1
1141,R132,B,Sensitivity/Response,High Grade Glioma,3417.0,Bevacizumab+Sunitinib,IDH1
1142,R132L,B,Sensitivity/Response,Acute Myeloid Leukemia,3417.0,Ivosidenib,IDH1
1143,E542K,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,Pictilisib,PIK3CA
1144,E542K,D,Sensitivity/Response,Breast Cancer,5290.0,Pictilisib,PIK3CA
1145,E545K,D,Sensitivity/Response,Breast Cancer,5290.0,Pictilisib,PIK3CA
1146,Loss,B,Resistance,Her2-receptor Positive Breast Cancer,5728.0,Trastuzumab,PTEN
1147,E545K,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,5290.0,PI103,PIK3CA
1148,G13D,D,Resistance,Breast Cancer,3845.0,Pictilisib,KRAS
1149,Loss,B,Resistance,Breast Cancer,5728.0,Trastuzumab,PTEN
1150,Loss,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5728.0,Pictilisib,PTEN
1151,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib+Gefitinib,EGFR
1152,E542K,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,PI-103,PIK3CA
1153,E545K,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,Pictilisib,PIK3CA
1154,Amplification,D,Sensitivity/Response,Breast Cancer,2064.0,Pictilisib,ERBB2
1155,Mutation,C,Resistance,Breast Cancer,5290.0,Trastuzumab,PIK3CA
1156,C420R,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,Pictilisib,PIK3CA
1157,K111N,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,Pictilisib,PIK3CA
1158,Mutation,B,Resistance,Breast Cancer,5290.0,Trastuzumab,PIK3CA
1159,H1047L,D,Sensitivity/Response,Breast Cancer,5290.0,Pictilisib,PIK3CA
1160,H1047R,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,Pictilisib,PIK3CA
1161,Mutation,B,Resistance,Her2-receptor Positive Breast Cancer,5290.0,Trastuzumab,PIK3CA
1162,H1047R,D,Sensitivity/Response,Breast Cancer,5290.0,Pictilisib,PIK3CA
1163,H1047R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,5290.0,PI103,PIK3CA
1164,V600E,B,Resistance,Colorectal Cancer,673.0,Panitumumab+Cetuximab,BRAF
1165,V600E,B,Resistance,Colorectal Cancer,673.0,Oxaliplatin,BRAF
1166,V600E,B,Resistance,Colorectal Cancer,673.0,Irinotecan,BRAF
1167,V600E,C,Resistance,Colorectal Cancer,673.0,Irinotecan,BRAF
1168,V600E,B,Resistance,Colorectal Cancer,673.0,Capecitabine+Oxaliplatin+Bevacizumab,BRAF
1169,V600E,D,Sensitivity/Response,Melanoma,673.0,Sorafenib,BRAF
1170,V600E,D,Sensitivity/Response,Melanoma,673.0,Sorafenib,BRAF
1171,V600E,D,Sensitivity/Response,Melanoma,673.0,Mirdametinib,BRAF
1172,V600E,D,Sensitivity/Response,Melanoma,673.0,Mirdametinib,BRAF
1173,V600E,B,Sensitivity/Response,Melanoma,673.0,Dabrafenib,BRAF
1174,V600E,D,Sensitivity/Response,Melanoma,673.0,Dabrafenib,BRAF
1175,V600E,D,Sensitivity/Response,Melanoma,673.0,Dabrafenib,BRAF
1176,V600E,D,Sensitivity/Response,Melanoma,673.0,Selumetinib,BRAF
1177,V600E,D,Sensitivity/Response,Melanoma,673.0,Selumetinib,BRAF
1178,V600E,D,Sensitivity/Response,Melanoma,673.0,Trametinib,BRAF
1179,V600E,D,Sensitivity/Response,Melanoma,673.0,Dabrafenib,BRAF
1180,V600E,D,Sensitivity/Response,Melanoma,673.0,Dabrafenib,BRAF
1181,V600E,D,Sensitivity/Response,Melanoma,673.0,Trametinib,BRAF
1182,V600E,B,Sensitivity/Response,Melanoma,673.0,Trametinib,BRAF
1183,V600E,D,Sensitivity/Response,Thyroid Gland Cancer,673.0,MEK Inhibitor CI-1040,BRAF
1184,V600E,B,Sensitivity/Response,Thyroid Gland Cancer,673.0,MEK Inhibitor CI-1040,BRAF
1185,V600E,D,Sensitivity/Response,Thyroid Gland Cancer,673.0,RDEA 119,BRAF
1186,V600E,B,Sensitivity/Response,Thyroid Gland Cancer,673.0,RDEA 119,BRAF
1187,V600E,B,Sensitivity/Response,Thyroid Gland Cancer,673.0,RDEA 119,BRAF
1188,V600E,D,Sensitivity/Response,Thyroid Gland Cancer,673.0,Sorafenib,BRAF
1189,V600E,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,673.0,Mirdametinib,BRAF
1190,V600E,D,Sensitivity/Response,High Grade Glioma,673.0,Selumetinib,BRAF
1191,V600E,B,Sensitivity/Response,High Grade Glioma,673.0,Selumetinib,BRAF
1192,V600E,B,Sensitivity/Response,Skin Melanoma,673.0,Dabrafenib,BRAF
1193,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1194,L747_S752del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1195,L747_S752del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1196,L747_S752del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1197,L747_S752del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1198,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1199,L747_S752del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1200,Ex19 del L858R,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1201,T790M,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Osimertinib,EGFR
1202,T790M,C,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib+Gefitinib,EGFR
1203,T790M,C,Resistance,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1204,T790M,D,Resistance,Lung Non-small Cell Carcinoma,1956.0,Lapatinib,EGFR
1205,T790M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Dacomitinib,EGFR
1206,T790M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Neratinib,EGFR
1207,T790M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1208,T790M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1209,T790M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Canertinib,EGFR
1210,T790M,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Osimertinib,EGFR
1211,BCR-ABL F359V,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1212,BCR-ABL F359V,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1213,BCR-ABL F359V,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1214,BCR-ABL F359V,D,Resistance,Chronic Myeloid Leukemia,25.0,Nilotinib,ABL1
1215,Q61H,D,Sensitivity/Response,Colorectal Cancer,4893.0,Dactolisib,NRAS
1216,Q61H,C,Sensitivity/Response,Colorectal Cancer,4893.0,Dactolisib,NRAS
1217,Q61H,C,Sensitivity/Response,Colorectal Cancer,4893.0,Dactolisib,NRAS
1218,Q61H,D,Sensitivity/Response,Colorectal Cancer,4893.0,Selumetinib,NRAS
1219,Q61H,C,Sensitivity/Response,Colorectal Cancer,4893.0,Selumetinib,NRAS
1220,Q61H,C,Sensitivity/Response,Colorectal Cancer,4893.0,Selumetinib,NRAS
1221,Q61L,D,Sensitivity/Response,Colorectal Cancer,4893.0,Dactolisib,NRAS
1222,G13D,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1223,Q61L,C,Sensitivity/Response,Colorectal Cancer,4893.0,Dactolisib,NRAS
1224,Q61L,D,Sensitivity/Response,Colorectal Cancer,4893.0,Selumetinib,NRAS
1225,Q61L,C,Resistance,Colorectal Cancer,4893.0,Irinotecan+Cetuximab,NRAS
1226,Q61L,C,Sensitivity/Response,Colorectal Cancer,4893.0,Selumetinib,NRAS
1227,G13D,D,Sensitivity/Response,Colorectal Cancer,3845.0,Selumetinib+Dactolisib,KRAS
1228,Q61R,C,Resistance,Colorectal Cancer,4893.0,Cetuximab,NRAS
1229,Q61R,C,Sensitivity/Response,Colorectal Cancer,4893.0,Selumetinib,NRAS
1230,Q61R,D,Sensitivity/Response,Colorectal Cancer,4893.0,Dactolisib,NRAS
1231,Mutation,B,Resistance,Colorectal Cancer,673.0,Cetuximab+Chemotherapy,BRAF
1232,Q61R,C,Sensitivity/Response,Colorectal Cancer,4893.0,Dactolisib,NRAS
1233,Q61K,C,Resistance,Colorectal Cancer,4893.0,Cetuximab+Chemotherapy,NRAS
1234,Q61K,C,Sensitivity/Response,Colorectal Cancer,4893.0,Selumetinib,NRAS
1235,Q61K,C,Resistance,Melanoma,4893.0,Vemurafenib,NRAS
1236,Q61K,D,Sensitivity/Response,Colorectal Cancer,4893.0,Selumetinib+Dactolisib,NRAS
1237,G12D,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1238,Q61K,B,Sensitivity/Response,Colorectal Cancer,4893.0,Dactolisib,NRAS
1239,Q61K,C,Sensitivity/Response,Colorectal Cancer,4893.0,Dactolisib,NRAS
1240,Q61K,D,Sensitivity/Response,Colorectal Cancer,4893.0,Dactolisib,NRAS
1241,G13C,D,Sensitivity/Response,Colorectal Cancer,4893.0,Dactolisib,NRAS
1242,G13C,C,Sensitivity/Response,Colorectal Cancer,4893.0,Dactolisib,NRAS
1243,G13C,D,Sensitivity/Response,Colorectal Cancer,4893.0,Selumetinib,NRAS
1244,G13C,C,Sensitivity/Response,Colorectal Cancer,4893.0,Selumetinib,NRAS
1245,G13R,D,Sensitivity/Response,Colorectal Cancer,4893.0,Dactolisib,NRAS
1246,G13R,C,Resistance,Colorectal Cancer,4893.0,Cetuximab+Irinotecan,NRAS
1247,G13R,C,Sensitivity/Response,Colorectal Cancer,4893.0,Dactolisib,NRAS
1248,A146T,D,Sensitivity/Response,Colorectal Cancer,3845.0,Dactolisib+Selumetinib,KRAS
1249,G12D,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1250,G13R,C,Sensitivity/Response,Colorectal Cancer,4893.0,Selumetinib,NRAS
1251,A146V,D,Sensitivity/Response,Colorectal Cancer,3845.0,Selumetinib+Dactolisib,KRAS
1252,Mutation,B,Resistance,Colorectal Cancer,4893.0,Cetuximab+Chemotherapy,NRAS
1253,G12C,C,Sensitivity/Response,Colorectal Cancer,4893.0,Dactolisib,NRAS
1254,G12C,D,Sensitivity/Response,Colorectal Cancer,3845.0,Dactolisib+Selumetinib,KRAS
1255,G12C,C,Sensitivity/Response,Colorectal Cancer,4893.0,Selumetinib,NRAS
1256,G12S,D,Sensitivity/Response,Colorectal Cancer,4893.0,Dactolisib,NRAS
1257,G12S,C,Sensitivity/Response,Colorectal Cancer,4893.0,Dactolisib,NRAS
1258,G12D,D,Sensitivity/Response,Colorectal Cancer,3845.0,Dactolisib+Selumetinib,KRAS
1259,G12V,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1260,G12S,C,Sensitivity/Response,Colorectal Cancer,4893.0,Selumetinib,NRAS
1261,T2666A,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1262,Mutation,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1263,R3008C,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1264,c.902-1G>T,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1265,A146P,C,Resistance,Colorectal Cancer,3845.0,Cetuximab+Irinotecan,KRAS
1266,A146T,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1267,Q61H,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1268,Q61L,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1269,Q61R,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1270,Q61K,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1271,G12V,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1272,G12V,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1273,G12V,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1274,G12V,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1275,G12D,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1276,G12D,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1277,G12D,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1278,G12D,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1279,G12D,B,Resistance,Lung Cancer,3845.0,Gefitinib,KRAS
1280,G12D,B,Resistance,Lung Cancer,3845.0,Gefitinib,KRAS
1281,Mutation,B,Resistance,Lung Non-small Cell Carcinoma,3845.0,Erlotinib,KRAS
1282,G12D,B,Resistance,Lung Cancer,3845.0,Gefitinib,KRAS
1283,G12D,B,Resistance,Lung Cancer,3845.0,Gefitinib,KRAS
1284,G12D,B,Resistance,Lung Cancer,3845.0,Gefitinib,KRAS
1285,G12D,C,Resistance,Lung Cancer,3845.0,Gefitinib,KRAS
1286,G12D,B,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1287,G12D,B,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1288,G12D,B,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1289,G12D,D,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1290,G12D,D,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1291,G12D,D,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1292,G12C,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1293,G12C,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1294,G12C,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1295,G12C,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1296,G12C,B,Resistance,Lung Cancer,3845.0,Gefitinib,KRAS
1297,G12C,B,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1298,G12C,B,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1299,G12C,B,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1300,G12C,D,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1301,G12C,D,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1302,G12C,D,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1303,G12R,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1304,G12R,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1305,G12R,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1306,G12R,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1307,G12V,C,Resistance,Lung Cancer,3845.0,Gefitinib,KRAS
1308,G12S,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1309,G12S,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1310,G12S,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1311,G12S,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1312,G12S,B,Resistance,Lung Cancer,3845.0,Gefitinib,KRAS
1313,G12S,B,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1314,G12S,B,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1315,G12S,B,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1316,G12S,D,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1317,G12S,D,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1318,G12S,D,Resistance,Multiple Myeloma,3845.0,Melphalan,KRAS
1319,R273L,C,Resistance,Ovarian Cancer,7157.0,Cisplatin+Carboplatin,TP53
1320,Y220C,C,Sensitivity/Response,Stomach Carcinoma,7157.0,Etoposide+Cisplatin+Mitomycin,TP53
1321,R175H,C,Sensitivity/Response,Stomach Carcinoma,7157.0,EAP Protocol,TP53
1322,LOSS,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,6794.0,Sirolimus,STK11
1323,LOSS,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,6794.0,Sirolimus,STK11
1324,LOSS,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,6794.0,Sirolimus,STK11
1325,LOSS,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,6794.0,Sirolimus,STK11
1326,LOSS,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,6794.0,Sirolimus,STK11
1327,LOSS,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,6794.0,MEK Inhibitor CI-1040,STK11
1328,LOSS,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,6794.0,MEK Inhibitor CI-1040,STK11
1329,LOSS,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,6794.0,MEK Inhibitor CI-1040,STK11
1330,LOSS,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,6794.0,MEK Inhibitor CI-1040,STK11
1331,LOSS,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,6794.0,MEK Inhibitor CI-1040,STK11
1332,R132H,B,Sensitivity/Response,Brain Glioma,3417.0,Temozolomide,IDH1
1333,R132H,D,Sensitivity/Response,Brain Glioma,3417.0,BPTES,IDH1
1334,R132H,D,Sensitivity/Response,Glioblastoma,3417.0,Pan-Mutant-IDH1 Inhibitor Bay-1436032,IDH1
1335,R132C,B,Sensitivity/Response,Brain Glioma,3417.0,Temozolomide,IDH1
1336,R132C,B,Sensitivity/Response,Brain Glioma,3417.0,Temozolomide,IDH1
1337,R132C,B,Sensitivity/Response,Brain Glioma,3417.0,Temozolomide,IDH1
1338,R132C,D,Sensitivity/Response,High Grade Glioma,3417.0,AGI-5198,IDH1
1339,R132,B,Sensitivity/Response,High Grade Glioma,3417.0,Bevacizumab,IDH1
1340,R132C,B,Sensitivity/Response,Acute Myeloid Leukemia,3417.0,Ivosidenib,IDH1
1341,R132C,D,Sensitivity/Response,Acute Myeloid Leukemia,3417.0,BPTES,IDH1
1342,R132G,B,Sensitivity/Response,Brain Glioma,3417.0,Temozolomide,IDH1
1343,R132G,B,Sensitivity/Response,Brain Glioma,3417.0,Temozolomide,IDH1
1344,R132G,B,Sensitivity/Response,Brain Glioma,3417.0,Temozolomide,IDH1
1345,R132S,B,Sensitivity/Response,Brain Glioma,3417.0,Temozolomide,IDH1
1346,R132S,B,Sensitivity/Response,Brain Glioma,3417.0,Temozolomide,IDH1
1347,R132S,B,Sensitivity/Response,Brain Glioma,3417.0,Temozolomide,IDH1
1348,R132S,B,Sensitivity/Response,High Grade Glioma,3417.0,Bevacizumab,IDH1
1349,R132S,B,Sensitivity/Response,Acute Myeloid Leukemia,3417.0,Ivosidenib,IDH1
1350,R1275Q,B,Sensitivity/Response,Neuroblastoma,238.0,Crizotinib,ALK
1351,R1275Q,B,Sensitivity/Response,Neuroblastoma,238.0,Crizotinib,ALK
1352,EML4-ALK L1196M,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Ceritinib,ALK
1353,F1174L,B,Resistance,Neuroblastoma,238.0,Crizotinib,ALK
1354,F1174L,B,Resistance,Neuroblastoma,238.0,Crizotinib,ALK
1355,Mutation,B,Resistance,Lung Non-small Cell Carcinoma,5290.0,Erlotinib+Gefitinib,PIK3CA
1356,Mutation,B,Resistance,Lung Non-small Cell Carcinoma,3845.0,Gefitinib+Erlotinib,KRAS
1357,Y503_F504insAY,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1358,K550_W557del,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1359,K550_K558del,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1360,P551L,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1361,M552_W557DEL,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1362,Y553D,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1363,Y553_K558DEL,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1364,DEL 554-558,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1365,E554D,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1366,T417_D419delinsY,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1367,V555_Q556DEL,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1368,V555_P573DEL,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1369,W557R,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1370,W557G,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1371,W557T,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1372,W557_K558del,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1373,W557_E561del,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1374,K558Q,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1375,K558_V559del,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1376,K558R,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1377,V559DEL,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1378,D816V,D,Resistance,Cancer,3815.0,Imatinib,KIT
1379,V559_V560DEL,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1380,V559A,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1381,V559G,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1382,V560DEL,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1383,D842V,D,Resistance,Cancer,5156.0,Imatinib,PDGFRA
1384,V560D,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1385,K484_G487DEL,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1386,Exon 9 Mutation,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1387,V560G,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1388,V560G,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1389,Exon 11 Mutation,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1390,T574A,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1391,V561D,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,5156.0,Imatinib,PDGFRA
1392,Exon 13 Mutation,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1393,Q575L,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1394,Exon 9 Mutation,B,Reduced Sensitivity,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1395,D842V,C,Resistance,Gastrointestinal Stromal Tumor,5156.0,Imatinib,PDGFRA
1396,L576P,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1397,EXPRESSION,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1398,P577L,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1399,D579del,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1400,Mutation,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,5156.0,Imatinib,PDGFRA
1401,EXPRESSION,B,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1402,T661I,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1403,T661I,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1404,T661I,B,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1405,T661I,B,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1406,S692L,B,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1407,S692L,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1408,S692L,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1409,S692L,B,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1410,S692L,B,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1411,Q694K,B,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1412,Q694K,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1413,Q694K,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1414,Q694K,B,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1415,Q694K,B,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1416,V600E,B,Sensitivity/Response,Thyroid Gland Cancer,673.0,Sorafenib,BRAF
1417,V600K,B,Sensitivity/Response,Melanoma,673.0,Dabrafenib,BRAF
1418,V600K,B,Sensitivity/Response,Melanoma,673.0,Trametinib,BRAF
1419,V600K,B,Sensitivity/Response,Melanoma,673.0,Dabrafenib,BRAF
1420,G719A,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1421,E746_A750del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1422,E746_A750del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1423,Wildtype,B,Resistance,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1424,E746_A750del,C,Sensitivity/Response,Bronchiolo-alveolar Adenocarcinoma,1956.0,Erlotinib,EGFR
1425,E746_A750del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1426,E746_A750del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1427,E746_A750del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1428,E746_A750del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Durvalumab,EGFR
1429,Exon 19 Deletion,B,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Gefitinib,EGFR
1430,E746_T751>I,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1431,E746_T751>I,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1432,E746_T751>I,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1433,E746_T751>I,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1434,E746_T751>I,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1435,E746_T751delinsA,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1436,E746_T751delinsA,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1437,E746_T751delinsA,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1438,E746V,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1439,E746V,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1440,E746V,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1441,E746V,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1442,E746V,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1443,L747_A750>P,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1444,L747_A750>P,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1445,L747_A750>P,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1446,L747_A750>P,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1447,L747_A750>P,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1448,L747_T751delLREAT,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1449,L747_T751>Q,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1450,L747_T751>Q,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1451,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1452,L747_T751>Q,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1453,L747_T751>Q,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1454,L747_T751>Q,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1455,E746_S752delinsD,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1456,E746_S752delinsD,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1457,E746_S752delinsD,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1458,E746_S752delinsD,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1459,E746_S752delinsD,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1460,L747_T751delinsP,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1461,L747_T751delinsP,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1462,L747_T751delinsP,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1463,L747_T751delinsP,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1464,L747_T751delinsP,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1465,L747_T751delinsP,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1466,L747_T751delLREAT,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1467,L747_T751delLREAT,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1468,L747_T751delLREAT,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1469,L747_P753>Q,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1470,L747_P753>Q,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1471,L747_P753>Q,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1472,L747_P753>Q,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1473,L747_P753>Q,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1474,L747_T751delLREAT,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1475,L747_P753delinsS,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1476,L747_P753delinsS,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1477,L747_P753delinsS,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1478,L747_P753delinsS,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1479,L747_P753delinsS,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1480,S768I,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1481,S768I,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1482,S768I,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1483,G719S,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1484,R831H,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1485,R831H,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1486,R831H,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1487,L858R,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1488,L858R,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1489,L858R,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Gefitinib,EGFR
1490,E746_A750del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1491,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Lapatinib,EGFR
1492,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Dacomitinib,EGFR
1493,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Neratinib,EGFR
1494,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1495,L858R,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1496,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Canertinib,EGFR
1497,L858R,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
1498,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Durvalumab,EGFR
1499,L858R,B,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Gefitinib,EGFR
1500,BCR-ABL M244V,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1501,BCR-ABL M244V,D,Sensitivity/Response,Cancer,25.0,Imatinib,ABL1
1502,BCR-ABL M244V,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Nilotinib,ABL1
1503,BCR-ABL L248V,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1504,BCR-ABL L248V,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1505,BCR-ABL L248V,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1506,BCR-ABL L248V,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib+Imatinib Mesylate+Nilotinib,ABL1
1507,BCR-ABL G250E,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1508,BCR-ABL G250E,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1509,BCR-ABL G250E,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1510,BCR-ABL G250E,D,Resistance,Chronic Myeloid Leukemia,25.0,Nilotinib,ABL1
1511,BCR-ABL Q252H,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1512,BCR-ABL Q252H,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1513,BCR-ABL Q252H,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1514,BCR-ABL Y253H,D,Resistance,Chronic Myeloid Leukemia,25.0,Nilotinib+Imatinib Mesylate,ABL1
1515,BCR-ABL Y253F,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1516,BCR-ABL E255V,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1517,BCR-ABL Y253F,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1518,BCR-ABL E255K,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1519,BCR-ABL E255K,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1520,BCR-ABL E255K,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1521,BCR-ABL E255K,D,Resistance,Chronic Myeloid Leukemia,25.0,Nilotinib,ABL1
1522,BCR-ABL D276G,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1523,BCR-ABL D276G,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1524,BCR-ABL D276G,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Nilotinib,ABL1
1525,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1526,BCR-ABL T315I,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1527,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1528,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,25.0,Nilotinib,ABL1
1529,BCR-ABL T315I,D,Resistance,Cancer,25.0,Bafetinib+Nilotinib+Imatinib+Dasatinib,ABL1
1530,BCR-ABL T315I,B,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Ponatinib,ABL1
1531,BCR-ABL T315I,D,Sensitivity/Response,Acute Lymphoblastic Leukemia,25.0,Ponatinib,ABL1
1532,BCR-ABL F317L,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1533,BCR-ABL F317L,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1534,BCR-ABL F317L,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1535,BCR-ABL F317L,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1536,BCR-ABL S417Y,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1537,BCR-ABL F317L,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1538,Overexpression,D,Resistance,Chronic Myeloid Leukemia,5243.0,Dasatinib+Bafetinib,
1539,BCR-ABL M351T,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1540,BCR-ABL M351T,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1541,BCR-ABL M351T,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1542,BCR-ABL M351T,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Nilotinib,ABL1
1543,BCR-ABL H396R,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1544,BCR-ABL H396R,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1545,BCR-ABL H396R,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
1546,L1600P,C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,4851.0,Prednisone,NOTCH1
1547,L1574P,C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,4851.0,Prednisone,NOTCH1
1548,Mutation,C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,4851.0,Prednisone,NOTCH1
1549,Mutation,C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,4851.0,Prednisone,NOTCH1
1550,Y234C,C,Resistance,Ovarian Cancer,7157.0,Carboplatin+Cisplatin,TP53
1551,ALTERATION,B,Resistance,Ovarian Cancer,7157.0,Carboplatin+Cisplatin,TP53
1552,DNA Binding Domain Mutation,B,Resistance,Breast Cancer,7157.0,Tamoxifen,TP53
1553,Mutation,C,Resistance,Breast Cancer,7157.0,Tamoxifen,TP53
1554,Overexpression,B,Sensitivity/Response,Stomach Cancer,7157.0,Etoposide+Cisplatin+Mitomycin,TP53
1555,Q61P,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1556,Q61P,B,Resistance,Colorectal Cancer,3845.0,Irinotecan,KRAS
1557,Q61E,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1558,Q61E,B,Resistance,Colorectal Cancer,3845.0,Irinotecan,KRAS
1559,Q61FS,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1560,G464V,D,Sensitivity/Response,Breast Cancer,673.0,Sorafenib,BRAF
1561,K601E,B,Sensitivity/Response,Skin Melanoma,673.0,Dabrafenib,BRAF
1562,D594N,B,Sensitivity/Response,Skin Melanoma,673.0,Dabrafenib,BRAF
1563,D594N,D,Sensitivity/Response,Skin Melanoma,673.0,Dabrafenib,BRAF
1564,D594N,D,Sensitivity/Response,Skin Melanoma,673.0,Dabrafenib,BRAF
1565,D594N,D,Sensitivity/Response,Skin Melanoma,673.0,Dabrafenib,BRAF
1566,D594N,D,Sensitivity/Response,Skin Melanoma,673.0,Dabrafenib,BRAF
1567,R282L,C,Sensitivity/Response,Stomach Carcinoma,7157.0,EAP Protocol,TP53
1568,R213P,C,Sensitivity/Response,Stomach Carcinoma,7157.0,EAP Protocol,TP53
1569,Mutation,C,Sensitivity/Response,Stomach Carcinoma,7157.0,Doxorubicin+Cisplatin+Etoposide,TP53
1570,F1592S,C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,4851.0,Prednisone,NOTCH1
1571,L1600Q,C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,4851.0,Prednisone,NOTCH1
1572,L1585R,C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,4851.0,Prednisone,NOTCH1
1573,V1577A,C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,4851.0,Prednisone,NOTCH1
1574,V1577E,C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,4851.0,Prednisone,NOTCH1
1575,L1574Q,C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,4851.0,Prednisone,NOTCH1
1576,BCR-ABL F486S,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Nilotinib,ABL1
1577,c.7089+1del,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1578,c.7515+1_2del,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1579,K293*,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1580,R2459C,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1581,Q984E,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1582,F1025L,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1583,Q1084*,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1584,D1930V,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1585,R2034P,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1586,E2187*,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1587,L2427P,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1588,F2732V,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1589,R777FS,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1590,V1268FS,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1591,D1682H,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1592,A2062V,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1593,R1575H,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1594,A2274T,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1595,C2488Y,D,Resistance,Chronic Lymphocytic Leukemia,472.0,Doxorubicin,ATM
1596,BCR-ABL E255V,D,Resistance,Chronic Myeloid Leukemia,25.0,Nilotinib,ABL1
1597,BCR-ABL E255V,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate+Nilotinib,ABL1
1598,F1592C,C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,4851.0,Prednisone,NOTCH1
1599,BCR-ABL E292V,D,Resistance,Chronic Myeloid Leukemia,25.0,Nilotinib,ABL1
1600,BCR-ABL F359C,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate+Nilotinib,ABL1
1601,S501_A502INSAY,B,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1602,S501_A502INSAY,B,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1603,S501_A502INSAY,B,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1604,S501_A502INSAY,B,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1605,E746_T751delinsVA,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1606,BCR-ABL L384M,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate+Nilotinib,ABL1
1607,BCR-ABL V299L,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Nilotinib,ABL1
1608,BCR-ABL L387F,D,Resistance,Chronic Myeloid Leukemia,25.0,Nilotinib,ABL1
1609,BCR-ABL G398R,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Nilotinib,ABL1
1610,EML4-ALK S1206Y,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Ceritinib,ALK
1611,Mutation,B,Sensitivity/Response,Ovarian Cancer,675.0,Rucaparib,BRCA2
1612,Q1467*,C,Sensitivity/Response,Ovarian Cancer,672.0,Rucaparib,BRCA1
1613,M1R,C,Sensitivity/Response,Ovarian Cancer,675.0,Rucaparib,BRCA2
1614,M1I,C,Sensitivity/Response,Ovarian Cancer,675.0,Rucaparib,BRCA2
1615,V159M,C,Sensitivity/Response,Ovarian Cancer,675.0,Rucaparib,BRCA2
1616,V211L,C,Sensitivity/Response,Ovarian Cancer,675.0,Rucaparib,BRCA2
1617,V211I,C,Sensitivity/Response,Ovarian Cancer,675.0,Rucaparib,BRCA2
1618,R2336P,C,Sensitivity/Response,Ovarian Cancer,675.0,Rucaparib,BRCA2
1619,D820Y,C,Resistance,Melanoma,3815.0,Imatinib,KIT
1620,D820Y,D,Sensitivity/Response,Melanoma,3815.0,Sunitinib,KIT
1621,K642E,C,Sensitivity/Response,Mucosal Melanoma,3815.0,Imatinib,KIT
1622,V600E,D,Sensitivity/Response,Colorectal Cancer,673.0,Sorafenib+Cetuximab,BRAF
1623,c.393T>C,B,Resistance,Esophageal Cancer,2778.0,Fluorouracil+Cisplatin,GNAS
1624,Underexpression,B,Sensitivity/Response,Glioblastoma,4255.0,Temozolomide,MGMT
1625,OVEREXPRESSION,D,Sensitivity/Response,Clear Cell Renal Cell Carcinoma,7015.0,UO126,TERT
1626,Underexpression,B,Sensitivity/Response,High Grade Glioma,4255.0,Temozolomide,MGMT
1627,Underexpression,B,Sensitivity/Response,Oligodendroglioma,4255.0,Temozolomide,MGMT
1628,Underexpression,B,Sensitivity/Response,Glioblastoma,4255.0,Temozolomide,MGMT
1629,Underexpression,B,Sensitivity/Response,Neuroendocrine Tumor,4255.0,Temozolomide,MGMT
1630,Underexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,6240.0,Gemcitabine+Cisplatin,RRM1
1631,Q61K,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,4893.0,Selumetinib+Trametinib,NRAS
1632,Q61K,D,Sensitivity/Response,Lung Cancer,4893.0,Selumetinib+Trametinib,NRAS
1633,EXPRESSION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,5792.0,Erlotinib Hydrochloride,
1634,OVEREXPRESSION,D,Resistance,Skin Melanoma,165.0,Vemurafenib,
1635,EXPRESSION,D,Resistance,Lung Non-small Cell Carcinoma,7852.0,Cisplatin,CXCR4
1636,Expression,D,Sensitivity/Response,Sarcoma,2260.0,"Infigratinib+FGFR Inhibitor AZD4547+FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074",FGFR1
1637,AMPLIFICATION,B,Adverse Response,Cancer,4193.0,Pembrolizumab+Nivolumab+Ipilimumab,MDM2
1638,EXPRESSION,B,Adverse Response,Cancer,4194.0,Atezolizumab+Pembrolizumab+Nivolumab,MDM4
1639,N822K,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1640,Y823D,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1641,C809G,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1642,D820A,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1643,D820G,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1644,D816H,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1645,T670I,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1646,AMPLIFICATION,B,Adverse Response,Cancer,4194.0,Atezolizumab+Nivolumab+Pembrolizumab,MDM4
1647,Mutation,B,Resistance,Cancer,1788.0,Pembrolizumab+Nivolumab+Atezolizumab,DNMT3A
1648,Amplification,B,Resistance,Colorectal Cancer,3845.0,Cetuximab+Encorafenib,KRAS
1649,Amplification,C,Resistance,Colorectal Cancer,673.0,Dabrafenib+Panitumumab,BRAF
1650,F53L,C,Resistance,Colorectal Cancer,5604.0,Trametinib+Dabrafenib,MAP2K1
1651,Mutation,B,Sensitivity/Response,Skin Melanoma,4893.0,Binimetinib+Ribociclib,NRAS
1652,Mutation,D,Sensitivity/Response,Brain Glioma,3418.0,Olaparib,IDH2
1653,Mutation,D,Sensitivity/Response,Brain Glioma,3417.0,Olaparib,IDH1
1654,G2032R,C,Resistance,Lung Adenocarcinoma,6098.0,Crizotinib,ROS1
1655,K57N,D,Sensitivity/Response,Lung Adenocarcinoma,5604.0,Selumetinib,MAP2K1
1656,Mutation,B,Sensitivity/Response,Skin Melanoma,4893.0,Binimetinib,NRAS
1657,G12,B,Resistance,Lung Cancer,3845.0,Gefitinib,KRAS
1658,Mutation,B,Sensitivity/Response,Lung Cancer,1956.0,Gefitinib,EGFR
1659,Overexpression,B,Sensitivity/Response,Multiple Myeloma,1485.0,Letetresgene Autoleucel,
1660,Overexpression,B,Sensitivity/Response,Multiple Myeloma,30848.0,Letetresgene Autoleucel,
1661,A146T,D,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1662,A146T,D,Sensitivity/Response,Colorectal Cancer,3845.0,Mirdametinib,KRAS
1663,AMPLIFICATION,D,Resistance,Lung Non-small Cell Carcinoma,6608.0,Gefitinib,SMO
1664,AMPLIFICATION,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,6608.0,Sonidegib+Gefitinib,SMO
1665,Fusion,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,4914.0,Entrectinib,NTRK1
1666,Fusion,B,Sensitivity/Response,Cancer,4914.0,Entrectinib,NTRK1
1667,Fusion,B,Sensitivity/Response,Cancer,4916.0,Entrectinib,NTRK3
1668,SQSTM1-NTRK1,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,4914.0,Entrectinib,NTRK1
1669,REARRANGEMENT,B,Sensitivity/Response,Cancer,6098.0,Entrectinib,ROS1
1670,Fusion,B,Sensitivity/Response,Cancer,238.0,Entrectinib,ALK
1671,Fusion,C,Sensitivity/Response,Cancer,4914.0,Larotrectinib,NTRK1
1672,Fusion,B,Sensitivity/Response,Cancer,4916.0,Larotrectinib,NTRK3
1673,LMNA::NTRK1 e2-e11,C,Sensitivity/Response,Sarcoma,4914.0,Larotrectinib,NTRK1
1674,Fusion,C,Sensitivity/Response,Sarcoma,4914.0,Larotrectinib,NTRK1
1675,OVEREXPRESSION,D,Sensitivity/Response,Clear Cell Renal Cell Carcinoma,23476.0,JQ1,BRD4
1676,LMNA::NTRK1 e11-e10,C,Sensitivity/Response,Colorectal Adenocarcinoma,4914.0,Entrectinib,NTRK1
1677,LMNA-NTRK1 G595R and G667C,C,Resistance,Colorectal Adenocarcinoma,4914.0,Entrectinib,NTRK1
1678,Wildtype,D,Sensitivity/Response,Cancer,7157.0,Nutlin-3a,TP53
1679,Wildtype,D,Sensitivity/Response,Cancer,7157.0,MDM2 Inhibitor AMGMDS3,TP53
1680,Wildtype,B,Sensitivity/Response,Leukemia,7157.0,RG7112,TP53
1681,Deleterious Mutation,B,Resistance,Leukemia,7157.0,RG7112,TP53
1682,Deleterious Mutation,D,Resistance,Cancer,7157.0,MDM2 Inhibitor AMGMDS3,TP53
1683,Deleterious Mutation,D,Resistance,Cancer,7157.0,Nutlin-3a,TP53
1684,CYTOPLASMIC EXPRESSION,B,Sensitivity/Response,Triple-receptor Negative Breast Cancer,1017.0,Carboplatin+Eribulin,
1685,Q61H,C,Resistance,Colorectal Cancer,3845.0,Panitumumab+Trametinib,KRAS
1686,K57T,C,Resistance,Colorectal Cancer,5604.0,Cetuximab,MAP2K1
1687,M511I,D,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,3718.0,Tofacitinib,JAK3
1688,V722I,C,Sensitivity/Response,Lung Adenocarcinoma,3718.0,Atezolizumab,JAK3
1689,S61C,C,Sensitivity/Response,Lung Adenocarcinoma,3718.0,Atezolizumab,JAK3
1690,P429S,C,Resistance,Melanoma,3716.0,Pembrolizumab,JAK1
1691,W690*,C,Resistance,Colon Carcinoma,3716.0,Pembrolizumab,JAK1
1692,LOSS-OF-FUNCTION,D,Sensitivity/Response,Ovarian Clear Cell Carcinoma,8289.0,Dasatinib,ARID1A
1693,LOSS-OF-FUNCTION,D,Sensitivity/Response,Ovarian Clear Cell Carcinoma,8289.0,GSK126,ARID1A
1694,E545K,D,Sensitivity/Response,Cervix Carcinoma,5290.0,Cisplatin+Pictilisib,PIK3CA
1695,E545K,D,Resistance,Cervical Cancer,5290.0,Cisplatin,PIK3CA
1696,F1245V,C,Sensitivity/Response,Neuroblastoma,238.0,Entrectinib,ALK
1697,Activating Mutation,D,Resistance,Melanoma,1499.0,Anti-PD-L1 Monoclonal Antibody+Anti-CTLA-4 Monoclonal Antibody,CTNNB1
1698,OVEREXPRESSION,D,Sensitivity/Response,Melanoma,10461.0,UNC1062,MERTK
1699,Overexpression,D,Sensitivity/Response,Estrogen-receptor Negative Breast Cancer,5979.0,Vandetanib,RET
1700,L858R,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
1701,Exon 19 Deletion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
1702,Exon 19 Deletion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1703,L858R,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
1704,Mutation,A,Resistance,Lung Non-small Cell Carcinoma,3845.0,Selumetinib+Docetaxel,KRAS
1705,Expression,B,Resistance,Head And Neck Squamous Cell Carcinoma,29126.0,Radiation Therapy,CD274
1706,OVEREXPRESSION,D,Resistance,Breast Cancer,10000.0,Pan-AKT Kinase Inhibitor GSK690693,AKT3
1707,Overexpression,D,Sensitivity/Response,Lung Small Cell Carcinoma,4609.0,Cisplatin+Prexasertib+Olaparib,MYC
1708,L755S,D,Resistance,Breast Cancer,2064.0,Lapatinib,ERBB2
1709,L755P,D,Resistance,Breast Cancer,2064.0,Lapatinib,ERBB2
1710,T798M,D,Resistance,Breast Cancer,2064.0,Lapatinib,ERBB2
1711,D835V,D,Resistance,Acute Myeloid Leukemia,2322.0,Tandutinib,FLT3
1712,D835V,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sunitinib+Cytarabine,FLT3
1713,D835V,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Daunorubicin+Sunitinib,FLT3
1714,Overexpression,B,Resistance,Ovarian Cancer,7157.0,Cisplatin+Carboplatin,TP53
1715,Amplification,D,Resistance,Lung Non-small Cell Carcinoma,1956.0,Rociletinib+Osimertinib,EGFR
1716,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1717,V600E,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,673.0,Trametinib+Dabrafenib,BRAF
1718,Q61L,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,4893.0,Trametinib+Selumetinib,NRAS
1719,Q61R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,4893.0,Trametinib+Selumetinib,NRAS
1720,L768S,D,Sensitivity/Response,Breast Cancer,2064.0,Trastuzumab,ERBB2
1721,L638S,D,Sensitivity/Response,Breast Cancer,2064.0,Lapatinib,ERBB2
1722,V773,D,Sensitivity/Response,Breast Cancer,2064.0,Trastuzumab,ERBB2
1723,V773L,D,Sensitivity/Response,Breast Cancer,2064.0,Lapatinib,ERBB2
1724,K753E,D,Resistance,Breast Cancer,2064.0,Lapatinib,ERBB2
1725,L753E,B,Resistance,Breast Cancer,2064.0,Trastuzumab,ERBB2
1726,K755S,B,Resistance,Breast Cancer,2064.0,Trastuzumab,ERBB2
1727,Amplification,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,2260.0,Dovitinib,FGFR1
1728,V559D,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
1729,V559D,D,Sensitivity/Response,Cancer,3815.0,Dasatinib+Sunitinib+PD-180970+Tandutinib+Imatinib,KIT
1730,V559,D,Sensitivity/Response,Gastrointestinal System Cancer,3815.0,Imatinib+Dasatinib,KIT
1731,D835V,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,JQ-1,FLT3
1732,V559D,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Nilotinib+Sorafenib+Dasatinib+Imatinib,KIT
1733,D835V,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,AS602868+Tyrphostin AG 1296,FLT3
1734,G13V,B,Resistance,Head And Neck Squamous Cell Carcinoma,4893.0,Cetuximab,NRAS
1735,L3 Domain Mutation,B,Resistance,Breast Cancer,7157.0,Tamoxifen,TP53
1736,Overexpression,D,Sensitivity/Response,Uveal Melanoma,4233.0,Mitogen-Activated Protein Kinase Kinase Inhibitor+C-Met Inhibitor+ERBB3 Inhibitor,MET
1737,Overexpression,D,Resistance,Uveal Melanoma,4233.0,Selumetinib+Trametinib,MET
1738,E17K,B,Sensitivity/Response,Cancer,207.0,Capivasertib,AKT1
1739,Mutation,B,Sensitivity/Response,Cancer,5290.0,Capivasertib,PIK3CA
1740,R248Q,D,Resistance,Cancer,7157.0,MDM2 Inhibitor AMGMDS3,TP53
1741,R201H,C,Sensitivity/Response,Thyroid Gland Follicular Carcinoma,2778.0,Radioactive Iodine,GNAS
1742,MUTATION,B,Sensitivity/Response,Uveal Melanoma,2767.0,Cabozantinib,GNA11
1743,Overexpression,D,Resistance,Uveal Melanoma,2065.0,Selumetinib+Trametinib,ERBB3
1744,EXPRESSION,D,Sensitivity/Response,Melanoma,2065.0,Pertuzumab,ERBB3
1745,NON-AMPLIFICATION,B,Sensitivity/Response,Her2-receptor Negative Breast Cancer,2064.0,Lapatinib,ERBB2
1746,Overexpression,B,Sensitivity/Response,Breast Cancer,2065.0,Lapatinib,ERBB3
1747,Q61H,C,Resistance,Colorectal Cancer,4893.0,Cetuximab+Irinotecan,NRAS
1748,G12D,D,Resistance,Colorectal Cancer,4893.0,Cetuximab,NRAS
1749,G12D,D,Resistance,Colorectal Cancer,4893.0,Cetuximab,NRAS
1750,G12D,B,Resistance,Colorectal Cancer,4893.0,Cetuximab,NRAS
1751,C634W,D,Resistance,Thyroid Gland Medullary Carcinoma,5979.0,Axitinib,RET
1752,C634W,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,5979.0,Regorafenib,RET
1753,M918T,D,Resistance,Thyroid Gland Medullary Carcinoma,5979.0,Axitinib,RET
1754,G12D,D,Resistance,Head And Neck Cancer,3265.0,Erlotinib,HRAS
1755,G12D,C,Resistance,Skin Squamous Cell Carcinoma,3265.0,Vemurafenib,HRAS
1756,G12A,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1757,G12A,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1758,G12A,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1759,G12A,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1760,Mutation,B,Resistance,Colorectal Cancer,3845.0,Chemotherapy+Cetuximab,KRAS
1761,G12A,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1762,G12A,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1763,G12A,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1764,G12A,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1765,G12A,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1766,G12A,D,Resistance,Colorectal Cancer,3845.0,Regorafenib,KRAS
1767,G12A,D,Resistance,Colorectal Cancer,3845.0,Sunitinib,KRAS
1768,G12A,C,Resistance,Lung Cancer,3845.0,Erlotinib,KRAS
1769,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,3845.0,Erlotinib+Teprotumumab,KRAS
1770,G12A,C,Resistance,Lung Non-small Cell Carcinoma,3845.0,Erlotinib,KRAS
1771,G12A,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,3845.0,Regorafenib,KRAS
1772,G12A,C,Resistance,Colon Cancer,3845.0,Cetuximab,KRAS
1773,R132,B,Sensitivity/Response,Glioblastoma,3417.0,Cetuximab,IDH1
1774,E545K,D,Resistance,Melanoma,5290.0,Vemurafenib,PIK3CA
1775,E545G,D,Resistance,Melanoma,5290.0,Vemurafenib,PIK3CA
1776,H1047R,D,Resistance,Colorectal Cancer,5290.0,Vemurafenib,PIK3CA
1777,W535L,D,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
1778,W535L,C,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
1779,V600E,B,Resistance,Colorectal Cancer,673.0,Cetuximab,BRAF
1780,V600E,C,Resistance,Colorectal Cancer,673.0,Irinotecan+Cetuximab,BRAF
1781,V600E,B,Resistance,Colorectal Cancer,673.0,Cetuximab+FOLFOX-4 Regimen,BRAF
1782,V600E,C,Resistance,Colorectal Cancer,673.0,Cetuximab,BRAF
1783,V600E,D,Sensitivity/Response,Colorectal Cancer,673.0,Vemurafenib,BRAF
1784,V600E,C,Sensitivity/Response,Colorectal Cancer,673.0,Vemurafenib,BRAF
1785,V600E,C,Sensitivity/Response,Thyroid Gland Anaplastic Carcinoma,673.0,Vemurafenib+Radiation Therapy,BRAF
1786,V600E,C,Sensitivity/Response,Thyroid Gland Anaplastic Carcinoma,673.0,Vemurafenib,BRAF
1787,V600E,D,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
1788,V600E,D,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
1789,V600E,D,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
1790,V600E,D,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
1791,V600E,C,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
1792,V600E,B,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
1793,V600E,D,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
1794,V600E,D,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
1795,V600E,D,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
1796,V600E,C,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
1797,V600E,B,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
1798,V600E,D,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
1799,V600E,B,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
1800,V600E,B,Sensitivity/Response,Skin Melanoma,673.0,Trametinib+Dabrafenib,BRAF
1801,V600E,D,Resistance,Melanoma,673.0,Dasatinib,BRAF
1802,V600E,D,Sensitivity/Response,Thyroid Gland Cancer,673.0,Vemurafenib,BRAF
1803,V600E,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,673.0,Vemurafenib,BRAF
1804,V600E,D,Sensitivity/Response,High Grade Glioma,673.0,Vemurafenib,BRAF
1805,V600E,B,Sensitivity/Response,High Grade Glioma,673.0,Vemurafenib,BRAF
1806,V600E,B,Sensitivity/Response,High Grade Glioma,673.0,Vemurafenib,BRAF
1807,V600E,B,Sensitivity/Response,High Grade Glioma,673.0,Vemurafenib,BRAF
1808,V600E,C,Sensitivity/Response,Hairy Cell Leukemia,673.0,Vemurafenib,BRAF
1809,V600E,C,Sensitivity/Response,Hairy Cell Leukemia,673.0,Vemurafenib,BRAF
1810,V600E,C,Sensitivity/Response,Hairy Cell Leukemia,673.0,Vemurafenib,BRAF
1811,V600E,C,Sensitivity/Response,Hairy Cell Leukemia,673.0,Vemurafenib,BRAF
1812,V600E,C,Sensitivity/Response,Hairy Cell Leukemia,673.0,Vemurafenib,BRAF
1813,V600E,C,Sensitivity/Response,Glioblastoma,673.0,Vemurafenib,BRAF
1814,V600E,C,Sensitivity/Response,Pilocytic Astrocytoma,673.0,Vemurafenib,BRAF
1815,V600E,C,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,673.0,Vemurafenib,BRAF
1816,V600E,C,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,673.0,Vemurafenib,BRAF
1817,V600E,D,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,673.0,Dasatinib,BRAF
1818,V600E,D,Sensitivity/Response,Colon Cancer,673.0,Regorafenib,BRAF
1819,V600E,C,Sensitivity/Response,Childhood Pilocytic Astrocytoma,673.0,Vemurafenib,BRAF
1820,V600E,C,Sensitivity/Response,Ganglioglioma,673.0,Vemurafenib,BRAF
1821,V600E,C,Sensitivity/Response,Clear Cell Sarcoma,673.0,Vemurafenib,BRAF
1822,V600E,C,Sensitivity/Response,Lung Adenocarcinoma,673.0,Vemurafenib,BRAF
1823,V600E,C,Sensitivity/Response,Lung Adenocarcinoma,673.0,Vemurafenib,BRAF
1824,V600E,B,Sensitivity/Response,Lung Adenocarcinoma,673.0,Vemurafenib,BRAF
1825,V600E,C,Sensitivity/Response,Lung Adenocarcinoma,673.0,Vemurafenib,BRAF
1826,V600E,D,Sensitivity/Response,Thyroid Gland Carcinoma,673.0,Vemurafenib,BRAF
1827,V600E,D,Sensitivity/Response,Thyroid Gland Carcinoma,673.0,Vemurafenib,BRAF
1828,V600E,C,Sensitivity/Response,Pleomorphic Xanthoastrocytoma,673.0,Vemurafenib,BRAF
1829,V600E,C,Sensitivity/Response,Ovarian Serous Carcinoma,673.0,Vemurafenib,BRAF
1830,V600E,C,Sensitivity/Response,Malignant Peripheral Nerve Sheath Tumor,673.0,Vemurafenib,BRAF
1831,V600E,C,Sensitivity/Response,Histiocytoma,673.0,Vemurafenib,BRAF
1832,V600E,C,Sensitivity/Response,Malignant Conjunctival Melanoma,673.0,Vemurafenib,BRAF
1833,Ex19 del L858R,B,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
1834,E709_T710>D,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1835,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
1836,L747_S752del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
1837,Overexpression,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
1838,L747_S752del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
1839,T790M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
1840,L861Q,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
1841,S752_I759delSPKANKEI,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
1842,T790M,C,Resistance,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
1843,T790M,C,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
1844,T790M,D,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
1845,T790M,D,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
1846,T790M,D,Resistance,Cancer,1956.0,Multikinase Inhibitor AEE788+Erlotinib+Gefitinib,EGFR
1847,L858R,D,Sensitivity/Response,Cancer,1956.0,Multikinase Inhibitor AEE788+Erlotinib+Gefitinib,EGFR
1848,E884K,C,Resistance,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
1849,BCR-ABL F359V,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
1850,BCR-ABL F359V,C,Reduced Sensitivity,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
1851,BCR-ABL F359V,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
1852,BCR-ABL F359V,C,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
1853,BCR-ABL F359V,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
1854,Q61H,C,Resistance,Colorectal Cancer,4893.0,Cetuximab,NRAS
1855,G12V,C,Resistance,Colorectal Cancer,3845.0,Panitumumab,KRAS
1856,Q61L,D,Resistance,Melanoma,4893.0,Vemurafenib,NRAS
1857,V600E,C,Resistance,Colorectal Cancer,673.0,Panitumumab,BRAF
1858,Q61R,D,Resistance,Colorectal Cancer,4893.0,Cetuximab,NRAS
1859,Q61R,D,Resistance,Skin Melanoma,4893.0,Vemurafenib,NRAS
1860,Q61R,D,Resistance,Thyroid Gland Carcinoma,4893.0,Vemurafenib,NRAS
1861,Q61K,B,Resistance,Colorectal Cancer,4893.0,Cetuximab,NRAS
1862,Q61K,D,Resistance,Colorectal Cancer,4893.0,Cetuximab,NRAS
1863,Q61K,D,Resistance,Melanoma,4893.0,Vemurafenib,NRAS
1864,Q61K,D,Resistance,Melanoma,4893.0,Vemurafenib,NRAS
1865,Q61K,D,Resistance,Skin Melanoma,4893.0,Vemurafenib,NRAS
1866,Q61K,D,Resistance,Lung Non-small Cell Carcinoma,4893.0,Erlotinib,NRAS
1867,G13D,D,Resistance,Colorectal Cancer,4893.0,Cetuximab,NRAS
1868,H1047R,C,Resistance,Colorectal Cancer,5290.0,Cetuximab+Irinotecan,PIK3CA
1869,G13R,C,Resistance,Colorectal Cancer,4893.0,Panitumumab,NRAS
1870,G13R,C,Resistance,Melanoma,4893.0,Vemurafenib,NRAS
1871,G12C,C,Resistance,Colorectal Cancer,4893.0,Cetuximab+Chemotherapy,NRAS
1872,G12C,D,Resistance,Colorectal Cancer,4893.0,Cetuximab,NRAS
1873,G1049R,C,Resistance,Colorectal Cancer,5290.0,Cetuximab,PIK3CA
1874,Q61L,C,Resistance,Skin Squamous Cell Carcinoma,3265.0,Vemurafenib,HRAS
1875,Q61R,C,Resistance,Skin Squamous Cell Carcinoma,3265.0,Vemurafenib,HRAS
1876,Q61K,C,Resistance,Skin Squamous Cell Carcinoma,3265.0,Vemurafenib,HRAS
1877,G13D,C,Resistance,Skin Squamous Cell Carcinoma,3265.0,Vemurafenib,HRAS
1878,G13D,D,Resistance,Colorectal Cancer,3265.0,Cetuximab,HRAS
1879,G13R,D,Resistance,Thyroid Gland Carcinoma,3265.0,Vemurafenib,HRAS
1880,G12V,D,Resistance,Head And Neck Cancer,3265.0,Erlotinib,HRAS
1881,G12V,D,Resistance,Colorectal Cancer,3265.0,Cetuximab,HRAS
1882,A146P,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1883,A146T,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1884,A146T,B,Resistance,Colorectal Cancer,3845.0,Cetuximab+FOLFOX-4 Regimen,KRAS
1885,A146T,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1886,Q61H,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1887,Q61H,C,Resistance,Colorectal Cancer,3845.0,Cetuximab+Chemotherapy,KRAS
1888,Q61H,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1889,Q61H,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1890,Mutation,B,Sensitivity/Response,Lung Cancer,1956.0,Erlotinib,EGFR
1891,Q61H,D,Resistance,Lung Non-small Cell Carcinoma,3845.0,Vemurafenib,KRAS
1892,Q61L,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1893,Q61L,C,Resistance,Colorectal Cancer,3845.0,Cetuximab+Chemotherapy,KRAS
1894,Q61L,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1895,Q61R,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1896,Q61R,C,Resistance,Colorectal Cancer,3845.0,Cetuximab+Irinotecan,KRAS
1897,Q61K,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1898,Q61K,C,Resistance,Colorectal Cancer,3845.0,Chemotherapy+Cetuximab,KRAS
1899,G13D,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1900,G13D,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1901,G13D,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1902,G13D,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1903,G13D,D,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1904,G13D,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1905,G13D,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1906,G13D,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1907,G13D,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1908,G13D,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1909,G13D,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1910,G13D,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1911,G13D,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1912,G13D,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1913,G13D,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1914,G13D,D,Resistance,Colorectal Cancer,3845.0,Regorafenib,KRAS
1915,G13D,D,Resistance,Colorectal Cancer,3845.0,Sunitinib,KRAS
1916,G13D,D,Sensitivity/Response,Colorectal Cancer,3845.0,Palbociclib,KRAS
1917,G13D,C,Resistance,Lung Non-small Cell Carcinoma,3845.0,Erlotinib,KRAS
1918,G13D,C,Resistance,Lung Non-small Cell Carcinoma,3845.0,Erlotinib,KRAS
1919,Mutation,B,Resistance,Lung Non-small Cell Carcinoma,3845.0,Erlotinib,KRAS
1920,G13D,C,Resistance,Colon Cancer,3845.0,Cetuximab,KRAS
1921,G13D,D,Sensitivity/Response,Colon Cancer,3845.0,Regorafenib,KRAS
1922,G13C,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1923,G13C,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1924,G13C,C,Resistance,Lung Non-small Cell Carcinoma,3845.0,Erlotinib,KRAS
1925,G13C,C,Resistance,Lung Non-small Cell Carcinoma,3845.0,Erlotinib,KRAS
1926,G13R,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1927,G13R,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1928,G13S,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1929,G13S,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1930,G12V,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1931,G12V,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1932,G12V,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1933,G12V,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1934,G12V,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1935,Q61,B,Resistance,Colorectal Cancer,3845.0,Chemotherapy+Cetuximab,KRAS
1936,G12V,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1937,G12V,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1938,G12V,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1939,G12V,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1940,G12V,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1941,G12V,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1942,G12V,D,Resistance,Colorectal Cancer,3845.0,Regorafenib,KRAS
1943,G12V,D,Resistance,Colorectal Cancer,3845.0,Sunitinib,KRAS
1944,G12V,D,Sensitivity/Response,Colorectal Cancer,3845.0,Palbociclib,KRAS
1945,G12V,C,Resistance,Lung Non-small Cell Carcinoma,3845.0,Erlotinib,KRAS
1946,G12V,C,Resistance,Lung Non-small Cell Carcinoma,3845.0,Erlotinib,KRAS
1947,G12V,C,Resistance,Colon Cancer,3845.0,Cetuximab,KRAS
1948,G12V,D,Sensitivity/Response,Colon Cancer,3845.0,Regorafenib,KRAS
1949,G12D,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1950,G12D,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1951,G12D,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1952,G12D,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1953,G12D,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1954,G12D,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1955,G12D,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1956,G12D,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1957,G12D,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1958,G12D,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1959,G12D,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1960,G12D,D,Resistance,Colorectal Cancer,3845.0,Regorafenib,KRAS
1961,G12D,C,Resistance,Colorectal Cancer,3845.0,Regorafenib,KRAS
1962,G12D,D,Resistance,Colorectal Cancer,3845.0,Sunitinib,KRAS
1963,G12D,C,Resistance,Lung Cancer,3845.0,Erlotinib,KRAS
1964,G12D,B,Resistance,Lung Cancer,3845.0,Erlotinib,KRAS
1965,G12D,B,Resistance,Lung Cancer,3845.0,Erlotinib,KRAS
1966,G12D,B,Resistance,Lung Cancer,3845.0,Erlotinib,KRAS
1967,G12D,B,Resistance,Lung Cancer,3845.0,Erlotinib,KRAS
1968,G12D,C,Resistance,Lung Non-small Cell Carcinoma,3845.0,Erlotinib,KRAS
1969,G12D,D,Resistance,Melanoma,3845.0,Vemurafenib,KRAS
1970,G12D,D,Resistance,Ovarian Cancer,3845.0,Cetuximab,KRAS
1971,G12D,D,Resistance,Pancreatic Cancer,3845.0,Vemurafenib,KRAS
1972,G12D,C,Resistance,Colon Cancer,3845.0,Cetuximab,KRAS
1973,G12D,C,Resistance,Skin Squamous Cell Carcinoma,3845.0,Vemurafenib,KRAS
1974,G12C,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1975,G12C,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1976,G12C,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1977,G12C,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1978,G12C,B,Resistance,Colorectal Cancer,3845.0,Cetuximab+Chemotherapy,KRAS
1979,G12C,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1980,G12C,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1981,G12C,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1982,G12C,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1983,G12C,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1984,G12C,D,Resistance,Colorectal Cancer,3845.0,Regorafenib,KRAS
1985,G12C,D,Resistance,Colorectal Cancer,3845.0,Sunitinib,KRAS
1986,G12C,D,Sensitivity/Response,Colorectal Cancer,3845.0,Palbociclib,KRAS
1987,G12C,C,Resistance,Lung Non-small Cell Carcinoma,3845.0,Erlotinib,KRAS
1988,G12C,C,Resistance,Lung Non-small Cell Carcinoma,3845.0,Erlotinib,KRAS
1989,G12C,C,Resistance,Lung Non-small Cell Carcinoma,3845.0,Crizotinib,KRAS
1990,G12C,C,Resistance,Colon Cancer,3845.0,Cetuximab,KRAS
1991,G12C,C,Resistance,Skin Squamous Cell Carcinoma,3845.0,Vemurafenib,KRAS
1992,G12C,C,Resistance,Lung Adenocarcinoma,3845.0,Crizotinib,KRAS
1993,G12R,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1994,G12R,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1995,G12R,C,Resistance,Colorectal Cancer,3845.0,Chemotherapy+Cetuximab,KRAS
1996,G12R,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1997,G12R,D,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1998,G12R,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
1999,G12R,D,Resistance,Colorectal Cancer,3845.0,Regorafenib,KRAS
2000,G12R,D,Resistance,Colorectal Cancer,3845.0,Sunitinib,KRAS
2001,G12R,C,Resistance,Lung Non-small Cell Carcinoma,3845.0,Erlotinib,KRAS
2002,G12R,C,Resistance,Lung Non-small Cell Carcinoma,3845.0,Erlotinib,KRAS
2003,G12R,D,Sensitivity/Response,Thyroid Gland Cancer,3845.0,Dasatinib,KRAS
2004,G12R,C,Resistance,Colon Cancer,3845.0,Cetuximab,KRAS
2005,G12R,D,Resistance,Thyroid Gland Carcinoma,3845.0,Vemurafenib,KRAS
2006,G12S,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
2007,G12S,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
2008,G12S,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
2009,G12S,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
2010,G12S,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
2011,G12S,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
2012,G12S,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
2013,G12S,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
2014,G12S,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
2015,G12S,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
2016,G12S,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
2017,G12S,D,Resistance,Colorectal Cancer,3845.0,Regorafenib,KRAS
2018,G12S,C,Resistance,Lung Non-small Cell Carcinoma,3845.0,Erlotinib,KRAS
2019,G12S,D,Resistance,Colorectal Cancer,3845.0,Sunitinib,KRAS
2020,G12S,C,Resistance,Lung Non-small Cell Carcinoma,3845.0,Erlotinib,KRAS
2021,G12S,D,Resistance,Lung Non-small Cell Carcinoma,3845.0,Erlotinib,KRAS
2022,G12S,D,Resistance,Lung Non-small Cell Carcinoma,3845.0,Vemurafenib,KRAS
2023,G12S,D,Resistance,Lung Squamous Cell Carcinoma,3845.0,Dasatinib,KRAS
2024,D835E,C,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sunitinib,FLT3
2025,D835V,C,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sunitinib,FLT3
2026,D835V,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sunitinib,FLT3
2027,D835,C,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sunitinib,FLT3
2028,D835,C,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sunitinib,FLT3
2029,D835,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sunitinib,FLT3
2030,D835H,C,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sunitinib,FLT3
2031,D835H,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sunitinib,FLT3
2032,E17K,D,Resistance,Melanoma,207.0,Vemurafenib,AKT1
2033,F57C,C,Sensitivity/Response,Melanoma,5605.0,Vemurafenib,MAP2K2
2034,R132,B,Sensitivity/Response,Glioblastoma,3417.0,Cetuximab,IDH1
2035,R132S,B,Sensitivity/Response,Glioblastoma,3417.0,Cetuximab,IDH1
2036,EML4-ALK L1196M,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2037,EML4-ALK L1196M,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2038,EML4-ALK L1196M,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2039,EML4-ALK L1196M,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2040,EML4-ALK L1196M,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2041,EML4-ALK L1196M,D,Resistance,Lung Adenocarcinoma,238.0,Crizotinib,ALK
2042,EML4-ALK L1196M,C,Resistance,Lung Adenocarcinoma,238.0,Crizotinib,ALK
2043,F1174L,D,Resistance,Lung Large Cell Carcinoma,238.0,Crizotinib,ALK
2044,EML4-ALK C1156Y,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2045,EML4-ALK C1156Y,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2046,EML4-ALK C1156Y,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2047,EML4-ALK C1156Y,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2048,EML4-ALK C1156Y,C,Resistance,Lung Adenocarcinoma,238.0,Crizotinib,ALK
2049,N345K,C,Resistance,Colorectal Cancer,5290.0,Cetuximab,PIK3CA
2050,K650E,D,Resistance,Skin Melanoma,2261.0,Vemurafenib,FGFR3
2051,D842V,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,5156.0,Dasatinib,PDGFRA
2052,D842V,B,Resistance,Gastrointestinal Stromal Tumor,5156.0,Sunitinib,PDGFRA
2053,D842V,D,Resistance,Gastrointestinal Stromal Tumor,5156.0,Sunitinib,PDGFRA
2054,D842V,D,Resistance,Cancer,5156.0,Sunitinib,PDGFRA
2055,V560_L576DEL,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Regorafenib,KIT
2056,K550_K558del,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2057,K550_K558del,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2058,Y553_K558DEL,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2059,Y553_K558DEL,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2060,Exon 11 Mutation,B,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2061,DEL 554-558,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2062,W557G,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2063,W557_K558del,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2064,W557_K558del,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2065,W557_K558del,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib+Ponatinib,KIT
2066,W557_K558del,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2067,W557_K558del,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib+Regorafenib,KIT
2068,W557_E561del,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2069,W557_E561del,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2070,K558_V559del,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2071,K558_V559del,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2072,V559DEL,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2073,Exon 9 Mutation,C,Reduced Sensitivity,Gastrointestinal Stromal Tumor,3815.0,Regorafenib,KIT
2074,V559_V560DEL,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2075,V559_V560DEL,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2076,V559D,D,Sensitivity/Response,Melanoma,3815.0,Dasatinib,KIT
2077,V559D,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2078,V559D,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2079,V559D,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2080,V559D,D,Sensitivity/Response,Solid Tumor,3815.0,Dasatinib,KIT
2081,V559G,C,Sensitivity/Response,Thymus Squamous Cell Carcinoma,3815.0,Sunitinib,KIT
2082,V560DEL,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2083,V560DEL,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2084,V560D,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2085,V560D,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2086,V560D,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2087,P551_E554delPMYE,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Ponatinib,KIT
2088,V560D,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Imatinib+Ponatinib+Regorafenib+Sunitinib,KIT
2089,V560G,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2090,V560G,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2091,V560G,D,Sensitivity/Response,Chronic Myeloid Leukemia,3815.0,Bosutinib,KIT
2092,V560G,D,Sensitivity/Response,Chronic Myeloid Leukemia,3815.0,Dasatinib,KIT
2093,L576P,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2094,L576P,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2095,Exon 9 Mutation,B,Reduced Sensitivity,Gastrointestinal Stromal Tumor,3815.0,Regorafenib,KIT
2096,L576P,D,Sensitivity/Response,Cancer,3815.0,Imatinib+Dasatinib,KIT
2097,D579del,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2098,D579del,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2099,WILDTYPE,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Regorafenib,KIT
2100,K642E,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2101,K642E,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Regorafenib,KIT
2102,K642E,C,Sensitivity/Response,Melanoma,3815.0,Dasatinib,KIT
2103,V654A,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Regorafenib,KIT
2104,V654A,D,Sensitivity/Response,Chronic Myeloid Leukemia,3815.0,Bosutinib,KIT
2105,V654A,D,Sensitivity/Response,Chronic Myeloid Leukemia,3815.0,Dasatinib,KIT
2106,D816H,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2107,D816H,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Regorafenib,KIT
2108,D816H,D,Sensitivity/Response,Chronic Myeloid Leukemia,3815.0,Bosutinib,KIT
2109,D816H,D,Sensitivity/Response,Chronic Myeloid Leukemia,3815.0,Dasatinib,KIT
2110,D816Y,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2111,D816Y,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Regorafenib,KIT
2112,D816G,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Regorafenib,KIT
2113,D816G,C,Resistance,Lung Adenocarcinoma,3815.0,Crizotinib,KIT
2114,D816V,C,Sensitivity/Response,Acute Myeloid Leukemia,3815.0,Dasatinib,KIT
2115,D816V,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2116,D816V,D,Resistance,Chronic Myeloid Leukemia,3815.0,Bosutinib,KIT
2117,D816V,D,Sensitivity/Response,Chronic Myeloid Leukemia,3815.0,Dasatinib,KIT
2118,D816V,D,Sensitivity/Response,Chronic Myeloid Leukemia,3815.0,Dasatinib,KIT
2119,D820A,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Regorafenib,KIT
2120,D820G,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Regorafenib,KIT
2121,N822K,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2122,N822K,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2123,N822K,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Regorafenib,KIT
2124,V600R,C,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
2125,V600R,D,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
2126,V600R,C,Sensitivity/Response,Skin Melanoma,673.0,Vemurafenib,BRAF
2127,V600K,D,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
2128,V600K,C,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
2129,V600K,C,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
2130,V600K,C,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
2131,V600K,B,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
2132,V600K,D,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
2133,V600K,C,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
2134,V600K,B,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
2135,V600K,B,Sensitivity/Response,Skin Melanoma,673.0,Trametinib+Dabrafenib,BRAF
2136,G469A,C,Resistance,Colorectal Cancer,673.0,Cetuximab,BRAF
2137,G469A,D,Resistance,Melanoma,673.0,Vemurafenib,BRAF
2138,G469A,D,Resistance,Lung Non-small Cell Carcinoma,673.0,Erlotinib,BRAF
2139,S768I,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2140,R108K,D,Sensitivity/Response,High Grade Glioma,1956.0,Erlotinib,EGFR
2141,T263P,D,Sensitivity/Response,High Grade Glioma,1956.0,Erlotinib,EGFR
2142,A289V,D,Sensitivity/Response,High Grade Glioma,1956.0,Erlotinib,EGFR
2143,G719,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib+Gefitinib,EGFR
2144,G719S,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2145,G719S,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2146,G719S,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2147,G719A,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
2148,G719A,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2149,G719A,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2150,G719A,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2151,V742A,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2152,E746_A750del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
2153,E746_A750del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2154,Mutation,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2155,E746_A750del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2156,E746_A750del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2157,E746_A750del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2158,E746_A750del,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2159,E746_A750del,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2160,E746_A750del,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2161,E746_A750del,D,Sensitivity/Response,Hematologic Cancer,1956.0,Erlotinib,EGFR
2162,E746_T751>I,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Gefitinib,EGFR
2163,G719D,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib+Gefitinib,EGFR
2164,E746_T751>I,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2165,Expression,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2166,E746_A750del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2167,E746_A750del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Cetuximab,EGFR
2168,E746_T751delinsA,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2169,E746_T751delinsA,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2170,V774A,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
2171,E746_S752>A,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2172,E746V,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2173,V834I,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
2174,L838P,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
2175,L858R,D,Sensitivity/Response,Cancer,1956.0,Erlotinib,EGFR
2176,L747_P753delinsS,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2177,L747_P753delinsS,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2178,L747_P753delinsS,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2179,S768N,B,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2180,S768N,D,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2181,S768I,C,Resistance,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2182,D770_N771insSVD,D,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2183,H773_V774insH,D,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2184,R831H,D,Sensitivity/Response,Malignant Mesothelioma,1956.0,Erlotinib,EGFR
2185,L838V,D,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2186,P848L,D,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2187,T854A,C,Resistance,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2188,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2189,L858R,D,Sensitivity/Response,Cancer,1956.0,Erlotinib,EGFR
2190,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2191,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2192,L858R,C,Resistance,Lung Non-small Cell Carcinoma,1956.0,Crizotinib,EGFR
2193,L858R,B,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2194,L858R,D,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2195,L858R,D,Sensitivity/Response,Lung Small Cell Carcinoma,1956.0,Erlotinib,EGFR
2196,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Osimertinib,EGFR
2197,L858R,D,Sensitivity/Response,High Grade Glioma,1956.0,Erlotinib,EGFR
2198,A859T,D,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2199,A859T,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2200,L861,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib+Erlotinib,EGFR
2201,L861Q,D,Sensitivity/Response,High Grade Glioma,1956.0,Erlotinib,EGFR
2202,L861R,C,Resistance,Lung Adenocarcinoma,1956.0,Crizotinib,EGFR
2203,E868G,D,Sensitivity/Response,Malignant Mesothelioma,1956.0,Erlotinib,EGFR
2204,BCR-ABL M244V,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2205,BCR-ABL M244V,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2206,BCR-ABL L248V,D,Resistance,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2207,BCR-ABL L248V,D,Resistance,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2208,BCR-ABL G250E,D,Resistance,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2209,BCR-ABL G250E,C,Reduced Sensitivity,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2210,BCR-ABL G250E,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2211,BCR-ABL G250E,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2212,BCR-ABL G250E,C,Reduced Sensitivity,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2213,BCR-ABL G250E,D,Resistance,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2214,BCR-ABL G250E,D,Resistance,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2215,BCR-ABL Q252H,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2216,BCR-ABL Q252H,D,Resistance,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2217,BCR-ABL Q252H,D,Resistance,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2218,BCR-ABL Q252H,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2219,BCR-ABL Q252H,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2220,BCR-ABL Q252H,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2221,BCR-ABL Y253H,D,Resistance,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2222,BCR-ABL Y253H,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2223,BCR-ABL Y253H,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2224,BCR-ABL Y253H,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2225,BCR-ABL Y253F,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2226,BCR-ABL Y253F,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2227,BCR-ABL Y253F,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2228,BCR-ABL Y253F,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2229,BCR-ABL Y253F,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2230,BCR-ABL Y253F,D,Resistance,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2231,BCR-ABL E255K,D,Resistance,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2232,BCR-ABL E255K,C,Resistance,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2233,BCR-ABL E255K,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2234,BCR-ABL E255K,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2235,BCR-ABL E255K,C,Reduced Sensitivity,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2236,BCR-ABL E255K,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2237,BCR-ABL E255K,D,Resistance,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2238,BCR-ABL D276G,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2239,BCR-ABL D276G,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2240,BCR-ABL D276G,D,Resistance,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2241,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2242,BCR-ABL T315I,C,Resistance,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2243,BCR-ABL T315I,C,Resistance,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2244,BCR-ABL T315I,B,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2245,BCR-ABL T315I,C,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2246,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2247,BCR-ABL T315I,C,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2248,BCR-ABL T315I,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2249,BCR-ABL T315I,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2250,BCR-ABL T315I,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2251,BCR-ABL T315I,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2252,BCR-ABL T315I,C,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2253,BCR-ABL T315I,C,Resistance,Acute Lymphoblastic Leukemia,25.0,Dasatinib,ABL1
2254,BCR-ABL T315I,C,Resistance,Acute Lymphoblastic Leukemia,25.0,Dasatinib,ABL1
2255,BCR-ABL T315I,C,Resistance,Acute Lymphoblastic Leukemia,25.0,Dasatinib,ABL1
2256,BCR-ABL T315I,D,Resistance,Acute Lymphoblastic Leukemia,25.0,Dasatinib,ABL1
2257,BCR-ABL T315I,D,Resistance,Acute Lymphoblastic Leukemia,25.0,Dasatinib,ABL1
2258,BCR-ABL F317L,D,Resistance,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2259,BCR-ABL F317L,C,Reduced Sensitivity,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2260,BCR-ABL F317L,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2261,BCR-ABL F317L,C,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2262,BCR-ABL F317L,C,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2263,BCR-ABL F317L,C,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2264,BCR-ABL M244V,C,Resistance,Acute Lymphoblastic Leukemia,25.0,Dasatinib,ABL1
2265,BCR-ABL F317L,C,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2266,BCR-ABL F317L,C,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2267,BCR-ABL F317L,D,Resistance,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2268,BCR-ABL F317L,D,Resistance,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2269,BCR-ABL M351T,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2270,BCR-ABL M351T,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2271,BCR-ABL M351T,C,Reduced Sensitivity,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2272,BCR-ABL M351T,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2273,BCR-ABL M351T,C,Reduced Sensitivity,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2274,BCR-ABL M351T,D,Resistance,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2275,BCR-ABL E355G,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2276,BCR-ABL E355G,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2277,BCR-ABL L387M,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2278,BCR-ABL H396R,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2279,BCR-ABL H396R,C,Resistance,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2280,BCR-ABL H396R,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2281,BCR-ABL H396R,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2282,BCR-ABL H396R,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2283,BCR-ABL H396R,D,Resistance,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2284,G13V,C,Resistance,Skin Squamous Cell Carcinoma,3265.0,Vemurafenib,HRAS
2285,P278S,C,Resistance,Skin Squamous Cell Carcinoma,7157.0,Vemurafenib,TP53
2286,FIP1L1-PDGFRA T674I,D,Resistance,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",5156.0,Dasatinib,PDGFRA
2287,Q61P,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
2288,Q61E,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
2289,Q61FS,C,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
2290,K117N,D,Resistance,Clear Cell Sarcoma,3845.0,Vemurafenib,KRAS
2291,F595L,D,Resistance,Histiocytoma,673.0,Vemurafenib,BRAF
2292,D473H,D,Resistance,Medulloblastoma,6608.0,Vismodegib,SMO
2293,Y772_A775DUP,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,2064.0,Bosutinib,ERBB2
2294,G12A,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
2295,F1174C,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2296,T1151M,D,Resistance,Lung Large Cell Carcinoma,238.0,Crizotinib,ALK
2297,H1047L,C,Resistance,Colorectal Cancer,5290.0,Cetuximab+Irinotecan,PIK3CA
2298,S438C,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2299,BCR-ABL,C,Sensitivity/Response,Acute Lymphoblastic Leukemia,25.0,Dasatinib,ABL1
2300,E450G,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2301,BCR-ABL F486S,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2302,BCR-ABL F486S,C,Resistance,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2303,BCR-ABL E255V,D,Resistance,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2304,BCR-ABL E255V,D,Resistance,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2305,BCR-ABL E255V,C,Reduced Sensitivity,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2306,BCR-ABL E255V,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2307,BCR-ABL E255V,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2308,BCR-ABL E255V,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2309,BCR-ABL E255V,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2310,V777L,D,Resistance,Colorectal Cancer,2064.0,Cetuximab,ERBB2
2311,P551_E554delPMYE,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2312,P551_E554delPMYE,B,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2313,P551_E554delPMYE,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2314,V559D,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Ponatinib+Regorafenib+Imatinib,KIT
2315,W557_V559insC,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2316,W557_V559insC,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2317,S158L,C,Resistance,Colorectal Cancer,5290.0,Cetuximab+Irinotecan,PIK3CA
2318,G12V,D,Resistance,Colorectal Cancer,4893.0,Cetuximab,NRAS
2319,R93W,C,Resistance,Colorectal Cancer,5290.0,Oxaliplatin+Fluorouracil+Cetuximab,PIK3CA
2320,R776C,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2321,S784F,C,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2322,R505C,D,Resistance,Colorectal Cancer,55294.0,Regorafenib,FBXW7
2323,R505H,D,Resistance,Colorectal Cancer,55294.0,Regorafenib,FBXW7
2324,D594G,C,Resistance,Colorectal Cancer,673.0,Cetuximab+Irinotecan,BRAF
2325,F1174V,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2326,BCR-ABL E292V,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2327,L298V,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2328,BCR-ABL F311I,D,Resistance,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2329,BCR-ABL F311I,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2330,BCR-ABL F359C,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2331,BCR-ABL L364I,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2332,Q456*,D,Sensitivity/Response,Ovarian Clear Cell Carcinoma,8289.0,Dasatinib,ARID1A
2333,V600D,D,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
2334,V600D,D,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
2335,S768_D770dup,C,Resistance,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2336,D770_N771insNPG,D,Sensitivity/Response,Hematologic Cancer,1956.0,Erlotinib,EGFR
2337,D770_N771insNPG,D,Sensitivity/Response,Hematologic Cancer,1956.0,Cetuximab,EGFR
2338,H773_V774insNPH,C,Resistance,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2339,D770_N771insGL,C,Resistance,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2340,A864T,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2341,N826S,D,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2342,A763_Y764insFQEA,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2343,Q79K,D,Resistance,Melanoma,207.0,Vemurafenib,AKT1
2344,G466A,C,Resistance,Colorectal Cancer,673.0,Cetuximab,BRAF
2345,VIII,D,Sensitivity/Response,High Grade Glioma,1956.0,Erlotinib,EGFR
2346,S501_A502INSAY,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2347,S501_A502INSAY,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2348,S501_A502INSAY,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2349,S501_A502INSAY,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2350,A502_Y503insAY,D,Resistance,Cancer,3815.0,Imatinib,KIT
2351,S501_A502INSAY,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2352,S501_A502INSAY,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2353,G13V,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
2354,T670I,D,Resistance,Solid Tumor,3815.0,Dasatinib,KIT
2355,T670I,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Regorafenib,KIT
2356,D842_M844del,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,5156.0,Dasatinib,PDGFRA
2357,L861Q,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2358,S310F/Y,D,Resistance,Colorectal Cancer,2064.0,Cetuximab,ERBB2
2359,L755S,D,Resistance,Colorectal Cancer,2064.0,Cetuximab,ERBB2
2360,V842I,D,Resistance,Colorectal Cancer,2064.0,Cetuximab,ERBB2
2361,E17K,D,Resistance,Melanoma,10000.0,Vemurafenib,AKT3
2362,Q2223K,D,Sensitivity/Response,Clear Cell Renal Cell Carcinoma,2475.0,Temsirolimus,MTOR
2363,W110*,D,Sensitivity/Response,Melanoma,1029.0,Palbociclib,CDKN2A
2364,A20P,D,Sensitivity/Response,Melanoma,1029.0,Palbociclib,CDKN2A
2365,BCR-ABL L384M,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2366,BCR-ABL L384M,C,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2367,BCR-ABL L384M,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2368,BCR-ABL M343T,D,Resistance,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2369,BCR-ABL F317V,D,Resistance,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2370,BCR-ABL F317V,C,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2371,BCR-ABL V299L,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
2372,BCR-ABL V299L,C,Reduced Sensitivity,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2373,BCR-ABL V299L,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2374,BCR-ABL V299L,C,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2375,BCR-ABL V299L,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2376,BCR-ABL E279K,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2377,BCR-ABL E279K,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2378,BCR-ABL F311L,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2379,BCR-ABL F311L,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2380,BCR-ABL N331S,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2381,BCR-ABL L387F,C,Resistance,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2382,BCR-ABL L387F,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2383,BCR-ABL H396P,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2384,BCR-ABL H396P,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2385,BCR-ABL H396P,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2386,BCR-ABL H396P,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2387,BCR-ABL G398R,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2388,BCR-ABL G398R,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2389,BCR-ABL I432T,C,Resistance,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2390,BCR-ABL E450V,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2391,BCR-ABL E453K,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2392,F486Y,C,Resistance,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2393,F486Y,D,Resistance,Chronic Myeloid Leukemia,25.0,Bosutinib,ABL1
2394,BCR-ABL F486S,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2395,F486Y,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2396,W559_R560DELWR,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,5156.0,Sunitinib,PDGFRA
2397,L579M,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,5156.0,Sunitinib,PDGFRA
2398,Q556_I571DEL,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2399,Y553_W557DELYEVQW,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2400,V555_I571DEL,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2401,E611_F612INS25,C,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sunitinib,FLT3
2402,E611_F612INS25,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Palbociclib,FLT3
2403,K550_W557del,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Regorafenib+Ponatinib+Imatinib+Sunitinib,KIT
2404,T417_D419DELTYDINSI,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2405,D579_H580insIDPTQLPYD,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2406,Y570_L576DEL,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2407,Y570_L576DEL,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2408,D820Y,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Regorafenib,KIT
2409,K558NP,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2410,K558NP,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib+Regorafenib+Ponatinib+Imatinib,KIT
2411,N822K,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Regorafenib,KIT
2412,D842V,C,Resistance,Gastrointestinal Stromal Tumor,5156.0,Sunitinib,PDGFRA
2413,V560_L576DEL,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2414,Exon 11 Mutation,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Regorafenib,KIT
2415,V569_L576DEL,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2416,V569_L576DEL,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
2417,Exon 15 Mutation,C,Resistance,Gastrointestinal Stromal Tumor,673.0,Regorafenib,BRAF
2418,E278E,C,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,5594.0,Erlotinib,MAPK1
2419,EML4-ALK T1151INST,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2420,L1196Q,D,Resistance,Anaplastic Large Cell Lymphoma,238.0,Crizotinib,ALK
2421,ALK Fusion I1171,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2422,ALK Fusion I1171,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2423,ALK Fusion I1171,D,Resistance,Anaplastic Large Cell Lymphoma,238.0,Crizotinib,ALK
2424,L1152P,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2425,G2032R,C,Resistance,Lung Non-small Cell Carcinoma,6098.0,Crizotinib,ROS1
2426,G2032R,D,Resistance,Lung Non-small Cell Carcinoma,6098.0,Crizotinib,ROS1
2427,G2032R,D,Resistance,Lung Non-small Cell Carcinoma,6098.0,Crizotinib,ROS1
2428,EML4-ALK G1269A,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2429,EML4-ALK G1269A,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2430,EML4-ALK G1269A,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2431,EML4-ALK G1269A,C,Resistance,Lung Adenocarcinoma,238.0,Crizotinib,ALK
2432,EML4-ALK G1269A,D,Resistance,Lung Large Cell Carcinoma,238.0,Crizotinib,ALK
2433,EML4-ALK S1206Y,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2434,W1815X,D,Sensitivity/Response,Endometrioid Ovary Carcinoma,672.0,Olaparib,BRCA1
2435,ALK Fusion G1202R,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2436,ALK Fusion G1202R,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2437,L1198P,D,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2438,G776INSV_G/C,D,Resistance,Lung Non-small Cell Carcinoma,2064.0,Erlotinib,ERBB2
2439,Exon 9 Mutation,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Regorafenib,KIT
2440,Exon 11 Mutation,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Regorafenib,KIT
2441,D816E,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib+Sunitinib,KIT
2442,HIP1-ALK I1171N,D,Resistance,Anaplastic Large Cell Lymphoma,238.0,Crizotinib,ALK
2443,HIP1-ALK I1171N,C,Resistance,Lung Adenocarcinoma,238.0,Crizotinib,ALK
2444,D473G,C,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
2445,D473Y,C,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
2446,S278I,C,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
2447,W281C,D,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
2448,W281C,D,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
2449,Q477E,D,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
2450,D770_N771insSVD,D,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2451,E746_A750del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2452,D770_N771insGT,C,Resistance,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2453,V774_C775insHV,C,Resistance,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2454,Exon 20 Insertion,C,Resistance,Lung Adenocarcinoma,1956.0,Gefitinib,EGFR
2455,A763_Y764insFQEA,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2456,A763_Y764insFQEA,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2457,V769_770insASV,C,Resistance,Lung Adenocarcinoma,1956.0,Gefitinib,EGFR
2458,Exon 20 Insertion,C,Resistance,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2459,D770_N771insNPG,D,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2460,L412F,D,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
2461,L412F,D,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
2462,L412F,C,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
2463,W731L,D,Sensitivity/Response,Malignant Mesothelioma,1956.0,Erlotinib,EGFR
2464,E734Q,D,Sensitivity/Response,Malignant Mesothelioma,1956.0,Erlotinib,EGFR
2465,T785A,D,Sensitivity/Response,Malignant Mesothelioma,1956.0,Erlotinib,EGFR
2466,C797Y,D,Sensitivity/Response,Malignant Mesothelioma,1956.0,Erlotinib,EGFR
2467,Y801H,D,Sensitivity/Response,Malignant Mesothelioma,1956.0,Erlotinib,EGFR
2468,V321M,C,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
2469,V321M,D,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
2470,V321M,D,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
2471,E709_T710>D,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2472,V769A,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2473,A767_V769dupASV,C,Resistance,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2474,A767_V769dupASV,D,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2475,L747_S752delinsQ,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2476,L861R,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
2477,N771>GY,C,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2478,P546S,D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,1956.0,Cetuximab,EGFR
2479,L866M,D,Resistance,Colorectal Cancer,2064.0,Cetuximab,ERBB2
2480,W281L,C,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
2481,G497W,C,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
2482,I408V,D,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
2483,C469Y,D,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
2484,T241M,D,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
2485,A459V,D,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
2486,S533N,D,Resistance,Basal Cell Carcinoma,6608.0,Vismodegib,SMO
2487,W170X,C,Sensitivity/Response,Basal Cell Carcinoma,5727.0,Vismodegib,PTCH1
2488,W712X,C,Sensitivity/Response,Basal Cell Carcinoma,5727.0,Vismodegib,PTCH1
2489,Q787X,C,Sensitivity/Response,Basal Cell Carcinoma,5727.0,Vismodegib,PTCH1
2490,Q17X,C,Sensitivity/Response,Basal Cell Carcinoma,5727.0,Vismodegib,PTCH1
2491,Exon 11 Mutation,C,Resistance,Melanoma,3815.0,Dasatinib,KIT
2492,H201L,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2493,Y232S,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2494,M237V,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2495,I242T,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2496,G250V,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2497,BCR-ABL Q252R,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2498,E258D,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2499,L273M,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2500,E281K,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2501,V289I,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2502,Y342H,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2503,D363Y,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2504,BCR-ABL A365V,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2505,BCR-ABL A366G,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2506,BCR-ABL V379I,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2507,BCR-ABL V379I,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2508,BCR-ABL,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2509,M388L,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2510,Y393C,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2511,BCR-ABL A397P,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2512,BCR-ABL S417Y,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2513,BCR-ABL S417Y,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2514,I418V,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2515,I418S,B,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2516,P441L,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2517,E450K,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2518,BCR-ABL E255K,C,Resistance,Acute Lymphoblastic Leukemia,25.0,Dasatinib,ABL1
2519,E450A,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2520,E453V,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2521,E459G,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2522,E459G,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2523,M472I,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2524,P480L,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2525,G514S,C,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2526,BCR-ABL F317I,C,Resistance,Acute Lymphoblastic Leukemia,25.0,Dasatinib,ABL1
2527,Q56P,C,Resistance,Melanoma,5604.0,Vemurafenib,MAP2K1
2528,E203K,C,Resistance,Melanoma,5604.0,Vemurafenib,MAP2K1
2529,R163X,C,Resistance,Melanoma,4763.0,Vemurafenib,NF1
2530,Y591_V592INSVDFREYE,C,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sunitinib,FLT3
2531,Y591_V592INSVDFREYE,C,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sunitinib,FLT3
2532,Y591_V592INSVDFREYE,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sunitinib,FLT3
2533,Y591_V592INSVDFREYE,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Palbociclib,FLT3
2534,E588_Y589INSKYFYVDFRE,C,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sunitinib,FLT3
2535,E588_Y589INSKYFYVDFRE,C,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sunitinib,FLT3
2536,E588_Y589INSKYFYVDFRE,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sunitinib,FLT3
2537,E588_Y589INSKYFYVDFRE,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Palbociclib,FLT3
2538,V592_D593INSDFREY,C,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sunitinib,FLT3
2539,V592_D593INSDFREY,C,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sunitinib,FLT3
2540,V592_D593INSDFREY,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sunitinib,FLT3
2541,V592_D593INSDFREY,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Palbociclib,FLT3
2542,E746_A750>IP,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2543,RARE Exon 18-21 Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib+Gefitinib,EGFR
2544,Ex19 del L858R,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib+Gefitinib,EGFR
2545,K745_E749delKELRE,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2546,Exon 19 Deletion,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2547,D2033N,C,Resistance,Lung Adenocarcinoma,6098.0,Crizotinib,ROS1
2548,Y956N,C,Sensitivity/Response,Lung Adenocarcinoma,5424.0,Pembrolizumab,POLD1
2549,Q225X,C,Sensitivity/Response,Lung Adenocarcinoma,6334.0,Pembrolizumab,
2550,P1460T,C,Sensitivity/Response,Lung Adenocarcinoma,137902.0,Pembrolizumab,
2551,Y1520X,C,Sensitivity/Response,Lung Adenocarcinoma,60676.0,Pembrolizumab,
2552,A59E,C,Sensitivity/Response,Lung Adenocarcinoma,56655.0,Pembrolizumab,POLE4
2553,C284Y,C,Sensitivity/Response,Lung Adenocarcinoma,5424.0,Pembrolizumab,POLD1
2554,E374K,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,5424.0,Pembrolizumab,POLD1
2555,D1010Y,C,Sensitivity/Response,Lung Adenocarcinoma,4233.0,Crizotinib,MET
2556,G596V,C,Sensitivity/Response,Lung Adenocarcinoma,673.0,Vemurafenib,BRAF
2557,D1010N,C,Sensitivity/Response,Lung Adenocarcinoma,4233.0,Crizotinib,MET
2558,D1010N,C,Sensitivity/Response,Lung Squamous Cell Carcinoma,4233.0,Crizotinib,MET
2559,L1198F,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
2560,N561D,D,Resistance,Melanoma,5296.0,Vemurafenib,PIK3R2
2561,D350G,D,Resistance,Melanoma,5290.0,Vemurafenib,PIK3CA
2562,Q179X,B,Resistance,Colorectal Cancer,4893.0,Cetuximab,NRAS
2563,EXON 14 SKIPPING MUTATION,C,Sensitivity/Response,Lung Adenocarcinoma,4233.0,Crizotinib,MET
2564,R351W,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,25.0,Dasatinib,ABL1
2565,G340L,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,25.0,Dasatinib+Imatinib Mesylate,ABL1
2566,V600_K601DELINSD,C,Sensitivity/Response,Skin Melanoma,673.0,Vemurafenib,BRAF
2567,V600_K601DELINSD,C,Sensitivity/Response,Melanoma,673.0,Vemurafenib,BRAF
2568,S628N,D,Sensitivity/Response,Cancer,3815.0,Dasatinib+Imatinib,KIT
2569,D1010H,C,Sensitivity/Response,Lung Adenocarcinoma,4233.0,Crizotinib,MET
2570,D1010H,C,Sensitivity/Response,Lung Adenocarcinoma,4233.0,Crizotinib,MET
2571,EML4-ALK I1171S,D,Resistance,Lung Large Cell Carcinoma,238.0,Crizotinib,ALK
2572,R1192P,D,Resistance,Lung Large Cell Carcinoma,238.0,Crizotinib,ALK
2573,N771DELinsVH,C,Resistance,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2574,E322K,D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,5594.0,Erlotinib,MAPK1
2575,DELNVTAP,D,Resistance,Pancreatic Cancer,673.0,Vemurafenib,BRAF
2576,M766_A767insAI,D,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2577,Y764_V765insHH,D,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2578,D770delinsGY,C,Resistance,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2579,P772_H773insYNP,C,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2580,Y508F,D,Sensitivity/Response,Chronic Myeloid Leukemia,4067.0,Axitinib,LYN
2581,Y508F,D,Sensitivity/Response,Chronic Myeloid Leukemia,4067.0,Dasatinib,LYN
2582,S1986Y,D,Resistance,Lung Non-small Cell Carcinoma,6098.0,Crizotinib,ROS1
2583,S1986F,D,Resistance,Lung Non-small Cell Carcinoma,6098.0,Crizotinib,ROS1
2584,Y69FS*11,D,Resistance,Esophagus Squamous Cell Carcinoma,1956.0,Erlotinib,EGFR
2585,G1109C,D,Resistance,Head And Neck Squamous Cell Carcinoma,2066.0,Erlotinib,ERBB4
2586,E380Q,C,Sensitivity/Response,Breast Cancer,2099.0,Palbociclib,ESR1
2587,L536R,C,Sensitivity/Response,Breast Cancer,2099.0,Palbociclib,ESR1
2588,Y537C,C,Sensitivity/Response,Breast Cancer,2099.0,Palbociclib,ESR1
2589,D538G,C,Sensitivity/Response,Breast Cancer,2099.0,Palbociclib,ESR1
2590,S463P,C,Sensitivity/Response,Breast Cancer,2099.0,Palbociclib,ESR1
2591,Y537N,C,Sensitivity/Response,Breast Cancer,2099.0,Palbociclib,ESR1
2592,Y537N,B,Sensitivity/Response,Breast Cancer,2099.0,Palbociclib,ESR1
2593,Y537S,C,Sensitivity/Response,Breast Cancer,2099.0,Palbociclib,ESR1
2594,Y537S,B,Sensitivity/Response,Breast Cancer,2099.0,Palbociclib,ESR1
2595,S668FS*39,D,Resistance,Colorectal Cancer,55294.0,Regorafenib,FBXW7
2596,L403FS*34,D,Resistance,Colorectal Cancer,55294.0,Regorafenib,FBXW7
2597,G579W,D,Resistance,Colorectal Cancer,55294.0,Regorafenib,FBXW7
2598,R658Q,D,Resistance,Colorectal Cancer,55294.0,Regorafenib,FBXW7
2599,R391W,D,Resistance,Melanoma,5894.0,Vemurafenib,RAF1
2600,Splice Site (c.1641+2T>G),C,Resistance,Melanoma,3717.0,Pembrolizumab,JAK2
2601,P1175FS*5,D,Sensitivity/Response,Ovarian Clear Cell Carcinoma,8289.0,Dasatinib,ARID1A
2602,R214H,C,Sensitivity/Response,Nasal Type Extranodal NK/T-cell Lymphoma,238.0,Crizotinib,ALK
2603,Loss-of-function,D,Sensitivity/Response,Renal Cell Carcinoma,7428.0,Temsirolimus,VHL
2604,Loss-of-function,B,Resistance,Renal Cell Carcinoma,7428.0,Anti-VEGF Monoclonal Antibody,VHL
2605,MUTATION,B,Resistance,Renal Cell Carcinoma,7428.0,Anti-VEGF Monoclonal Antibody,VHL
2606,Mutation,D,Sensitivity/Response,Acute Myeloid Leukemia,3418.0,Enasidenib,IDH2
2607,AMPLIFICATION,D,Sensitivity/Response,Breast Cancer,5710.0,Talazoparib,
2608,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Brigatinib,ALK
2609,T790M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Panitumumab+Cetuximab+Brigatinib,EGFR
2610,C797S,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Panitumumab+Cetuximab+Brigatinib,EGFR
2611,Loss-of-function,B,Sensitivity/Response,Breast Cancer,672.0,Talazoparib,BRCA1
2612,Loss-of-function,B,Sensitivity/Response,Breast Cancer,675.0,Talazoparib,BRCA2
2613,Overexpression,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Trastuzumab Emtansine,ERBB2
2614,AMPLIFICATION,B,Sensitivity/Response,Liposarcoma,1019.0,Palbociclib,CDK4
2615,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,3845.0,Abemaciclib,KRAS
2616,Fusion,B,Sensitivity/Response,Lung Adenocarcinoma,5979.0,Cabozantinib,RET
2617,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,5979.0,Vandetanib,RET
2618,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,5979.0,Vandetanib,RET
2619,Fusion,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,5979.0,Alectinib,RET
2620,KIF5B-RET G810A,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,5979.0,Lenvatinib+Ponatinib,RET
2621,Mutation,D,Sensitivity/Response,Thyroid Gland Carcinoma,5979.0,Sapanisertib+NVP-AST487,RET
2622,Expression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,29126.0,Atezolizumab+Pembrolizumab+Nivolumab+Durvalumab+Avelumab,CD274
2623,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Crizotinib+Alectinib,ALK
2624,Exon 19 Deletion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib+Dacomitinib,EGFR
2625,L858R,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Dacomitinib,EGFR
2626,Fusion,C,Sensitivity/Response,Adrenal Carcinoma,2261.0,Erdafitinib,FGFR3
2627,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,3845.0,Pemetrexed+Trametinib+Docetaxel,KRAS
2628,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,3845.0,Nivolumab+Atezolizumab,KRAS
2629,Mutation,E,Sensitivity/Response,Lung Non-small Cell Carcinoma,3845.0,Immune Checkpoint Inhibitor,KRAS
2630,Mutation,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,3845.0,Pembrolizumab,KRAS
2631,Mutation,D,Sensitivity/Response,Colorectal Cancer,3845.0,Binimetinib+Palbociclib,KRAS
2632,G691R,D,Sensitivity/Response,Lung Adenocarcinoma,2261.0,Infigratinib+PD173074,FGFR3
2633,S249C,D,Sensitivity/Response,Lung Adenocarcinoma,2261.0,Infigratinib+PD173074,FGFR3
2634,EXPRESSION,D,Sensitivity/Response,Sarcoma,1019.0,Palbociclib,CDK4
2635,p16 Expression,D,Resistance,Sarcoma,1029.0,Palbociclib,CDKN2A
2636,Overexpression,D,Sensitivity/Response,Lung Small Cell Carcinoma,1111.0,Olaparib+Cisplatin+Prexasertib,CHEK1
2637,Loss-of-function,B,Sensitivity/Response,Ovarian Cancer,675.0,Talazoparib,BRCA2
2638,Loss-of-function,B,Sensitivity/Response,Ovarian Cancer,672.0,Talazoparib,BRCA1
2639,Expression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
2640,R248W,D,Resistance,Cancer,7157.0,MDM2 Inhibitor AMGMDS3,TP53
2641,R175H,D,Resistance,Cancer,7157.0,MDM2 Inhibitor AMGMDS3,TP53
2642,R273C,D,Resistance,Cancer,7157.0,MDM2 Inhibitor AMGMDS3,TP53
2643,R273H,D,Resistance,Cancer,7157.0,MDM2 Inhibitor AMGMDS3,TP53
2644,G245S,D,Resistance,Cancer,7157.0,MDM2 Inhibitor AMGMDS3,TP53
2645,Y220C,D,Resistance,Cancer,7157.0,MDM2 Inhibitor AMGMDS3,TP53
2646,M237I,D,Resistance,Glioblastoma,7157.0,MDM2 Inhibitor AMGMDS3,TP53
2647,R158H,D,Resistance,Cancer,7157.0,MDM2 Inhibitor AMGMDS3,TP53
2648,V157F,D,Resistance,Cancer,7157.0,MDM2 Inhibitor AMGMDS3,TP53
2649,R249S,D,Resistance,Cancer,7157.0,MDM2 Inhibitor AMGMDS3,TP53
2650,R280K,D,Resistance,Cancer,7157.0,MDM2 Inhibitor AMGMDS3,TP53
2651,R280T,D,Resistance,Cancer,7157.0,MDM2 Inhibitor AMGMDS3,TP53
2652,R158L,D,Resistance,Cancer,7157.0,MDM2 Inhibitor AMGMDS3,TP53
2653,L597Q,C,Sensitivity/Response,Skin Melanoma,673.0,Trametinib,BRAF
2654,Gain-of-function,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
2655,MUTATION,B,Sensitivity/Response,Uveal Melanoma,2776.0,Cabozantinib,GNAQ
2656,Mutation,A,Sensitivity/Response,Acute Myeloid Leukemia,3418.0,Enasidenib,IDH2
2657,LOSS,D,Resistance,Pancreatic Cancer,23152.0,Trametinib,CIC
2658,LOSS,D,Resistance,Lung Cancer,23152.0,Trametinib,CIC
2659,LOSS,D,Resistance,Lung Cancer,23152.0,Vemurafenib,CIC
2660,LOSS,D,Resistance,Colon Cancer,23152.0,Trametinib,CIC
2661,LOSS,D,Resistance,Colon Cancer,23152.0,Vemurafenib,CIC
2662,LOSS,D,Resistance,Melanoma,23152.0,Trametinib,CIC
2663,LOSS,D,Resistance,Melanoma,23152.0,Vemurafenib,CIC
2664,LOSS,D,Resistance,Pancreatic Cancer,23152.0,Selumetinib,CIC
2665,LOSS,D,Resistance,Lung Cancer,23152.0,Selumetinib,CIC
2666,Overexpression,D,Resistance,Pancreatic Cancer,2115.0,Trametinib,ETV1
2667,Overexpression,D,Resistance,Lung Cancer,2115.0,Trametinib,ETV1
2668,OVEREXPRESSION,D,Resistance,Pancreatic Cancer,2118.0,Trametinib,ETV4
2669,OVEREXPRESSION,D,Resistance,Pancreatic Cancer,2119.0,Trametinib,ETV5
2670,OVEREXPRESSION,D,Resistance,Lung Cancer,2118.0,Trametinib,ETV4
2671,OVEREXPRESSION,D,Resistance,Lung Cancer,2119.0,Trametinib,ETV5
2672,LOSS,D,Resistance,Pancreatic Cancer,342371.0,Trametinib,
2673,LOSS,B,Resistance,Melanoma,342371.0,Dabrafenib+Vemurafenib,
2674,LOSS,D,Sensitivity/Response,Lung Cancer,472.0,Trametinib,ATM
2675,F858L,D,Sensitivity/Response,Lung Cancer,472.0,Selumetinib,ATM
2676,Underexpression,B,Sensitivity/Response,Stomach Cancer,472.0,Olaparib+Paclitaxel,ATM
2677,Mutation,A,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Midostaurin,FLT3
2678,MUTATION,B,Sensitivity/Response,Renal Cell Carcinoma,7428.0,Everolimus,VHL
2679,DELETION,D,Resistance,Medulloblastoma,51684.0,Sonidegib,SUFU
2680,Amplification,D,Resistance,Medulloblastoma,4613.0,Sonidegib,MYCN
2681,DELETION,D,Sensitivity/Response,Medulloblastoma,5727.0,Sonidegib,PTCH1
2682,Amplification,D,Sensitivity/Response,Medulloblastoma,4613.0,Arsenic Trioxide,MYCN
2683,Mutation,B,Sensitivity/Response,Breast Cancer,2064.0,Neratinib,ERBB2
2684,Mutation,B,Resistance,Renal Cell Carcinoma,8314.0,Everolimus+Sunitinib,BAP1
2685,Mutation,A,Resistance,Colorectal Cancer,4893.0,Panitumumab+Cetuximab,NRAS
2686,Mutation,A,Resistance,Colorectal Cancer,3845.0,Panitumumab+Cetuximab,KRAS
2687,D842V,D,Resistance,Cancer,5156.0,Imatinib Mesylate,PDGFRA
2688,V560D,D,Sensitivity/Response,Cancer,3815.0,Imatinib Mesylate,KIT
2689,Overexpression,D,Sensitivity/Response,Multiple Myeloma,4609.0,JQ-1,MYC
2690,Underexpression,B,Sensitivity/Response,Pancreatic Cancer,6240.0,Gemcitabine,RRM1
2691,Underexpression,B,Sensitivity/Response,Pancreatic Cancer,6240.0,Gemcitabine,RRM1
2692,AMPLIFICATION,C,Sensitivity/Response,Liposarcoma,4193.0,HDM2 Inhibitor MK-8242,MDM2
2693,Underexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,6240.0,Gemcitabine,RRM1
2694,F354L,B,Sensitivity/Response,Breast Cancer,6794.0,Everolimus+Exemestane,STK11
2695,MUTATION,D,Sensitivity/Response,Acute Promyelocytic Leukemia,3815.0,Nilotinib,KIT
2696,Mutation,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Nilotinib,FLT3
2697,Mutation,B,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Nilotinib,FLT3
2698,Underexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,6240.0,Paclitaxel+Vinorelbine+Gemcitabine,RRM1
2699,Y646,D,Sensitivity/Response,Melanoma,2146.0,Dabrafenib+JQEZ5+GSK126+UNC1999,EZH2
2700,V9 EXPRESSION,E,Resistance,Prostate Cancer,367.0,Abiraterone Acetate,AR
2701,V774_C775insHV,D,Resistance,Cancer,1956.0,Erlotinib,EGFR
2702,EXPRESSION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1493.0,Atezolizumab,CTLA4
2703,Expression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,29126.0,Pembrolizumab,CD274
2704,UNDEREXPRESSION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,6376.0,Atezolizumab,
2705,S1088F,C,Sensitivity/Response,Prostate Cancer,2175.0,Cisplatin,FANCA
2706,Loss-of-function,B,Sensitivity/Response,Her2-receptor Negative Breast Cancer,672.0,Olaparib,BRCA1
2707,Loss-of-function,B,Sensitivity/Response,Her2-receptor Negative Breast Cancer,675.0,Olaparib,BRCA2
2708,V777L,C,Resistance,Her2-receptor Positive Breast Cancer,2064.0,Trastuzumab Emtansine+Trastuzumab,ERBB2
2709,D761N,D,Sensitivity/Response,Cancer,1956.0,Multikinase Inhibitor AEE788,EGFR
2710,S784F,D,Sensitivity/Response,Cancer,1956.0,Multikinase Inhibitor AEE788,EGFR
2711,G810S,D,Sensitivity/Response,Cancer,1956.0,Multikinase Inhibitor AEE788,EGFR
2712,Overexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2713,OVEREXPRESSION,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2264.0,"Dovitinib+FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074",FGFR4
2714,L1237F,C,Sensitivity/Response,Ureter Small Cell Carcinoma,10111.0,Checkpoint Kinase Inhibitor AZD7762+Irinotecan,RAD50
2715,Mutation,B,Sensitivity/Response,Her2-receptor Negative Breast Cancer,672.0,Olaparib,BRCA1
2716,Mutation,B,Sensitivity/Response,Breast Cancer,675.0,Olaparib,BRCA2
2717,Underexpression,D,Sensitivity/Response,Osteosarcoma,546.0,VE-821+AZ20,ATRX
2718,Loss-of-function,B,Sensitivity/Response,Renal Cell Carcinoma,7248.0,MTOR Inhibitor,TSC1
2719,LOSS-OF-FUNCTION,B,Sensitivity/Response,Renal Cell Carcinoma,7249.0,MTOR Inhibitor,TSC2
2720,Gain-of-Function,B,Sensitivity/Response,Renal Cell Carcinoma,2475.0,MTOR Inhibitor,MTOR
2721,ATP1B1-NRG1,C,Sensitivity/Response,Cholangiocarcinoma,3084.0,Afatinib,NRG1
2722,SDC4-NRG1,C,Sensitivity/Response,Lung Adenocarcinoma,3084.0,Afatinib,NRG1
2723,A829P,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Ponatinib,KIT
2724,E384*,C,Sensitivity/Response,Cholangiocarcinoma,54206.0,Erlotinib,ERRFI1
2725,EXPRESSION,D,Sensitivity/Response,Lung Small Cell Carcinoma,91607.0,Temozolomide+Talazoparib,SLFN11
2726,EXPRESSION,D,Sensitivity/Response,Ewing Sarcoma,91607.0,Temozolomide+Niraparib,SLFN11
2727,V600E,C,Sensitivity/Response,Cholangiocarcinoma,673.0,Trametinib+Dabrafenib,BRAF
2728,V600E,C,Sensitivity/Response,Intrahepatic Cholangiocarcinoma,673.0,Dabrafenib+Trametinib,BRAF
2729,V600E,C,Sensitivity/Response,Intrahepatic Cholangiocarcinoma,673.0,Dabrafenib+Trametinib,BRAF
2730,V600,B,Sensitivity/Response,Cholangiocarcinoma,673.0,Vemurafenib,BRAF
2731,V600E,C,Sensitivity/Response,Cholangiocarcinoma,673.0,Panitumumab+Vemurafenib+Irinotecan,BRAF
2732,Amplification,B,Resistance,Melanoma,3815.0,Nilotinib,KIT
2733,Fusion,B,Sensitivity/Response,Cholangiocarcinoma,2263.0,Infigratinib,FGFR2
2734,EGFR-RAD51,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
2735,OVEREXPRESSION,C,Sensitivity/Response,Breast Angiosarcoma,3791.0,Sunitinib,KDR
2736,AMPLIFICATION,C,Sensitivity/Response,Angiosarcoma,2324.0,Pazopanib,FLT4
2737,Mutation,B,Sensitivity/Response,Cholangiocarcinoma,2263.0,Infigratinib,FGFR2
2738,Mutation,B,Sensitivity/Response,Pancreatic Cancer,675.0,Olaparib,BRCA2
2739,Mutation,B,Sensitivity/Response,Pancreatic Cancer,672.0,Olaparib,BRCA1
2740,Mutation,B,Sensitivity/Response,Pancreatic Cancer,672.0,Cisplatin+Oxaliplatin,BRCA1
2741,Mutation,B,Sensitivity/Response,Pancreatic Cancer,675.0,Platinum Compound,BRCA2
2742,EXPRESSION,B,Sensitivity/Response,Head And Neck Cancer,80380.0,Pembrolizumab,PDCD1LG2
2743,Expression,B,Sensitivity/Response,Lung Small Cell Carcinoma,10683.0,Rovalpituzumab Tesirine,
2744,FUS-DDIT3,D,Sensitivity/Response,Myxoid Liposarcoma,1649.0,NVP-AEW541,DDIT3
2745,L1678P,C,Sensitivity/Response,Adult T-cell Leukemia,4851.0,Nirogacestat,NOTCH1
2746,L858R,D,Sensitivity/Response,Cancer,1956.0,Erlotinib,EGFR
2747,Mutation,B,Sensitivity/Response,Peritoneal Mesothelioma,1956.0,Cytoreductive Surgery+Hyperthermic Intraperitoneal Chemotherapy,EGFR
2748,Amplification,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib+Gefitinib,EGFR
2749,Amplification,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib+Erlotinib,EGFR
2750,KMT2E-ASNS,D,Resistance,T-cell Lymphoblastic Leukemia/lymphoma,440.0,Asparaginase,
2751,G12C,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,3845.0,ARS-1620,KRAS
2752,INACTIVATING MUTATION,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,6597.0,Tozasertib,SMARCA4
2753,ALTERNATIVE TRANSCRIPT (ATI),D,Sensitivity/Response,Malignant Mesothelioma,8314.0,Olaparib+Apitolisib,BAP1
2754,LOSS,D,Sensitivity/Response,Renal Carcinoma,8314.0,Olaparib,BAP1
2755,Mutation,B,Sensitivity/Response,Pancreatic Cancer,672.0,Gemcitabine+Veliparib+Cisplatin,BRCA1
2756,Mutation,B,Sensitivity/Response,Pancreatic Cancer,675.0,Veliparib+Gemcitabine+Cisplatin,BRCA2
2757,Mutation,C,Sensitivity/Response,Pancreatic Cancer,675.0,Iniparib,BRCA2
2758,A763_Y764insFQEA,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2759,D770delinsGY,C,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2760,V769_770insASV,C,Resistance,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2761,L747_P753delinsS,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib+Afatinib,EGFR
2762,E746_A750del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2763,E746_A750del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Afatinib,EGFR
2764,A767_V769dupASV,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2765,A763_Y764insFQEA,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib+Afatinib,EGFR
2766,STRN-ALK,C,Sensitivity/Response,Colon Adenocarcinoma,238.0,Ceritinib,ALK
2767,LOSS-OF-FUNCTION,D,Sensitivity/Response,Colorectal Cancer,580.0,Olaparib,BARD1
2768,Fusion,C,Sensitivity/Response,Thyroid Gland Anaplastic Carcinoma,238.0,Crizotinib,ALK
2769,V600E,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,673.0,Vemurafenib,BRAF
2770,V600E,B,Sensitivity/Response,Ovarian Cancer,673.0,Vemurafenib,BRAF
2771,V600E,C,Sensitivity/Response,Colorectal Cancer,673.0,Vemurafenib,BRAF
2772,V600E,C,Sensitivity/Response,Thyroid Gland Anaplastic Carcinoma,673.0,Vemurafenib+Pertuzumab,BRAF
2773,V600E,C,Sensitivity/Response,Laryngeal Squamous Cell Carcinoma,673.0,Vemurafenib,BRAF
2774,CUX1-BRAF,C,Sensitivity/Response,Pancreatic Cancer,673.0,Vemurafenib,BRAF
2775,MUTATION,B,Sensitivity/Response,Cancer,5727.0,Vismodegib,PTCH1
2776,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,2064.0,Pertuzumab+Trastuzumab,ERBB2
2777,Amplification,B,Sensitivity/Response,Colorectal Cancer,2064.0,Pertuzumab+Trastuzumab,ERBB2
2778,Amplification,B,Sensitivity/Response,Bladder Carcinoma,2064.0,Pertuzumab+Trastuzumab,ERBB2
2779,Amplification,B,Sensitivity/Response,Biliary Tract Cancer,2064.0,Trastuzumab+Pertuzumab,ERBB2
2780,Amplification,B,Sensitivity/Response,Salivary Gland Carcinoma,2064.0,Trastuzumab+Pertuzumab,ERBB2
2781,Amplification,B,Sensitivity/Response,Pancreatic Cancer,2064.0,Trastuzumab+Pertuzumab,ERBB2
2782,LOSS,D,Sensitivity/Response,Sarcoma,445.0,Chloroquine+Pegargiminase,
2783,LOSS,D,Resistance,Ovarian Cancer,445.0,Platinum Compound,
2784,Mutation,C,Sensitivity/Response,Papillary Renal Cell Carcinoma,201163.0,Everolimus,FLCN
2785,Loss,D,Sensitivity/Response,Renal Carcinoma,201163.0,Sirolimus,FLCN
2786,LOSS,D,Sensitivity/Response,Kabuki Syndrome,8085.0,HDAC Inhibitor AR-42,KMT2D
2787,LOSS-OF-FUNCTION,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,5921.0,Trametinib,RASA1
2788,Loss-of-function,D,Sensitivity/Response,Lung Adenocarcinoma,472.0,Olaparib,ATM
2789,Mutation,B,Sensitivity/Response,Renal Cell Carcinoma,55193.0,Sunitinib+Everolimus,PBRM1
2790,MUTATION,B,Sensitivity/Response,Renal Cell Carcinoma,8242.0,Sunitinib+Everolimus,KDM5C
2791,ISOFORM EXPRESSION,D,Sensitivity/Response,Malignant Pleural Mesothelioma,580.0,Apitolisib+Olaparib,BARD1
2792,Overexpression,D,Sensitivity/Response,Melanoma,7178.0,Sertraline,
2793,AMPLIFICATION,D,Sensitivity/Response,Breast Cancer,11011.0,GF109203X+Go6983,
2794,D594G,D,Sensitivity/Response,Skin Melanoma,673.0,Sorafenib,BRAF
2795,D594G,D,Resistance,Skin Melanoma,673.0,U0126,BRAF
2796,G469E,D,Sensitivity/Response,Skin Melanoma,673.0,Sorafenib,BRAF
2797,G469E,D,Resistance,Skin Melanoma,673.0,U0126,BRAF
2798,L747_P753delinsS,C,Sensitivity/Response,Pancreatic Adenocarcinoma,1956.0,Erlotinib,EGFR
2799,Amplification,D,Sensitivity/Response,Neuroblastoma,4613.0,JQ1,MYCN
2800,Amplification,D,Sensitivity/Response,Neuroblastoma,4613.0,Birabresib,MYCN
2801,Amplification,D,Sensitivity/Response,Neuroblastoma,4613.0,JQ1+Panobinostat,MYCN
2802,Amplification,D,Sensitivity/Response,Neuroblastoma,4613.0,JQEZ5+GSK126,MYCN
2803,A702S,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
2804,E709K and G719A,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib+Erlotinib,EGFR
2805,E709Q,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
2806,Exon 18 deletion,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib+Erlotinib,EGFR
2807,E709A and G719C,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2808,G719S,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2809,I744_K745insKIPVAI,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
2810,Fusion,C,Sensitivity/Response,Vagina Sarcoma,238.0,Crizotinib,ALK
2811,Fusion,C,Sensitivity/Response,Epithelioid Inflammatory Myofibroblastic Sarcoma,238.0,Crizotinib,ALK
2812,V600,A,Sensitivity/Response,Melanoma,673.0,Vemurafenib+Cobimetinib,BRAF
2813,V600E,B,Sensitivity/Response,Thyroid Gland Anaplastic Carcinoma,673.0,Vemurafenib,BRAF
2814,V600,B,Sensitivity/Response,Colorectal Cancer,673.0,Encorafenib+Cetuximab,BRAF
2815,V600,B,Sensitivity/Response,Colorectal Cancer,673.0,Encorafenib+Cetuximab+Alpelisib,BRAF
2816,T41A,C,Sensitivity/Response,Desmoid Tumor,1499.0,Celecoxib,CTNNB1
2817,T41A,B,Sensitivity/Response,Desmoid Tumor,1499.0,Meloxicam,CTNNB1
2818,Fusion,C,Sensitivity/Response,Pancreatic Cancer,4914.0,Larotrectinib,NTRK1
2819,Fusion,C,Sensitivity/Response,Cholangiocarcinoma,4914.0,Larotrectinib,NTRK1
2820,Loss-of-function,C,Sensitivity/Response,Renal Cell Carcinoma,7248.0,MTOR Inhibitor,TSC1
2821,Mutation,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,4763.0,Trametinib,NF1
2822,D1028N,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,4233.0,Crizotinib,MET
2823,Loss-of-function,B,Sensitivity/Response,Pancreatic Cancer,672.0,Olaparib,BRCA1
2824,Loss-of-function,B,Sensitivity/Response,Pancreatic Cancer,675.0,Olaparib,BRCA2
2825,T41A,B,Sensitivity/Response,Hepatoblastoma,1499.0,,CTNNB1
2826,S37C,E,Sensitivity/Response,Hepatoblastoma,1499.0,,CTNNB1
2827,G328V,D,Sensitivity/Response,"Diffuse Midline Glioma, H3 K27M-mutant",90.0,ALK2 Inhibitor LDN-193189,ACVR1
2828,Fusion,C,Sensitivity/Response,Mucinous Adenocarcinoma,3084.0,Anti-HER3 Monoclonal Antibody GSK2849330,NRG1
2829,MUTATION,C,Resistance,Breast Cancer,5925.0,Ribociclib+Palbociclib,RB1
2830,STRN-NTRK2,C,Sensitivity/Response,Sarcoma,4915.0,Larotrectinib,NTRK2
2831,ETV6-NTRK3,A,Sensitivity/Response,Congenital Fibrosarcoma,4916.0,Larotrectinib,NTRK3
2832,LMNA-NTRK1,C,Sensitivity/Response,Sarcoma,4914.0,Larotrectinib,NTRK1
2833,TPM3-NTRK1,C,Sensitivity/Response,Sarcoma,4914.0,Larotrectinib,NTRK1
2834,PDE4DIP-NTRK1,C,Sensitivity/Response,Sarcoma,4914.0,Larotrectinib,NTRK1
2835,SQSTM1-NTRK1,C,Sensitivity/Response,Congenital Fibrosarcoma,4914.0,Larotrectinib,NTRK1
2836,V600E,B,Sensitivity/Response,Colorectal Cancer,673.0,Trametinib+Panitumumab+Dabrafenib,BRAF
2837,Overexpression,C,Sensitivity/Response,Salivary Gland Cancer,2064.0,Paclitaxel+Trastuzumab,ERBB2
2838,Overexpression,C,Sensitivity/Response,Salivary Gland Cancer,2064.0,Trastuzumab+Zoledronic Acid+Capecitabine,ERBB2
2839,Y220C,C,Sensitivity/Response,Breast Cancer,7157.0,Bortezomib,TP53
2840,L869R,C,Sensitivity/Response,Breast Cancer,2064.0,Neratinib,ERBB2
2841,T798I,C,Resistance,Breast Cancer,2064.0,Neratinib,ERBB2
2842,A750T,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib+Gefitinib,EGFR
2843,V600E,B,Sensitivity/Response,Melanoma,673.0,Trametinib+Dabrafenib,BRAF
2844,V600K,B,Sensitivity/Response,Melanoma,673.0,Trametinib+Dabrafenib,BRAF
2845,V600,B,Sensitivity/Response,Melanoma,673.0,Dabrafenib+Trametinib,BRAF
2846,L858R,B,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Gefitinib,EGFR
2847,Exon 19 Deletion,B,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Gefitinib,EGFR
2848,Rare Mutation,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Gefitinib,EGFR
2849,BCR-ABL T315A,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2850,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib+Imatinib Mesylate,ABL1
2851,BCR-ABL E255K,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate+Dasatinib,ABL1
2852,BCR-ABL E255K,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib+Imatinib Mesylate+Nilotinib,ABL1
2853,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,25.0,Nilotinib,ABL1
2854,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate+Nilotinib,ABL1
2855,BCR-ABL T315I,B,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Omacetaxine Mepesuccinate,ABL1
2856,BCR-ABL Y253H,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate+Nilotinib,ABL1
2857,H1047R,D,Resistance,Breast Cancer,5290.0,Lapatinib,PIK3CA
2858,H1047R,D,Resistance,Breast Cancer,5290.0,Trastuzumab,PIK3CA
2859,H1047R,D,Resistance,Her2-receptor Positive Breast Cancer,5290.0,Lapatinib+Trastuzumab,PIK3CA
2860,H1047R,D,Sensitivity/Response,Breast Cancer,5290.0,Lapatinib+Dactolisib,PIK3CA
2861,E545K,D,Resistance,Her2-receptor Positive Breast Cancer,5290.0,Lapatinib,PIK3CA
2862,BCR-ABL F317V,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2863,E545K,D,Resistance,Her2-receptor Positive Breast Cancer,5290.0,Trastuzumab,PIK3CA
2864,BCR-ABL L248R,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate+Dasatinib,ABL1
2865,E545K,D,Resistance,Her2-receptor Positive Breast Cancer,5290.0,Trastuzumab+Lapatinib,PIK3CA
2866,BCR-ABL E255K,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate+Dasatinib,ABL1
2867,BCR-ABL F317L,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2868,BCR-ABL V299L,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2869,BCR-ABL F317I,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2870,BCR-ABL F317S,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2871,BCR-ABL Q252H,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2872,BCR-ABL T315I,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Omacetaxine Mepesuccinate,ABL1
2873,BCR-ABL E255K,C,Resistance,Chronic Myeloid Leukemia,25.0,Nilotinib+Imatinib Mesylate,ABL1
2874,BCR-ABL F359C,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate+Nilotinib,ABL1
2875,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate+Dasatinib,ABL1
2876,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib+Nilotinib,ABL1
2877,BCR-ABL L248V,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate+Nilotinib,ABL1
2878,BCR-ABL Y253H,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate+Nilotinib,ABL1
2879,BCR-ABL F311L,D,Resistance,Chronic Myeloid Leukemia,25.0,Nilotinib+Imatinib Mesylate,ABL1
2880,BCR-ABL F359C,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate+Nilotinib,ABL1
2881,BCR-ABL H396P,D,Resistance,Chronic Myeloid Leukemia,25.0,Nilotinib+Imatinib Mesylate,ABL1
2882,BCR-ABL V299L,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib+Imatinib Mesylate,ABL1
2883,BCR-ABL M244V,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
2884,BCR-ABL L248R,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
2885,BCR-ABL G250E,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
2886,BCR-ABL Q252H,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
2887,BCR-ABL D276G,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
2888,BCR-ABL V299L,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2889,BCR-ABL F311I,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
2890,BCR-ABL F311V,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
2891,BCR-ABL F317C,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2892,BCR-ABL F317I,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2893,BCR-ABL F317L,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
2894,BCR-ABL F317V,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2895,BCR-ABL M351T,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
2896,BCR-ABL E355G,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
2897,BCR-ABL F359V,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
2898,BCR-ABL V379I,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
2899,BCR-ABL H396R,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
2900,Q79K,C,Resistance,Melanoma,207.0,Dabrafenib,AKT1
2901,OVEREXPRESSION,D,Resistance,Melanoma,10000.0,Vemurafenib,AKT3
2902,V600E/K and Amplification,B,Resistance,Melanoma,673.0,Dabrafenib+Vemurafenib,BRAF
2903,Mutation,B,Resistance,Melanoma,4893.0,Dabrafenib+Vemurafenib,NRAS
2904,Mutation,B,Resistance,Melanoma,3845.0,Vemurafenib+Dabrafenib,KRAS
2905,OVEREXPRESSION,D,Resistance,Melanoma,5290.0,Vemurafenib,PIK3CA
2906,BCR-ABL G250E,D,Resistance,Chronic Myeloid Leukemia,25.0,Nilotinib,ABL1
2907,R172I,C,Resistance,Melanoma,80243.0,Vemurafenib,PREX2
2908,BCR-ABL F317L,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2909,Loss,D,Resistance,Melanoma,5728.0,Vemurafenib,PTEN
2910,WILD TYPE,D,Sensitivity/Response,Melanoma,5728.0,Vemurafenib,PTEN
2911,Fusion,C,Sensitivity/Response,Pancreatic Adenocarcinoma,3084.0,Afatinib,NRG1
2912,BCR-ABL Q252H,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2913,Amplification,D,Resistance,Melanoma,5290.0,Vemurafenib,PIK3CA
2914,BCR-ABL L384M,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
2915,BCR-ABL E255V,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
2916,BCR-ABL F359C,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
2917,BCR-ABL Y253H,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
2918,BCR-ABL L248V,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
2919,BCR-ABL L248V,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2920,BCR-ABL E255K,D,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
2921,BCR-ABL E255K,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2922,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2923,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,25.0,Nilotinib+Imatinib Mesylate+Dasatinib,ABL1
2924,G12/G13,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
2925,Mutation,B,Resistance,Colorectal Cancer,5290.0,Cetuximab,PIK3CA
2926,Mutation,B,Resistance,Colorectal Cancer,673.0,Oxaliplatin,BRAF
2927,Mutation,B,Resistance,Colorectal Cancer,673.0,Irinotecan,BRAF
2928,Mutation,B,Resistance,Colorectal Cancer,673.0,Bevacizumab,BRAF
2929,Mutation,B,Resistance,Colorectal Cancer,673.0,Cetuximab,BRAF
2930,BCR-ABL F317L,B,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
2931,G13V,C,Resistance,Colorectal Cancer,3845.0,Panitumumab+Cetuximab,KRAS
2932,G12S,C,Resistance,Colorectal Cancer,3845.0,Panitumumab+Cetuximab,KRAS
2933,Loss,B,Resistance,Colorectal Cancer,5728.0,Cetuximab+Panitumumab,PTEN
2934,G12D,C,Resistance,Colorectal Cancer,3845.0,Panitumumab+Cetuximab,KRAS
2935,Amplification,D,Resistance,Melanoma,3845.0,Vemurafenib,KRAS
2936,T790M,D,Resistance,Lung Non-small Cell Carcinoma,1956.0,Naquotinib+Mitogen-Activated Protein Kinase Kinase Inhibitor+Osimertinib,EGFR
2937,G12A,C,Resistance,Colorectal Cancer,3845.0,Panitumumab+Cetuximab,KRAS
2938,G13D,C,Resistance,Colorectal Cancer,3845.0,Cetuximab+Panitumumab,KRAS
2939,G12V,C,Resistance,Colorectal Cancer,3845.0,Panitumumab+Cetuximab,KRAS
2940,Mutation,B,Sensitivity/Response,Ovarian Serous Carcinoma,672.0,Olaparib,BRCA1
2941,Mutation,B,Sensitivity/Response,Ovarian Serous Carcinoma,675.0,Olaparib,BRCA2
2942,Y35N,D,Resistance,Kidney Cancer,6009.0,Sirolimus,RHEB
2943,Mutation,B,Sensitivity/Response,Ovarian Cancer,672.0,Rucaparib,BRCA1
2944,Mutation,B,Sensitivity/Response,Ovarian Cancer,675.0,Rucaparib,BRCA2
2945,Mutation,B,Resistance,Colorectal Cancer,5290.0,Panitumumab+Cetuximab,PIK3CA
2946,G12/G13,B,Resistance,Colorectal Cancer,3845.0,Panitumumab+Cetuximab,KRAS
2947,UNDEREXPRESSION,C,Sensitivity/Response,Cancer,6597.0,Tazemetostat,SMARCA4
2948,UNDEREXPRESSION,C,Sensitivity/Response,Cancer,6598.0,Tazemetostat,SMARCB1
2949,Mutation,B,Sensitivity/Response,Colorectal Cancer,5290.0,Aspirin,PIK3CA
2950,R351W,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,25.0,Imatinib,ABL1
2951,Exon 11 Mutation,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Regorafenib,KIT
2952,EWSR1-NR4A3,B,Sensitivity/Response,Extraskeletal Myxoid Chondrosarcoma,2130.0,Sunitinib,EWSR1
2953,UNDEREXPRESSION,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,54206.0,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,ERRFI1
2954,T618I,D,Sensitivity/Response,Chronic Neutrophilic Leukemia,1441.0,Ruxolitinib,CSF3R
2955,T618I,C,Sensitivity/Response,Chronic Neutrophilic Leukemia,1441.0,Ruxolitinib,CSF3R
2956,56_61QKQKVG>R,D,Resistance,Langerhans-cell Histiocytosis,5604.0,Trametinib,MAP2K1
2957,C121S and G128D,D,Resistance,Langerhans-cell Histiocytosis,5604.0,Trametinib,MAP2K1
2958,NTRK1-TRIM63,E,Sensitivity/Response,Melanoma,4914.0,Larotrectinib,NTRK1
2959,NTRK1-DDR2,E,Sensitivity/Response,Melanoma,4914.0,Larotrectinib,NTRK1
2960,NTRK1-GON4L,E,Sensitivity/Response,Melanoma,4914.0,Larotrectinib,NTRK1
2961,ETV6-NTRK3,C,Sensitivity/Response,Hematologic Cancer,4916.0,Larotrectinib,NTRK3
2962,ETV6-NTRK2,C,Sensitivity/Response,Acute Myeloid Leukemia,4915.0,Larotrectinib,NTRK2
2963,AMPLIFICATION,D,Resistance,Lung Non-small Cell Carcinoma,1399.0,Gefitinib,CRKL
2964,AMPLIFICATION,D,Sensitivity/Response,Stomach Cancer,1399.0,Dasatinib,CRKL
2965,LOSS-OF-FUNCTION,D,Sensitivity/Response,Ovarian Cancer,8289.0,Atezolizumab+Pembrolizumab+Nivolumab,ARID1A
2966,intron 10 rearrangement,B,Resistance,Melanoma,673.0,Vemurafenib+Dabrafenib,BRAF
2967,intron 9 rearrangement,B,Resistance,Melanoma,673.0,Vemurafenib+Dabrafenib,BRAF
2968,D594K,B,Resistance,Colorectal Cancer,673.0,Irinotecan,BRAF
2969,D594K,B,Resistance,Colorectal Cancer,673.0,Oxaliplatin,BRAF
2970,S249C,B,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,Infigratinib,FGFR3
2971,V443L,C,Resistance,Transitional Cell Carcinoma,2261.0,Infigratinib,FGFR3
2972,V443M,C,Resistance,Transitional Cell Carcinoma,2261.0,Infigratinib,FGFR3
2973,V496V,C,Resistance,Transitional Cell Carcinoma,2261.0,Infigratinib,FGFR3
2974,V555M,D,Resistance,Myeloid Neoplasm,2261.0,FGFR Inhibitor AZD4547+AZ12908010+PD173074,FGFR3
2975,FGFR3-TACC3,C,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,Infigratinib,FGFR3
2976,R248C,B,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,Infigratinib,FGFR3
2977,Y373C,C,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,Infigratinib,FGFR3
2978,Y375C,C,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,Infigratinib,FGFR3
2979,G380R,C,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,Infigratinib,FGFR3
2980,G370C,B,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,Infigratinib,FGFR3
2981,F386L,C,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,Infigratinib,FGFR3
2982,N78S (c.233A>G),C,Sensitivity/Response,Von Hippel-Lindau Disease,7428.0,Sunitinib,VHL
2983,Underexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,2067.0,Platinum Compound,ERCC1
2984,Underexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,2067.0,Cisplatin+Gemcitabine,ERCC1
2985,Underexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,6240.0,Gemcitabine+Cisplatin,RRM1
2986,Underexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,2067.0,Cisplatin,ERCC1
2987,Underexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,6240.0,Gemcitabine+Platinum Compound,RRM1
2988,OVEREXPRESSION,B,Resistance,Lung Non-small Cell Carcinoma,2067.0,Gemcitabine+Nedaplatin,ERCC1
2989,Underexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,6240.0,Gemcitabine+Cisplatin,RRM1
2990,UNDEREXPRESSION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,4089.0,Gemcitabine,SMAD4
2991,R132,D,Sensitivity/Response,Intrahepatic Cholangiocarcinoma,3417.0,Dasatinib,IDH1
2992,Mutation,B,Resistance,Lung Adenocarcinoma,6794.0,Nivolumab+Pembrolizumab+Atezolizumab,STK11
2993,E102_I103delEI,C,Sensitivity/Response,Langerhans-cell Histiocytosis,5604.0,Trametinib,MAP2K1
2994,LOSS-OF-FUNCTION,B,Resistance,Colorectal Cancer,4089.0,Lysine,SMAD4
2995,Mutation,B,Sensitivity/Response,Endometrial Cancer,2263.0,Fulvestrant+Dovitinib,FGFR2
2996,Mutation,B,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
2997,Mutation,D,Resistance,Lung Non-small Cell Carcinoma,1956.0,Afatinib+Gefitinib,EGFR
2998,ETV6-NTRK3,C,Sensitivity/Response,Congenital Fibrosarcoma,4916.0,Larotrectinib,NTRK3
2999,ETV6-NTRK3,C,Sensitivity/Response,Breast Secretory Carcinoma,4916.0,Larotrectinib,NTRK3
3000,LOSS-OF-FUNCTION,B,Resistance,Breast Cancer,58508.0,Letrozole+Anastrozole+Exemestane,KMT2C
3001,Fusion,B,Sensitivity/Response,Solid Tumor,4914.0,Larotrectinib,NTRK1
3002,Fusion,A,Sensitivity/Response,Solid Tumor,4916.0,Larotrectinib,NTRK3
3003,Fusion,B,Sensitivity/Response,Sarcoma,4914.0,Larotrectinib,NTRK1
3004,AMPLIFICATION,D,Sensitivity/Response,Melanoma,4893.0,Binimetinib,NRAS
3005,Amplification,B,Sensitivity/Response,Gastric Adenocarcinoma,1956.0,Cetuximab,EGFR
3006,Amplification,D,Sensitivity/Response,Esophageal Carcinoma,4609.0,Ibrutinib,MYC
3007,Amplification,D,Sensitivity/Response,Esophageal Cancer,2064.0,Ibrutinib,ERBB2
3008,ETV6-NTRK3,D,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,4916.0,Larotrectinib,NTRK3
3009,LOSS-OF-FUNCTION,D,Sensitivity/Response,Triple-receptor Negative Breast Cancer,5782.0,Sunitinib+Crizotinib,
3010,V600,B,Sensitivity/Response,Melanoma,673.0,Dabrafenib+Trametinib,BRAF
3011,V600E,B,Sensitivity/Response,Melanoma,673.0,Dabrafenib+Trametinib,BRAF
3012,V600K,B,Sensitivity/Response,Melanoma,673.0,Dabrafenib+Trametinib,BRAF
3013,V600E,B,Sensitivity/Response,Melanoma,673.0,Trametinib+Dabrafenib,BRAF
3014,V600K,B,Sensitivity/Response,Melanoma,673.0,Trametinib+Dabrafenib,BRAF
3015,KIF5B-RET,C,Sensitivity/Response,Lung Cancer,5979.0,Selpercatinib,RET
3016,Fusion,D,Sensitivity/Response,Cancer,5979.0,Selpercatinib,RET
3017,M918T,C,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,5979.0,Selpercatinib,RET
3018,V804M,C,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,5979.0,Selpercatinib,RET
3019,Y646F,D,Sensitivity/Response,Skin Melanoma,2146.0,JQEZ5,EZH2
3020,OVEREXPRESSION,B,Sensitivity/Response,Salivary Gland Cancer,367.0,Leuprolide+Bicalutamide,AR
3021,V7 EXPRESSION,C,Resistance,Salivary Gland Cancer,367.0,Abiraterone Acetate,AR
3022,D816V,E,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
3023,D816H,D,Resistance,Acute Myeloid Leukemia,3815.0,Imatinib Mesylate,KIT
3024,N822K,D,Sensitivity/Response,Acute Myeloid Leukemia,3815.0,Imatinib Mesylate,KIT
3025,Promoter Mutation,B,Resistance,Thyroid Gland Carcinoma,7015.0,Iodine I-131,TERT
3026,V600K,B,Sensitivity/Response,Melanoma,673.0,Trametinib+Dabrafenib,BRAF
3027,V600,B,Sensitivity/Response,Melanoma,673.0,Vemurafenib+Cobimetinib,BRAF
3028,ETV6-ABL1,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,25.0,Dasatinib,ABL1
3029,BCR-ABL F359V,C,Resistance,Chronic Myeloid Leukemia,25.0,Nilotinib+Imatinib Mesylate,ABL1
3030,BCR-ABL E255V,C,Resistance,Chronic Myeloid Leukemia,25.0,Nilotinib+Imatinib Mesylate,ABL1
3031,Overexpression,D,Sensitivity/Response,Ovarian Cancer,3481.0,Ganitumab,IGF2
3032,V600E,B,Sensitivity/Response,Thyroid Gland Anaplastic Carcinoma,673.0,Trametinib+Dabrafenib,BRAF
3033,EBF1-PDGFRB,C,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,5159.0,Imatinib,PDGFRB
3034,C475V,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3035,BCR-ABL F317L,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3036,BCR-ABL N336S,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3037,BCR-ABL E453A,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3038,BCR-ABL L387F,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3039,BCR-ABL V299L,B,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3040,BCR-ABL Q300R,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3041,BCR-ABL F359I,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3042,BCR-ABL F359C,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3043,BCR-ABL E255V,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3044,BCR-ABL F486S,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3045,BCR-ABL H396R,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3046,BCR-ABL M351T,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3047,BCR-ABL T315I,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3048,BCR-ABL E255K,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3049,BCR-ABL Y253H,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3050,BCR-ABL G250E,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
3051,BCR-ABL M244V,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3052,BCR-ABL F359V,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3053,AGGF1-PDGFRB C843G,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,5159.0,CHZ868,PDGFRB
3054,Overexpression,B,Sensitivity/Response,Pancreatic Adenocarcinoma,3481.0,Ganitumab+Gemcitabine,IGF2
3055,Overexpression,D,Sensitivity/Response,Pancreatic Cancer,4854.0,Tarextumab,NOTCH3
3056,Overexpression,D,Sensitivity/Response,Rectum Cancer,4854.0,Tarextumab,NOTCH3
3057,GOLGA5-JAK2,C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",3717.0,Ruxolitinib,JAK2
3058,PAX3-FOXO1,D,Sensitivity/Response,Alveolar Rhabdomyosarcoma,2308.0,BET Inhibitor,FOXO1
3059,Overexpression,D,Sensitivity/Response,Neuroblastoma,1025.0,Dinaciclib,
3060,Overexpression,B,Sensitivity/Response,Glioblastoma,7422.0,Bevacizumab,VEGFA
3061,Overexpression,B,Sensitivity/Response,Breast Cancer,2064.0,Lapatinib,ERBB2
3062,Overexpression,B,Sensitivity/Response,Breast Cancer,2064.0,Lapatinib,ERBB2
3063,OVEREXPRESSION,D,Sensitivity/Response,Malignant Peripheral Nerve Sheath Tumor,142.0,Olaparib,PARP1
3064,BRD4-NUTM1,C,Sensitivity/Response,NUT Midline Carcinoma,23476.0,Birabresib,BRD4
3065,FIP1L1-PDGFRA T674I,C,Resistance,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",5156.0,Imatinib,PDGFRA
3066,F694L,C,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,3717.0,Ruxolitinib,JAK2
3067,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
3068,EBF1-PDGFRB,C,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,5159.0,Imatinib,PDGFRB
3069,BCR-ABL F317L,C,Reduced Sensitivity,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
3070,BCR-ABL E255K,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3071,BCR-ABL V379I,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3072,BCR-ABL A397P,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3073,BCR-ABL F359C,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3074,BCR-ABL E355G,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3075,BCR-ABL M351T,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3076,BCR-ABL T315I,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3077,BCR-ABL E255K,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3078,BCR-ABL Y253H,B,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3079,BCR-ABL G250E,B,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3080,BCR-ABL M244V,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3081,BCR-ABL F359V,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3082,BCR-ABL L248V,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3083,BCR-ABL F317L,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3084,BCR-ABL E459K,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3085,Wildtype,B,Sensitivity/Response,Colorectal Cancer,3845.0,Oxaliplatin+Fluorouracil+Panitumumab+Leucovorin,KRAS
3086,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Brigatinib,ALK
3087,Expression,B,Sensitivity/Response,Renal Cell Carcinoma,3066.0,Abexinostat+Pazopanib,
3088,ITD,B,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Midostaurin,FLT3
3089,Overexpression,B,Sensitivity/Response,Gastroesophageal Junction Adenocarcinoma,2064.0,Trastuzumab,ERBB2
3090,Overexpression,B,Sensitivity/Response,Stomach Cancer,2064.0,Trastuzumab,ERBB2
3091,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,5979.0,Selpercatinib,RET
3092,KIF5B-RET,B,Sensitivity/Response,Lung Cancer,5979.0,Selpercatinib,RET
3093,V804M,C,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,5979.0,Selpercatinib,RET
3094,Fusion,B,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,5979.0,Selpercatinib,RET
3095,Mutation,B,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,5979.0,Selpercatinib,RET
3096,AMPLIFICATION,D,Sensitivity/Response,Colorectal Cancer,8660.0,Dual IGF-1R/InsR Inhibitor BMS-754807,IRS2
3097,G13D,D,Resistance,Colorectal Cancer,3845.0,Dual IGF-1R/InsR Inhibitor BMS-754807,KRAS
3098,V600E,D,Resistance,Colorectal Cancer,673.0,Dual IGF-1R/InsR Inhibitor BMS-754807,BRAF
3099,Overexpression,B,Sensitivity/Response,Salivary Gland Cancer,2064.0,Trastuzumab+Docetaxel,ERBB2
3100,I462K,B,Resistance,Colorectal Cancer,1956.0,Cetuximab+Panitumumab,EGFR
3101,I462R,B,Resistance,Colorectal Cancer,1956.0,Cetuximab+Panitumumab,EGFR
3102,S464L,B,Resistance,Colorectal Cancer,1956.0,Panitumumab+Cetuximab,EGFR
3103,S464T,B,Resistance,Colorectal Cancer,1956.0,Panitumumab+Cetuximab,EGFR
3104,G465R,B,Resistance,Colorectal Cancer,1956.0,Panitumumab+Cetuximab,EGFR
3105,G465E,B,Resistance,Colorectal Cancer,1956.0,Cetuximab+Panitumumab,EGFR
3106,G465V,B,Resistance,Colorectal Cancer,1956.0,Cetuximab+Panitumumab,EGFR
3107,K467N,B,Resistance,Colorectal Cancer,1956.0,Cetuximab+Panitumumab,EGFR
3108,K467T,B,Resistance,Colorectal Cancer,1956.0,Cetuximab+Panitumumab,EGFR
3109,K489Q,B,Resistance,Colorectal Cancer,1956.0,Panitumumab+Cetuximab,EGFR
3110,K489E,B,Resistance,Colorectal Cancer,1956.0,Panitumumab+Cetuximab,EGFR
3111,I491K,B,Resistance,Colorectal Cancer,1956.0,Cetuximab+Panitumumab,EGFR
3112,I491R,B,Resistance,Colorectal Cancer,1956.0,Panitumumab+Cetuximab,EGFR
3113,S492R,B,Resistance,Colorectal Cancer,1956.0,Cetuximab+Panitumumab,EGFR
3114,S492C,B,Resistance,Colorectal Cancer,1956.0,Panitumumab+Cetuximab,EGFR
3115,V441G,B,Resistance,Colorectal Cancer,1956.0,Panitumumab+Cetuximab,EGFR
3116,V441D,B,Resistance,Colorectal Cancer,1956.0,Cetuximab+Panitumumab,EGFR
3117,V441F,E,Resistance,Colorectal Cancer,1956.0,Panitumumab+Cetuximab,EGFR
3118,S442R,B,Resistance,Colorectal Cancer,1956.0,Cetuximab+Panitumumab,EGFR
3119,S442I,B,Resistance,Colorectal Cancer,1956.0,Cetuximab+Panitumumab,EGFR
3120,F404I,B,Resistance,Colorectal Cancer,1956.0,Panitumumab+Cetuximab,EGFR
3121,F404V,B,Resistance,Colorectal Cancer,1956.0,Panitumumab+Cetuximab,EGFR
3122,T415M,B,Resistance,Colorectal Cancer,1956.0,Cetuximab+Panitumumab,EGFR
3123,Amplification,C,Sensitivity/Response,Colorectal Cancer,2322.0,Sorafenib,FLT3
3124,Amplification,B,Resistance,Colorectal Cancer,3845.0,Panitumumab+Cetuximab,KRAS
3125,EBF1-PDGFRB,C,Sensitivity/Response,B-cell Adult Acute Lymphocytic Leukemia,5159.0,Imatinib,PDGFRB
3126,EBF1-PDGFRB,C,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,5159.0,Dasatinib+Imatinib,PDGFRB
3127,ATF7IP-PDGFRB,C,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,5159.0,Dasatinib,PDGFRB
3128,Overexpression,D,Sensitivity/Response,Alveolar Rhabdomyosarcoma,238.0,Crizotinib,ALK
3129,OVEREXPRESSION,D,Sensitivity/Response,Alveolar Rhabdomyosarcoma,2264.0,Ponatinib,FGFR4
3130,OVEREXPRESSION,D,Resistance,Alveolar Rhabdomyosarcoma,1019.0,Palbociclib+Ribociclib,CDK4
3131,AMPLIFICATION,C,Sensitivity/Response,Angiosarcoma,3791.0,Pazopanib,KDR
3132,Fusion,D,Sensitivity/Response,Anaplastic Large Cell Lymphoma,238.0,Crizotinib,ALK
3133,MUTATION,B,Sensitivity/Response,Melanoma,3815.0,Nilotinib,KIT
3134,LOSS,D,Sensitivity/Response,Ovarian Small Cell Carcinoma,6597.0,Ribociclib+Abemaciclib+Palbociclib,SMARCA4
3135,LOSS,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,6597.0,Palbociclib+Abemaciclib,SMARCA4
3136,R248Q,D,Resistance,Ovarian Cancer,7157.0,Paclitaxel+Doxorubicin+Etoposide,TP53
3137,A146T,D,Resistance,Colorectal Cancer,3845.0,Cetuximab,KRAS
3138,Q61P,D,Resistance,Colorectal Cancer,3845.0,Irinotecan+Cetuximab,KRAS
3139,G12S,D,Resistance,Lung Non-small Cell Carcinoma,3845.0,MUC1-targeted Peptide GO-203-2C,KRAS
3140,Activating Mutation,B,Sensitivity/Response,Pancreatic Cancer,3845.0,Salirasib,KRAS
3141,G12D,D,Sensitivity/Response,Pancreatic Cancer,3845.0,Phosphatidylinositide 3-Kinase Inhibitor,KRAS
3142,Activating Mutation,D,Sensitivity/Response,Pancreatic Cancer,3845.0,Inhibitor,KRAS
3143,G12,D,Resistance,Pancreatic Cancer,3845.0,Mitogen-Activated Protein Kinase Kinase Inhibitor,KRAS
3144,Activating Mutation,D,Sensitivity/Response,Pancreatic Cancer,3845.0,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor+Mitogen-Activated Protein Kinase Kinase Inhibitor,KRAS
3145,Mutation,B,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,5290.0,Sulindac+Celecoxib+Aspirin,PIK3CA
3146,Amplification,B,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,5290.0,Sulindac+Ibuprofen+Aspirin,PIK3CA
3147,Mutation,B,Sensitivity/Response,Colorectal Cancer,5290.0,Aspirin,PIK3CA
3148,M541L,E,Sensitivity/Response,Colon Signet Ring Adenocarcinoma,3815.0,Imatinib,KIT
3149,ATF7IP-PDGFRB,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,5159.0,Nilotinib+Imatinib+Rebastinib+Dasatinib+Bafetinib+Ponatinib,PDGFRB
3150,KIAA1549-BRAF,D,Sensitivity/Response,Childhood Low-grade Glioma,673.0,Everolimus+Trametinib,BRAF
3151,FAM131B-BRAF,D,Sensitivity/Response,Childhood Low-grade Glioma,673.0,Everolimus+Trametinib,BRAF
3152,KIAA1549-BRAF,D,Sensitivity/Response,Childhood Low-grade Glioma,673.0,Everolimus+Trametinib,BRAF
3153,Activating Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,2064.0,Afatinib,ERBB2
3154,A775_G776insYVMA,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,2064.0,Afatinib,ERBB2
3155,KIAA1549-BRAF,D,Adverse Response,Childhood Low-grade Glioma,673.0,Vemurafenib+PLX4720,BRAF
3156,Overexpression,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,2057.0,Inhibitor,EPOR
3157,NUP214-ABL1,C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",25.0,Vincristine+Dasatinib+Dexamethasone,ABL1
3158,F232C,D,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,64109.0,JAK Inhibitor I,CRLF2
3159,Overexpression,B,Sensitivity/Response,Stomach Cancer,7422.0,Bevacizumab,VEGFA
3160,Overexpression,B,Resistance,Ovarian Cancer,7422.0,Bevacizumab+Erlotinib,VEGFA
3161,SNX2-ABL1,C,Resistance,B-lymphoblastic Leukemia/lymphoma,25.0,Dasatinib,ABL1
3162,Overexpression,D,Sensitivity/Response,"Diffuse Midline Glioma, H3 K27M-mutant",7465.0,Adavosertib,WEE1
3163,Overexpression,D,Sensitivity/Response,"Diffuse Midline Glioma, H3 K27M-mutant",7465.0,Adavosertib,WEE1
3164,G284R,C,Sensitivity/Response,Breast Cancer,2065.0,Lapatinib+Trastuzumab,ERBB3
3165,BCR-ABL E255V,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib Mesylate,ABL1
3166,Amplification,C,Sensitivity/Response,Breast Cancer,2260.0,Pazopanib,FGFR1
3167,Mutation,B,Sensitivity/Response,Clear Cell Renal Cell Carcinoma,55193.0,Anti-PD-L1 Monoclonal Antibody+CTLA-4 Inhibitor,PBRM1
3168,RCSD1-ABL1,C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",25.0,Imatinib,ABL1
3169,RCSD1-ABL1,D,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",25.0,Dasatinib,ABL1
3170,Fusion,C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",27.0,Imatinib,ABL2
3171,Fusion,D,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",27.0,Dasatinib,ABL2
3172,D579del,C,Sensitivity/Response,Sinonasal Undifferentiated Carcinoma,3815.0,Imatinib Mesylate,KIT
3173,SNX2-ABL1,C,Reduced Sensitivity,B-lymphoblastic Leukemia/lymphoma,25.0,Imatinib,ABL1
3174,SSBP2-JAK2,C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",3717.0,Ruxolitinib,JAK2
3175,V600E,B,Sensitivity/Response,Colorectal Cancer,673.0,Encorafenib+Cetuximab+Binimetinib,BRAF
3176,Fusion,A,Sensitivity/Response,Transitional Cell Carcinoma,2263.0,Erdafitinib,FGFR2
3177,Fusion,A,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,Erdafitinib,FGFR3
3178,Mutation,A,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,Erdafitinib,FGFR3
3179,V600E,B,Sensitivity/Response,Biliary Tract Cancer,673.0,Dabrafenib+Trametinib,BRAF
3180,Loss,C,Sensitivity/Response,Neurofibroma,4763.0,Trametinib,NF1
3181,Mutation,B,Sensitivity/Response,Plexiform Neurofibroma,4763.0,Selumetinib,NF1
3182,G595R,B,Resistance,Solid Tumor,4914.0,Larotrectinib,NTRK1
3183,G623R,C,Resistance,Solid Tumor,4916.0,Larotrectinib,NTRK3
3184,G595R,C,Sensitivity/Response,Solid Tumor,4914.0,Selitrectinib,NTRK1
3185,G623R,C,Sensitivity/Response,Solid Tumor,4916.0,Selitrectinib,NTRK3
3186,EXON 14 SKIPPING MUTATION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,4233.0,Tepotinib,MET
3187,Exon 20 Insertion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,TAK-788,EGFR
3188,Mutation,A,Sensitivity/Response,Ovarian Cancer,672.0,Olaparib,BRCA1
3189,Mutation,A,Sensitivity/Response,Ovarian Cancer,672.0,Olaparib,BRCA1
3190,Mutation,A,Sensitivity/Response,Ovarian Cancer,675.0,Olaparib,BRCA2
3191,Mutation,A,Sensitivity/Response,Ovarian Cancer,672.0,Olaparib,BRCA1
3192,Mutation,A,Sensitivity/Response,Acute Myeloid Leukemia,3417.0,Ivosidenib,IDH1
3193,Mutation,A,Sensitivity/Response,Acute Myeloid Leukemia,3418.0,Enasidenib,IDH2
3194,Loss-of-function,A,Sensitivity/Response,Tuberous Sclerosis,7248.0,Everolimus,TSC1
3195,LOSS-OF-FUNCTION,A,Sensitivity/Response,Tuberous Sclerosis,7249.0,Everolimus,TSC2
3196,Fusion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,6098.0,Crizotinib,ROS1
3197,Mutation,B,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Gilteritinib,FLT3
3198,Fusion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Alectinib,ALK
3199,Fusion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Ceritinib,ALK
3200,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Lorlatinib,ALK
3201,V600,A,Sensitivity/Response,Melanoma,673.0,Encorafenib+Binimetinib,BRAF
3202,V555_V559DEL,C,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
3203,FOXP1-ABL1,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,25.0,Dasatinib,ABL1
3204,MUTATION,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,867.0,SU11274,CBL
3205,Q294E,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,867.0,SU11274,CBL
3206,S80N and H94Y,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,867.0,SU11274,CBL
3207,V391I,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,867.0,SU11274,CBL
3208,W802*,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,867.0,SU11274,CBL
3209,LOSS-OF-FUNCTION,B,Sensitivity/Response,Renal Cell Carcinoma,55193.0,Ipilimumab,PBRM1
3210,Amplification,B,Sensitivity/Response,Colorectal Cancer,2064.0,Pertuzumab+Trastuzumab,ERBB2
3211,Promoter Methylation,A,Sensitivity/Response,Glioblastoma,4255.0,Temozolomide+Lomustine,MGMT
3212,DEK-AFF2,C,Sensitivity/Response,Head And Neck Cancer,7913.0,Pembrolizumab,DEK
3213,R248C,A,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,Erdafitinib,FGFR3
3214,S249C,A,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,Erdafitinib,FGFR3
3215,G370C,A,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,Erdafitinib,FGFR3
3216,Y373C,A,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,Erdafitinib,FGFR3
3217,KIF5B-MET,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,4233.0,Crizotinib,MET
3218,G12R,C,Sensitivity/Response,Histiocytosis-Lymphadenopathy Plus Syndrome,3845.0,Cobimetinib,KRAS
3219,KIAA1549-BRAF,C,Sensitivity/Response,Spindle Cell Sarcoma,673.0,Sorafenib+Bevacizumab+Temsirolimus,BRAF
3220,Mutation,A,Sensitivity/Response,Breast Cancer,5290.0,Fulvestrant+Alpelisib,PIK3CA
3221,EGFR-RAD51,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Icotinib,EGFR
3222,E542K,A,Sensitivity/Response,Breast Cancer,5290.0,Fulvestrant+Alpelisib,PIK3CA
3223,E545X,A,Sensitivity/Response,Breast Cancer,5290.0,Alpelisib+Fulvestrant,PIK3CA
3224,Mutation,A,Sensitivity/Response,Breast Cancer,5290.0,Fulvestrant+Alpelisib,PIK3CA
3225,H1047X,A,Sensitivity/Response,Breast Cancer,5290.0,Fulvestrant+Alpelisib,PIK3CA
3226,Fusion,C,Sensitivity/Response,Cholangiocarcinoma,2263.0,Futibatinib,FGFR2
3227,T1977K,D,Sensitivity/Response,Solid Tumor,2475.0,Sirolimus,MTOR
3228,C1483F,D,Sensitivity/Response,Solid Tumor,2475.0,Sirolimus,MTOR
3229,F1888L,D,Sensitivity/Response,Solid Tumor,2475.0,Sirolimus,MTOR
3230,S2215F,D,Sensitivity/Response,Solid Tumor,2475.0,Sirolimus,MTOR
3231,L2230V,D,Sensitivity/Response,Solid Tumor,2475.0,Sirolimus,MTOR
3232,LOSS-OF-FUNCTION,D,Sensitivity/Response,Liver Cancer,8289.0,Sorafenib,ARID1A
3233,Fusion,B,Sensitivity/Response,Cholangiocarcinoma,2263.0,Derazantinib,FGFR2
3234,OVEREXPRESSION,D,Sensitivity/Response,Colorectal Cancer,5710.0,Carfilzomib,
3235,ｍRNA expression low,B,Sensitivity/Response,Breast Cancer,898.0,Fulvestrant+Palbociclib,CCNE1
3236,Q61H,B,Sensitivity/Response,Melanoma,4893.0,Ipilimumab,NRAS
3237,V600,B,Sensitivity/Response,Colorectal Cancer,673.0,Irinotecan+Vemurafenib+Cetuximab,BRAF
3238,D820E,C,Sensitivity/Response,Thymic Carcinoma,3815.0,Sorafenib,KIT
3239,V559G,C,Sensitivity/Response,Thymic Carcinoma,3815.0,Imatinib Mesylate,KIT
3240,Y553N,C,Sensitivity/Response,Thymic Carcinoma,3815.0,Imatinib Mesylate,KIT
3241,V560DEL,C,Sensitivity/Response,Thymic Carcinoma,3815.0,Imatinib Mesylate,KIT
3242,P577_D579DEL,C,Sensitivity/Response,Thymic Carcinoma,3815.0,Sorafenib,KIT
3243,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Dacomitinib,EGFR
3244,DELETION,B,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,10320.0,Cytarabine+Methotrexate+Daunorubicin+Imatinib+Fludarabine,IKZF1
3245,R832L,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib,EGFR
3246,R832L,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,EGFR
3247,ITD,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Ponatinib,FLT3
3248,ITD,D,Sensitivity/Response,Leukemia,2322.0,Sorafenib,FLT3
3249,ITD,D,Sensitivity/Response,Leukemia,2322.0,Sunitinib,FLT3
3250,FIP1L1-PDGFRA,D,Sensitivity/Response,Acute Myeloid Leukemia,5156.0,Sorafenib,PDGFRA
3251,FIP1L1-PDGFRA,D,Sensitivity/Response,Acute Myeloid Leukemia,5156.0,Sunitinib+Sorafenib,PDGFRA
3252,N822K,D,Sensitivity/Response,Acute Myeloid Leukemia,3815.0,Ponatinib,KIT
3253,FGFR1OP2-FGFR1,D,Sensitivity/Response,Acute Myeloid Leukemia,2260.0,Ponatinib,FGFR1
3254,FIP1L1-PDGFRA,D,Sensitivity/Response,Acute Myeloid Leukemia,5156.0,Ponatinib,PDGFRA
3255,ITD,D,Sensitivity/Response,Leukemia,2322.0,Sunitinib+Sorafenib,FLT3
3256,Loss-of-function,A,Sensitivity/Response,Pancreatic Adenocarcinoma,672.0,Olaparib,BRCA1
3257,Loss-of-function,A,Sensitivity/Response,Pancreatic Adenocarcinoma,675.0,Olaparib,BRCA2
3258,Overexpression,B,Sensitivity/Response,Endometrial Serous Adenocarcinoma,2064.0,Paclitaxel+Carboplatin+Trastuzumab,ERBB2
3259,G12C,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,3845.0,Sotorasib,KRAS
3260,M766Q,C,Resistance,Lung Non-small Cell Carcinoma,1956.0,Osimertinib,EGFR
3261,M766Q,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Neratinib,EGFR
3262,M766Q,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Poziotinib,EGFR
3263,A502_Y503insAY,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
3264,V560G,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Ponatinib+Regorafenib+Imatinib,KIT
3265,V560G,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Regorafenib+Imatinib+Ponatinib,KIT
3266,V560G,E,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib,KIT
3267,K642E,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Sunitinib+Ponatinib,KIT
3268,KIAA1549-BRAF,D,Resistance,Childhood Pilocytic Astrocytoma,673.0,Vemurafenib+Sorafenib,BRAF
3269,N822K,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Ponatinib,KIT
3270,D816H,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Ponatinib,KIT
3271,D816G,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Ponatinib,KIT
3272,D820A,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Ponatinib,KIT
3273,D820G,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,Ponatinib,KIT
3274,N822K,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib+Imatinib,KIT
3275,A829P,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Sunitinib+Imatinib,KIT
3276,T670I,D,Resistance,Gastrointestinal Stromal Tumor,3815.0,Imatinib,KIT
3277,ETV6-NTRK3,C,Sensitivity/Response,Congenital Fibrosarcoma,4916.0,Larotrectinib,NTRK3
3278,TPM3-NTRK1,C,Sensitivity/Response,Spindle Cell Sarcoma,4914.0,Larotrectinib,NTRK1
3279,PDE4DIP-NTRK1,C,Sensitivity/Response,Sarcoma,4914.0,Larotrectinib,NTRK1
3280,Mutation,A,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,Erdafitinib,FGFR3
3281,Fusion,A,Sensitivity/Response,Transitional Cell Carcinoma,2263.0,Erdafitinib,FGFR2
3282,Fusion,A,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,Erdafitinib,FGFR3
3283,MUTATION,B,Sensitivity/Response,Lung Squamous Cell Carcinoma,4780.0,Sapanisertib,NFE2L2
3284,Overexpression,B,Sensitivity/Response,Breast Cancer,2065.0,Patritumab Deruxtecan,ERBB3
3285,EML6::ALK e1-e20 and FBXO11::ALK e1-e20,C,Sensitivity/Response,Lung Adenocarcinoma,238.0,Crizotinib,ALK
3286,R273H,D,Resistance,Osteosarcoma,7157.0,Methotrexate+Doxorubicin,TP53
3287,Mutation,C,Sensitivity/Response,Pancreatic Cancer,675.0,Rucaparib,BRCA2
3288,LOSS-OF-FUNCTION,D,Sensitivity/Response,Cancer,5071.0,Phosphatidylinositide 3-Kinase Inhibitor,PRKN
3289,MUTATION,B,Sensitivity/Response,Lung Squamous Cell Carcinoma,4780.0,Sapanisertib,NFE2L2
3290,Mutation,B,Sensitivity/Response,Cholangiocarcinoma,3417.0,Ivosidenib,IDH1
3291,R132,B,Sensitivity/Response,Glioma,3417.0,Mutant IDH1 Inhibitor DS-1001,IDH1
3292,Mutation,B,Sensitivity/Response,Melanoma,4893.0,Belvarafenib,NRAS
3293,V600E,B,Sensitivity/Response,Cholangiocarcinoma,673.0,Dabrafenib+Trametinib,BRAF
3294,V600E,B,Sensitivity/Response,Ovarian Cancer,673.0,Dabrafenib+Trametinib,BRAF
3295,G12C,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,3845.0,Sotorasib,KRAS
3296,ATM,B,Sensitivity/Response,Prostate Cancer,672.0,Olaparib,BRCA1
3297,Mutation,B,Sensitivity/Response,Prostate Cancer,675.0,Olaparib,BRCA2
3298,Mutation,B,Sensitivity/Response,Prostate Cancer,672.0,Olaparib,BRCA1
3299,Mutation,B,Sensitivity/Response,Breast Cancer,79728.0,Rucaparib,PALB2
3300,LOSS,B,Sensitivity/Response,Solid Tumor,472.0,Elimusertib,ATM
3301,D816V,C,Resistance,Cancer,3815.0,Dasatinib+Imatinib,KIT
3302,NRG1 FUSIONS,C,Sensitivity/Response,Pancreatic Cancer,3084.0,Afatinib,NRG1
3303,E545,A,Sensitivity/Response,Breast Cancer,5290.0,Alpelisib+Fulvestrant,PIK3CA
3304,MUTATION,C,Sensitivity/Response,Colorectal Cancer,5426.0,Pembrolizumab,POLE
3305,Mutation,B,Sensitivity/Response,Prostate Cancer,672.0,Olaparib,BRCA1
3306,Mutation,B,Sensitivity/Response,Prostate Cancer,675.0,Olaparib,BRCA2
3307,Mutation,B,Sensitivity/Response,Prostate Cancer,472.0,Olaparib,ATM
3308,Mutation,B,Sensitivity/Response,Prostate Cancer,79728.0,Olaparib,PALB2
3309,D842V,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,5156.0,Avapritinib,PDGFRA
3310,CCDC6-RET,C,Sensitivity/Response,Colorectal Cancer,5979.0,Agerafenib,RET
3311,CAD-ALK,C,Sensitivity/Response,Colorectal Cancer,238.0,Entrectinib,ALK
3312,GOPC-ROS1,D,Sensitivity/Response,Glioblastoma,6098.0,Lorlatinib,ROS1
3313,V600E,B,Sensitivity/Response,Childhood Pilocytic Astrocytoma,673.0,Selumetinib,BRAF
3314,KIAA1549-BRAF,B,Sensitivity/Response,Childhood Pilocytic Astrocytoma,673.0,Selumetinib,BRAF
3315,Mutation,B,Sensitivity/Response,Childhood Low-grade Glioma,4763.0,Selumetinib,NF1
3316,Amplification,B,Sensitivity/Response,Breast Cancer,2260.0,Lucitanib,FGFR1
3317,SLC3A2-NRG1,C,Sensitivity/Response,Mucinous Adenocarcinoma,3084.0,Afatinib,NRG1
3318,CD74-NRG1,C,Sensitivity/Response,Mucinous Adenocarcinoma,3084.0,Afatinib,NRG1
3319,SLC3A2-NRG1,C,Sensitivity/Response,Lung Adenocarcinoma,3084.0,Afatinib,NRG1
3320,ATP1B1-NRG1,C,Sensitivity/Response,Pancreatic Ductal Adenocarcinoma,3084.0,Afatinib,NRG1
3321,APP-NRG1,C,Sensitivity/Response,Pancreatic Ductal Adenocarcinoma,3084.0,Afatinib,NRG1
3322,CD74-NRG1,C,Sensitivity/Response,Mucinous Adenocarcinoma,3084.0,Afatinib,NRG1
3323,SLC3A2-NRG1,C,Sensitivity/Response,Mucinous Adenocarcinoma,3084.0,Erlotinib+Lumretuzumab,NRG1
3324,ETV6-NTRK3,A,Sensitivity/Response,Solid Tumor,4916.0,Larotrectinib,NTRK3
3325,R1004G,C,Sensitivity/Response,Head And Neck Cancer,4233.0,Crizotinib,MET
3326,Amplification,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,4233.0,Crizotinib,MET
3327,Exon 14 Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,4233.0,Crizotinib,MET
3328,N549H,D,Sensitivity/Response,Chronic Myeloid Leukemia,2263.0,Bosutinib,FGFR2
3329,N549H,D,Sensitivity/Response,Chronic Myeloid Leukemia,2263.0,Dasatinib,FGFR2
3330,V561M,D,Resistance,Chronic Myeloid Leukemia,2260.0,Bosutinib,FGFR1
3331,V561M,D,Resistance,Chronic Myeloid Leukemia,2260.0,Dasatinib,FGFR1
3332,D842V,D,Sensitivity/Response,Chronic Myeloid Leukemia,5156.0,Bosutinib,PDGFRA
3333,KIF5B-RET V804L,D,Resistance,Chronic Myeloid Leukemia,5979.0,Dasatinib,RET
3334,V804M,D,Resistance,Chronic Myeloid Leukemia,5979.0,Dasatinib,RET
3335,R849W,D,Resistance,Chronic Myeloid Leukemia,7010.0,Bosutinib,TEK
3336,Overexpression,D,Sensitivity/Response,Hepatocellular Carcinoma,9965.0,FGFR4 Inhibitor H3B-6527,FGF19
3337,Overexpression,D,Resistance,Hepatocellular Carcinoma,9965.0,Sorafenib,FGF19
3338,OVEREXPRESSION,D,Resistance,Lung Adenocarcinoma,2264.0,Erlotinib,FGFR4
3339,OVEREXPRESSION,D,Sensitivity/Response,Lung Adenocarcinoma,2264.0,FGFR Inhibitor AZD4547+Erlotinib,FGFR4
3340,ITD N676K,C,Resistance,Acute Myeloid Leukemia,2322.0,Midostaurin,FLT3
3341,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Alectinib,ALK
3342,Fusion,C,Sensitivity/Response,Pancreatic Adenocarcinoma,3084.0,Erlotinib+Pertuzumab,NRG1
3343,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Ceritinib,ALK
3344,LOSS-OF-FUNCTION,B,Sensitivity/Response,Renal Cell Carcinoma,55193.0,Pembrolizumab+Nivolumab,PBRM1
3345,LOSS-OF-FUNCTION,B,Sensitivity/Response,Renal Cell Carcinoma,55193.0,Atezolizumab+Durvalumab,PBRM1
3346,CD74-ROS1 G2032R,D,Sensitivity/Response,Lung Adenocarcinoma,6098.0,DS-6501b,ROS1
3347,AMPLIFICATION,C,Sensitivity/Response,Ewing Sarcoma,2324.0,Pazopanib,FLT4
3348,Mutation,B,Sensitivity/Response,Solid Tumor,7157.0,Vorinostat+Pazopanib,TP53
3349,Fusion,C,Sensitivity/Response,Anaplastic Large Cell Lymphoma,238.0,Ceritinib,ALK
3350,Fusion,C,Sensitivity/Response,Inflammatory Myofibroblastic Tumor,238.0,Ceritinib,ALK
3351,G466V,D,Sensitivity/Response,Colorectal Cancer,673.0,Panitumumab+Irinotecan,BRAF
3352,L525R,D,Resistance,Solid Tumor,673.0,Cetuximab,BRAF
3353,N486_P490del,D,Sensitivity/Response,Solid Tumor,673.0,Mitogen-Activated Protein Kinase Kinase Inhibitor,BRAF
3354,Mutation,B,Sensitivity/Response,Urinary Bladder Cancer,2261.0,Cisplatin+Gemcitabine,FGFR3
3355,G12C,D,Sensitivity/Response,Solid Tumor,3845.0,KRAS G12C Inhibitor MRTX849,KRAS
3356,D594E,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,673.0,Trametinib+Dabrafenib,BRAF
3357,Class 3 Mutations,B,Sensitivity/Response,Colorectal Cancer,673.0,Cetuximab+Panitumumab,BRAF
3358,V211D,C,Resistance,Colorectal Cancer,5604.0,Binimetinib+Panitumumab,MAP2K1
3359,V211D,D,Sensitivity/Response,Colorectal Cancer,5604.0,MAP855,MAP2K1
3360,Fusion,D,Sensitivity/Response,Acute Biphenotypic Leukemia,4297.0,EPZ004777,KMT2A
3361,V600E,B,Sensitivity/Response,Langerhans Cell Sarcoma,673.0,Vemurafenib,BRAF
3362,LOSS-OF-FUNCTION,B,Sensitivity/Response,Renal Cell Carcinoma,55193.0,Nivolumab,PBRM1
3363,Exon 19 Deletion,B,Resistance,Lung Non-small Cell Carcinoma,1956.0,Pembrolizumab+Nivolumab,EGFR
3364,Exon 19 Deletion,B,Resistance,Lung Non-small Cell Carcinoma,1956.0,Durvalumab+Atezolizumab+Avelumab,EGFR
3365,gBRCAm,B,Sensitivity/Response,Her2-receptor Negative Breast Cancer,672.0,Olaparib,BRCA1
3366,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Lorlatinib,ALK
3367,EML4-ALK G1202R and L1196M,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Lorlatinib,ALK
3368,EML4-ALK G1202R and L1196M,D,Resistance,Cancer,238.0,Lorlatinib+Ceritinib+Brigatinib+Alectinib+Crizotinib,ALK
3369,ALK Fusion G1202R,D,Sensitivity/Response,Cancer,238.0,Lorlatinib,ALK
3370,EML4-ALK L1196M and L1198F,D,Sensitivity/Response,Cancer,238.0,Crizotinib,ALK
3371,EML4-ALK G1202R and L1198F,D,Resistance,Cancer,238.0,Lorlatinib+Brigatinib+Ceritinib+Alectinib,ALK
3372,FRAMESHIFT MUTATION,C,Sensitivity/Response,Uveal Melanoma,8930.0,PD1 Inhibitor,MBD4
3373,EML4-ALK L1196M,D,Sensitivity/Response,Cancer,238.0,Brigatinib+Alectinib+Lorlatinib+Ceritinib,ALK
3374,EML4-ALK L1196M,D,Resistance,Cancer,238.0,Crizotinib,ALK
3375,EML4-ALK G1202del,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Ceritinib,ALK
3376,low expression,B,Sensitivity/Response,Glioblastoma,1816.0,Akt/ERK Inhibitor ONC201,
3377,K28M,B,Sensitivity/Response,Glioma,3020.0,Akt/ERK Inhibitor ONC201,H3-3A
3378,K27M,B,Sensitivity/Response,Glioma,8358.0,Akt/ERK Inhibitor ONC201,H3C2
3379,EML4-ALK L1198F,D,Sensitivity/Response,Cancer,238.0,Crizotinib,ALK
3380,G697R,D,Resistance,Acute Myeloid Leukemia,2322.0,Midostaurin+SU5614+K 252a,FLT3
3381,EML4::ALK C1156Y-L1198F,D,Sensitivity/Response,Cancer,238.0,Crizotinib,ALK
3382,Exon 20 Insertion,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Osimertinib,EGFR
3383,V600E,B,Sensitivity/Response,Colorectal Cancer,673.0,Cetuximab+Binimetinib+Encorafenib,BRAF
3384,EML4-ALK C1156Y,D,Resistance,Cancer,238.0,Crizotinib,ALK
3385,V600R,B,Sensitivity/Response,Melanoma,673.0,BRAF Inhibitor,BRAF
3386,V600D,C,Sensitivity/Response,Melanoma,673.0,BRAF Inhibitor,BRAF
3387,L597,C,Sensitivity/Response,Melanoma,673.0,BRAF Inhibitor,BRAF
3388,V600R,B,Sensitivity/Response,Melanoma,673.0,BRAF Inhibitor+Mitogen-Activated Protein Kinase Kinase Inhibitor,BRAF
3389,V600D,C,Sensitivity/Response,Melanoma,673.0,BRAF Inhibitor+Mitogen-Activated Protein Kinase Kinase Inhibitor,BRAF
3390,V600_K601>E,C,Sensitivity/Response,Melanoma,673.0,BRAF Inhibitor+Mitogen-Activated Protein Kinase Kinase Inhibitor,BRAF
3391,V600M,B,Sensitivity/Response,Melanoma,673.0,BRAF Inhibitor+Mitogen-Activated Protein Kinase Kinase Inhibitor,BRAF
3392,L597,B,Sensitivity/Response,Melanoma,673.0,BRAF Inhibitor+Mitogen-Activated Protein Kinase Kinase Inhibitor,BRAF
3393,V601E,B,Sensitivity/Response,Melanoma,673.0,BRAF Inhibitor+Mitogen-Activated Protein Kinase Kinase Inhibitor,BRAF
3394,G469,B,Sensitivity/Response,Melanoma,673.0,Mitogen-Activated Protein Kinase Kinase Inhibitor+BRAF Inhibitor,BRAF
3395,Overexpression,B,Sensitivity/Response,Hepatocellular Carcinoma,9965.0,Fisogatinib,FGF19
3396,Amplification,C,Sensitivity/Response,Cholangiocarcinoma,2064.0,Trastuzumab+Pertuzumab,ERBB2
3397,Amplification,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,4233.0,Crizotinib,MET
3398,EXON 14 SKIPPING MUTATION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,4233.0,Crizotinib,MET
3399,R683G,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,3717.0,Sirolimus,JAK2
3400,EXON 14 SKIPPING MUTATION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,4233.0,Crizotinib,MET
3401,EXON 14 SKIPPING MUTATION,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,4233.0,Crizotinib,MET
3402,Alternative Transcript (ATI),D,Sensitivity/Response,Cancer,238.0,Crizotinib,ALK
3403,Amplification,B,Sensitivity/Response,Stomach Cancer,2064.0,Trastuzumab Deruxtecan,ERBB2
3404,Amplification,B,Sensitivity/Response,Breast Cancer,2064.0,Trastuzumab Deruxtecan,ERBB2
3405,Fusion,C,Sensitivity/Response,Pancreatic Cancer,4914.0,Larotrectinib,NTRK1
3406,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Gefitinib+Pemetrexed,EGFR
3407,Expression,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,3084.0,Afatinib,NRG1
3408,Expression,C,Resistance,Lung Non-small Cell Carcinoma,3084.0,Gefitinib+Erlotinib,NRG1
3409,SNX2-ABL1,D,Resistance,B-lymphoblastic Leukemia/lymphoma,25.0,Dasatinib+Imatinib,ABL1
3410,D594H,D,Sensitivity/Response,Cancer,81607.0,Enfortumab Vedotin,
3411,V60E,C,Resistance,Melanoma,5604.0,Vemurafenib+Dabrafenib,MAP2K1
3412,G128V,C,Resistance,Melanoma,5604.0,Vemurafenib+Dabrafenib,MAP2K1
3413,V154I,C,Resistance,Melanoma,5604.0,Dabrafenib+Vemurafenib,MAP2K1
3414,P124S,C,Resistance,Melanoma,5604.0,Dabrafenib+Vemurafenib,MAP2K1
3415,P124L,C,Resistance,Melanoma,5604.0,Vemurafenib+Dabrafenib,MAP2K1
3416,C125S,C,Resistance,Melanoma,5605.0,Dabrafenib+Vemurafenib,MAP2K2
3417,V35M,C,Resistance,Melanoma,5605.0,Dabrafenib+Vemurafenib,MAP2K2
3418,L46F,C,Resistance,Melanoma,5605.0,Dabrafenib+Vemurafenib,MAP2K2
3419,N126D,C,Resistance,Melanoma,5605.0,Vemurafenib+Dabrafenib,MAP2K2
3420,Amplificatioin,C,Resistance,Melanoma,4286.0,Dabrafenib+Vemurafenib,MITF
3421,P29S,B,Resistance,Melanoma,5879.0,Vemurafenib+Dabrafenib,RAC1
3422,mutation,C,Resistance,Melanoma,3234.0,Dabrafenib+Vemurafenib,
3423,C125S,C,Resistance,Melanoma,5605.0,Dabrafenib+Trametinib,MAP2K2
3424,Amplification,C,Resistance,Melanoma,673.0,Dabrafenib+Trametinib,BRAF
3425,Q61K,B,Resistance,Melanoma,4893.0,Dabrafenib+Trametinib,NRAS
3426,Loss,B,Resistance,Melanoma,1029.0,Dabrafenib+Vemurafenib,CDKN2A
3427,Exon 20 Insertion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,2064.0,Trastuzumab Emtansine,ERBB2
3428,G2032R,B,Resistance,Lung Non-small Cell Carcinoma,6098.0,Crizotinib,ROS1
3429,D2033N,C,Resistance,Lung Cancer,6098.0,Crizotinib,ROS1
3430,S1986F,C,Resistance,Lung Non-small Cell Carcinoma,6098.0,Crizotinib,ROS1
3431,G2032R,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,6098.0,Repotrectinib,ROS1
3432,G623E,C,Sensitivity/Response,Mammary Analogue Secretory Carcinoma,4916.0,Repotrectinib,NTRK3
3433,S1986Y/F,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,6098.0,Lorlatinib,ROS1
3434,R2033N,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,6098.0,Cabozantinib,ROS1
3435,D2033N,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,6098.0,Cabozantinib,ROS1
3436,K57N,C,Resistance,Melanoma,5604.0,Selumetinib,MAP2K1
3437,M918T,B,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,5979.0,Cabozantinib,RET
3438,K3326*,C,Sensitivity/Response,Glioblastoma,675.0,Olaparib+Temozolomide,BRCA2
3439,Mutation,B,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Gilteritinib,FLT3
3440,Amplification,B,Sensitivity/Response,Stomach Cancer,4233.0,Savolitinib,MET
3441,N486_P490del,C,Sensitivity/Response,Pancreatic Cancer,673.0,Trametinib,BRAF
3442,H123Q,C,Resistance,Pancreatic Cancer,5605.0,Trametinib,MAP2K2
3443,G132D,C,Resistance,Pancreatic Adenocarcinoma,5605.0,Trametinib,MAP2K2
3444,G132S,C,Resistance,Pancreatic Adenocarcinoma,5605.0,Trametinib,MAP2K2
3445,AKAP9-BRAF,C,Sensitivity/Response,Congenital Melanocytic Nevus,673.0,Trametinib,BRAF
3446,D594G,D,Sensitivity/Response,Cancer,673.0,Trametinib,BRAF
3447,V600E,B,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,673.0,Dabrafenib,BRAF
3448,V600E,B,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,673.0,Trametinib+Dabrafenib,BRAF
3449,NRF1-BRAF,C,Sensitivity/Response,Transitional Cell Carcinoma,673.0,Trametinib,BRAF
3450,BCR-ABL T315V,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
3451,BCR-ABL V299L,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
3452,BCR-ABL T315A,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
3453,BCR-ABL E279K,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
3454,BCR-ABL F317R,D,Resistance,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
3455,BCR-ABL L248R F359I,D,Resistance,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
3456,BCR-ABL L248R,D,Resistance,Chronic Myeloid Leukemia,25.0,Axitinib,ABL1
3457,BCR-ABL T315I,D,Resistance,Acute Lymphoblastic Leukemia,25.0,Imatinib+Dasatinib+Nilotinib,ABL1
3458,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib+Nilotinib+Imatinib,ABL1
3459,BCR-ABL E255K V299L,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Ponatinib+Dasatinib,ABL1
3460,RCSD1-ABL1,C,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,92241.0,Imatinib,
3461,RCSD1-ABL1,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,25.0,Imatinib,ABL1
3462,Amplification,D,Sensitivity/Response,Glioblastoma,1956.0,Talazoparib,EGFR
3463,EXON 11-19 DELETION,C,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,1806.0,Fluorouracil+Leucovorin,
3464,Overexpression,C,Sensitivity/Response,Multiple Myeloma,595.0,Bortezomib,CCND1
3465,Amplification,B,Sensitivity/Response,Cancer,595.0,Ribociclib,CCND1
3466,Overexpression,D,Sensitivity/Response,Thyroid Gland Anaplastic Carcinoma,595.0,Ribociclib,CCND1
3467,Amplification,D,Sensitivity/Response,Ovarian Cancer,898.0,Dinaciclib,CCNE1
3468,Overexpression,D,Resistance,Ovarian Cancer,898.0,Palbociclib,CCNE1
3469,MET-ATXN7L1,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,4233.0,Crizotinib,MET
3470,LOSS-OF-FUNCTION,B,Adverse Response,Childhood Acute Lymphocytic Leukemia,55270.0,Mercaptopurine+Thioguanine+Azathioprine,NUDT15
3471,EXON 14 SKIPPING MUTATION,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,4233.0,Capmatinib,MET
3472,EXON 14 SKIPPING MUTATION,C,Sensitivity/Response,Histiocytic And Dendritic Cell Cancer,4233.0,Crizotinib,MET
3473,EXON 14 SKIPPING MUTATION,D,Sensitivity/Response,Cancer,4233.0,Capmatinib,MET
3474,EXPRESSION,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,1019.0,Dexamethasone+Ribociclib,CDK4
3475,Amplification,D,Sensitivity/Response,Ovarian Cancer,898.0,Cisplatin+Dinaciclib,CCNE1
3476,OVEREXPRESSION,D,Sensitivity/Response,Glioblastoma Proneural Subtype,1021.0,Palbociclib,CDK6
3477,EXPRESSION,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,1021.0,Dexamethasone+Ribociclib,CDK6
3478,Amplification,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Erlotinib,EGFR
3479,Overexpression,D,Sensitivity/Response,Glioma,1956.0,Radiation Therapy+Gefitinib,EGFR
3480,Overexpression,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,2065.0,Pertuzumab,ERBB3
3481,Overexpression,D,Resistance,Colorectal Cancer,2064.0,Cetuximab,ERBB2
3482,Overexpression,D,Sensitivity/Response,Colorectal Cancer,2064.0,Lapatinib+Trastuzumab,ERBB2
3483,Amplification,D,Sensitivity/Response,Colorectal Cancer,2064.0,Afatinib,ERBB2
3484,Amplification,D,Sensitivity/Response,Stomach Cancer,2064.0,Afatinib,ERBB2
3485,Exon 18 Mutation,A,Sensitivity/Response,Gastrointestinal Stromal Tumor,5156.0,Avapritinib,PDGFRA
3486,Amplification,B,Sensitivity/Response,Transitional Cell Carcinoma,2064.0,Afatinib,ERBB2
3487,Amplification,C,Sensitivity/Response,Adenosquamous Lung Carcinoma,2260.0,Pazopanib,FGFR1
3488,R367Q,C,Resistance,Childhood Acute Lymphocytic Leukemia,22978.0,Thioguanine+Mercaptopurine,NT5C2
3489,R238W,D,Resistance,Childhood Acute Lymphocytic Leukemia,22978.0,Thioguanine+Mercaptopurine,NT5C2
3490,S445F,D,Resistance,Childhood Acute Lymphocytic Leukemia,22978.0,Thioguanine+Mercaptopurine,NT5C2
3491,Rearrangement,D,Sensitivity/Response,Acute Biphenotypic Leukemia,4297.0,,KMT2A
3492,BCR-ABL D363G,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
3493,BCR-ABL E255V,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
3494,BCR-ABL E98G,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
3495,BCR-ABL L384M,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
3496,BCR-ABL M244V,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
3497,BCR-ABL L364I,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
3498,BCR-ABL V186A,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
3499,BCR-ABL Y253H,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
3500,Overexpression,D,Sensitivity/Response,Colon Cancer,2263.0,Rogaratinib,FGFR2
3501,Overexpression,D,Sensitivity/Response,Lung Cancer,2260.0,Rogaratinib+Docetaxel,FGFR1
3502,Overexpression,D,Sensitivity/Response,Colorectal Cancer,2263.0,Erdafitinib,FGFR2
3503,P253R,C,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,2263.0,Pazopanib,FGFR2
3504,S249C,C,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,Pazopanib,FGFR3
3505,Amplification,C,Sensitivity/Response,Ewing Sarcoma,2261.0,Pazopanib,FGFR3
3506,AMPLIFICATION,C,Sensitivity/Response,Ewing Sarcoma,2264.0,Pazopanib,FGFR4
3507,BCR-ABL,D,Sensitivity/Response,Chronic Myeloid Leukemia,25.0,Dasatinib+Bafetinib+Nilotinib,ABL1
3508,BCR-ABL F317L,D,Resistance,Cancer,25.0,Dasatinib+Imatinib,ABL1
3509,Exon 14 Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,4233.0,Crizotinib,MET
3510,BCR-ABL M351T,D,Resistance,Cancer,25.0,Imatinib,ABL1
3511,BCR-ABL T315A,D,Resistance,Cancer,25.0,Imatinib+Dasatinib,ABL1
3512,BCR-ABL F317V,D,Resistance,Cancer,25.0,Dasatinib,ABL1
3513,BCR-ABL H396P,D,Resistance,Cancer,25.0,Imatinib,ABL1
3514,BCR-ABL Y253F,D,Resistance,Cancer,25.0,Imatinib,ABL1
3515,BCR-ABL Q252H,D,Resistance,Cancer,25.0,Bafetinib+Imatinib,ABL1
3516,BCR-ABL M244V,D,Resistance,Cancer,25.0,Bafetinib+Imatinib,ABL1
3517,Overexpression,D,Resistance,Esophageal Carcinoma,3569.0,Cisplatin,
3518,OVEREXPRESSION,C,Sensitivity/Response,Sarcoma,3716.0,Ruxolitinib,JAK1
3519,BCR-ABL G250E,D,Resistance,Cancer,25.0,Imatinib+Bafetinib,ABL1
3520,OVEREXPRESSION,B,Sensitivity/Response,Neuroendocrine Tumor,3791.0,Pazopanib,KDR
3521,Amplification,B,Sensitivity/Response,Salivary Gland Cancer,2064.0,Trastuzumab Emtansine,ERBB2
3522,G719,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Osimertinib,EGFR
3523,L861Q,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Osimertinib,EGFR
3524,S768I,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Osimertinib,EGFR
3525,Y1021H,C,Sensitivity/Response,Lung Adenocarcinoma,4233.0,Crizotinib,MET
3526,G469E,C,Sensitivity/Response,Breast Ductal Carcinoma,673.0,Trametinib,BRAF
3527,R367Q,D,Resistance,Childhood Acute Lymphocytic Leukemia,22978.0,Mercaptopurine+Thioguanine,NT5C2
3528,EML4-ALK L1196M,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Ensartinib,ALK
3529,Expression,C,Sensitivity/Response,Glioblastoma,238.0,Crizotinib,ALK
3530,OVEREXPRESSION,D,Resistance,Breast Cancer,142.0,Olaparib,PARP1
3531,OVEREXPRESSION,D,Sensitivity/Response,Sarcoma,142.0,Trabectedin+Olaparib,PARP1
3532,Overexpression,D,Resistance,Lung Non-small Cell Carcinoma,5243.0,Ceritinib+Crizotinib,
3533,V559D,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,3815.0,CHMFL-KIT-031,KIT
3534,Fusion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Alectinib,ALK
3535,Amplification,D,Sensitivity/Response,Gastric Adenocarcinoma,4233.0,Cabozantinib,MET
3536,OVEREXPRESSION,D,Resistance,Chronic Myeloid Leukemia,4067.0,Nilotinib,LYN
3537,D183H,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,5631.0,Thioguanine+Mercaptopurine,
3538,T303S,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,5631.0,Mercaptopurine+Thioguanine,
3539,L191F,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,5631.0,Thioguanine+Mercaptopurine,
3540,D183E,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,5631.0,Thioguanine+Mercaptopurine,
3541,K176N,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,5631.0,Thioguanine+Mercaptopurine,
3542,G174E,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,5631.0,Mercaptopurine+Thioguanine,
3543,N144S,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,5631.0,Mercaptopurine+Thioguanine,
3544,N114D,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,5631.0,Mercaptopurine+Thioguanine,
3545,S103I,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,5631.0,Mercaptopurine+Thioguanine,
3546,S103N,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,5631.0,Thioguanine+Mercaptopurine,
3547,S103T,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,5631.0,Mercaptopurine+Thioguanine,
3548,A190V,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,5631.0,Thioguanine+Mercaptopurine,
3549,A190T,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,5631.0,Mercaptopurine+Thioguanine,
3550,N144S,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,5631.0,Cytarabine,
3551,L191F,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,5631.0,Cytarabine,
3552,S103T,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,5631.0,Mercaptopurine+Lometrexol,
3553,A190T,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,5631.0,Lometrexol+Mercaptopurine,
3554,EWSR1-ATF1,B,Sensitivity/Response,Clear Cell Sarcoma,2130.0,Crizotinib,EWSR1
3555,Overexpression,D,Sensitivity/Response,Ovarian Clear Cell Carcinoma,4233.0,Cabozantinib,MET
3556,REARRANGEMENT,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,6098.0,Crizotinib,ROS1
3557,Overexpression,D,Sensitivity/Response,High Grade Glioma,5156.0,Dasatinib,PDGFRA
3558,BCR-ABL S438C,C,Resistance,Chronic Myeloid Leukemia,25.0,Dasatinib,ABL1
3559,Overexpression,D,Resistance,Ovarian Cancer,6772.0,Cisplatin+Picoplatin,STAT1
3560,Overexpression,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,2260.0,FGFR Inhibitor AZD4547,FGFR1
3561,Amplification,D,Sensitivity/Response,Stomach Cancer,2263.0,Erdafitinib,FGFR2
3562,Amplification,D,Sensitivity/Response,Lung Cancer,2260.0,Erdafitinib,FGFR1
3563,Overexpression,D,Resistance,Rhabdomyosarcoma,3569.0,Bazedoxifene,
3564,S646F,D,Sensitivity/Response,Acute Lymphoblastic Leukemia,3716.0,Ruxolitinib,JAK1
3565,H1112L,D,Sensitivity/Response,Cancer,4233.0,Tepotinib,MET
3566,MUTATION,B,Sensitivity/Response,Hereditary Renal Cell Carcinoma,6390.0,Metformin+Vandetanib,SDHB
3567,Fusion,D,Sensitivity/Response,Cholangiocarcinoma,2263.0,Derazantinib,FGFR2
3568,G101V,C,Resistance,Chronic Lymphocytic Leukemia,596.0,Venetoclax,BCL2
3569,Mutation,B,Resistance,Glioblastoma,7157.0,Temozolomide,TP53
3570,M237I,D,Resistance,Glioblastoma,7157.0,Temozolomide,TP53
3571,R273H,D,Resistance,Glioblastoma,7157.0,Temozolomide,TP53
3572,Overexpression,B,Sensitivity/Response,Hepatocellular Carcinoma,7424.0,Sunitinib,
3573,Overexpression,D,Sensitivity/Response,Rhabdomyosarcoma,5156.0,Sunitinib,PDGFRA
3574,Amplification,D,Sensitivity/Response,Lung Squamous Cell Carcinoma,5156.0,Imatinib+Sunitinib,PDGFRA
3575,BCR-PDGFRA,C,Sensitivity/Response,B-cell Acute Lymphoblastic Leukemia,5156.0,Imatinib,PDGFRA
3576,COL1A1-PDGFB,C,Sensitivity/Response,Dermatofibrosarcoma Protuberans,5155.0,Sunitinib,PDGFB
3577,Overexpression,C,Sensitivity/Response,Dermatofibrosarcoma Protuberans,5159.0,Sunitinib,PDGFRB
3578,ETV6-NTRK3,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,4916.0,Larotrectinib,NTRK3
3579,ETV6-NTRK3,D,Sensitivity/Response,Acute Myeloid Leukemia,4916.0,Entrectinib,NTRK3
3580,E542K,D,Resistance,Breast Cancer,5290.0,PI-103,PIK3CA
3581,E545K,D,Resistance,Breast Cancer,5290.0,PI-103,PIK3CA
3582,H1047L,D,Sensitivity/Response,Breast Cancer,5290.0,PI-103,PIK3CA
3583,H1047R,D,Sensitivity/Response,Breast Cancer,5290.0,PI-103,PIK3CA
3584,K111N,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,PI-103,PIK3CA
3585,Loss,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5728.0,PI-103,PTEN
3586,E542K,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,PI3Ka/Di,PIK3CA
3587,E542K,D,Sensitivity/Response,Breast Cancer,5290.0,PI3Ka/Di,PIK3CA
3588,E545K,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,PI3Ka/Di,PIK3CA
3589,E545K,D,Sensitivity/Response,Breast Cancer,5290.0,PI3Ka/Di,PIK3CA
3590,H1047L,D,Sensitivity/Response,Breast Cancer,5290.0,PI3Ka/Di,PIK3CA
3591,K111N,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,PI3Ka/Di,PIK3CA
3592,Loss,D,Resistance,Breast Cancer,5728.0,PI3Ka/Di,PTEN
3593,Loss,D,Resistance,Her2-receptor Positive Breast Cancer,5728.0,PI3Ka/Di,PTEN
3594,C797S,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Cetuximab+Brigatinib,EGFR
3595,V600E,D,Sensitivity/Response,Thyroid Gland Cancer,673.0,PLX4720+Ponatinib,BRAF
3596,V600,B,Sensitivity/Response,Childhood Low-grade Glioma,673.0,Dabrafenib,BRAF
3597,G328V,D,Sensitivity/Response,"Diffuse Midline Glioma, H3 K27M-mutant",90.0,MEK-1/MEKK-1 Inhibitor E6201,ACVR1
3598,V600E,D,Sensitivity/Response,Thyroid Gland Cancer,673.0,Ponatinib+PLX4720,BRAF
3599,TPM3-NTRK1,C,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,4914.0,Larotrectinib,NTRK1
3600,Amplification,A,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Neratinib+Trastuzumab,ERBB2
3601,Amplification,A,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Neratinib+Capecitabine,ERBB2
3602,Amplification,A,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Trastuzumab+Neratinib,ERBB2
3603,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Neratinib+Capecitabine,ERBB2
3604,L718V and L718Q,C,Resistance,Lung Adenocarcinoma,1956.0,Osimertinib,EGFR
3605,L858R,C,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Osimertinib,EGFR
3606,L755S,C,Sensitivity/Response,Triple-receptor Negative Breast Cancer,2064.0,Capecitabine+Neratinib,ERBB2
3607,P29S,D,Resistance,Skin Melanoma,5879.0,PLX4720,RAC1
3608,C797S,D,Resistance,Lung Adenocarcinoma,1956.0,Osimertinib,EGFR
3609,L718Q,D,Resistance,Lung Adenocarcinoma,1956.0,Osimertinib,EGFR
3610,L718V,D,Resistance,Lung Adenocarcinoma,1956.0,Osimertinib,EGFR
3611,S249C,D,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,Ponatinib,FGFR3
3612,Amplification,D,Sensitivity/Response,Stomach Cancer,2261.0,Ponatinib,FGFR3
3613,Amplification,D,Sensitivity/Response,Stomach Cancer,2263.0,Ponatinib,FGFR2
3614,V955I,C,Resistance,Colorectal Cancer,5290.0,Cetuximab,PIK3CA
3615,G12C,B,Sensitivity/Response,Cancer,3845.0,Sotorasib,KRAS
3616,L718V,D,Sensitivity/Response,Cancer,1956.0,Erlotinib,EGFR
3617,C797S,D,Sensitivity/Response,Cancer,1956.0,Afatinib,EGFR
3618,L718Q,D,Sensitivity/Response,Cancer,1956.0,Afatinib,EGFR
3619,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Neratinib,ERBB2
3620,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,2064.0,Neratinib,ERBB2
3621,L718V,D,Sensitivity/Response,Cancer,1956.0,Afatinib,EGFR
3622,L718Q,D,Resistance,Cancer,1956.0,Erlotinib,EGFR
3623,C797S,D,Sensitivity/Response,Cancer,1956.0,Erlotinib,EGFR
3624,R238W,D,Resistance,Acute Lymphoblastic Leukemia,22978.0,Mercaptopurine+Thioguanine,NT5C2
3625,C797G,D,Resistance,Lung Adenocarcinoma,1956.0,Osimertinib,EGFR
3626,L792H,D,Resistance,Lung Adenocarcinoma,1956.0,Osimertinib,EGFR
3627,C797S,D,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Osimertinib+Erlotinib,EGFR
3628,L718Q,D,Sensitivity/Response,Lung Adenocarcinoma,1956.0,Osimertinib+Erlotinib,EGFR
3629,Overexpression,D,Resistance,Colorectal Cancer,2303.0,Oxaliplatin,
3630,Expression,D,Resistance,Colon Cancer,6935.0,Oxaliplatin,ZEB1
3631,BCR-ABL S417Y,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
3632,BCR-ABL E355G,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
3633,BCR-ABL F486S,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
3634,BCR-ABL E459K,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
3635,Double Ph,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
3636,P-Loop Mutation,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
3637,D835Y,D,Sensitivity/Response,Cancer,2322.0,Gilteritinib,FLT3
3638,D835Y,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Gilteritinib,FLT3
3639,OVEREXPRESSION,B,Resistance,Lung Non-small Cell Carcinoma,406991.0,Cisplatin,
3640,OVEREXPRESSION,D,Resistance,Lung Non-small Cell Carcinoma,406991.0,Cisplatin,
3641,E545K,D,Resistance,Cervical Cancer,5290.0,Radiation Ionizing Radiotherapy+Cisplatin,PIK3CA
3642,OVEREXPRESSION,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,1021.0,Dexamethasone+Ribociclib,CDK6
3643,OVEREXPRESSION,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,1019.0,Dexamethasone+Ribociclib,CDK4
3644,Expression,D,Sensitivity/Response,Glioblastoma,1436.0,Pexidartinib,CSF1R
3645,Expression,D,Sensitivity/Response,Glioblastoma,1436.0,Pexidartinib+Vatalanib,CSF1R
3646,Expression,D,Sensitivity/Response,Glioblastoma,1436.0,Pexidartinib+Dovitinib,CSF1R
3647,Fusion,B,Sensitivity/Response,Cholangiolocellular Carcinoma,2263.0,Pemigatinib,FGFR2
3648,G101V,B,Resistance,Chronic Lymphocytic Leukemia,596.0,Venetoclax,BCL2
3649,DELETION (p.K227_T233del),C,Resistance,Acute Promyelocytic Leukemia,5371.0,Tamibarotene+Tretinoin,PML
3650,Mutation,B,Resistance,Glioblastoma,5728.0,Pembrolizumab+Nivolumab,PTEN
3651,PML-RARA A216V,B,Resistance,Acute Promyelocytic Leukemia,5371.0,Arsenic Trioxide,PML
3652,PML-RARA S214L,B,Resistance,Acute Promyelocytic Leukemia,5371.0,Arsenic Trioxide,PML
3653,PML-RARA A216T,B,Resistance,Acute Promyelocytic Leukemia,5371.0,Arsenic Trioxide,PML
3654,E545K,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,Trastuzumab+Dactolisib,PIK3CA
3655,E545K,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,Dactolisib+Lapatinib+Trastuzumab,PIK3CA
3656,H1047R,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,Trastuzumab+Dactolisib,PIK3CA
3657,G101A,B,Resistance,Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma,596.0,Venetoclax,BCL2
3658,G101V,B,Resistance,Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma,596.0,Venetoclax,BCL2
3659,F104S,B,Resistance,Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma,596.0,Venetoclax,BCL2
3660,F104L,B,Resistance,Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma,596.0,Venetoclax,BCL2
3661,R107_R110dup,B,Resistance,Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma,596.0,Venetoclax,BCL2
3662,A113G,B,Resistance,Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma,596.0,Venetoclax,BCL2
3663,L119V,B,Resistance,Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma,596.0,Venetoclax,BCL2
3664,VIII,D,Sensitivity/Response,Glioblastoma,1956.0,Afatinib,EGFR
3665,VIII,D,Sensitivity/Response,Glioblastoma,1956.0,Afatinib+Pacritinib,EGFR
3666,G810,C,Resistance,Lung Non-small Cell Carcinoma,5979.0,Selpercatinib,RET
3667,G810,C,Resistance,Thyroid Gland Medullary Carcinoma,5979.0,Selpercatinib,RET
3668,G598V,D,Sensitivity/Response,Glioblastoma,1956.0,Afatinib+Osimertinib+Erlotinib,EGFR
3669,G598V,D,Sensitivity/Response,Glioblastoma,1956.0,Afatinib+Pacritinib,EGFR
3670,G598V,D,Sensitivity/Response,Glioblastoma,1956.0,Pacritinib+Erlotinib,EGFR
3671,EBF1-PDGFRB,C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",5159.0,Chemotherapy+Imatinib,PDGFRB
3672,G598V,D,Sensitivity/Response,Glioblastoma,1956.0,Lapatinib+Pacritinib,EGFR
3673,Amplification,D,Resistance,Her2-receptor Positive Breast Cancer,5290.0,Trastuzumab,PIK3CA
3674,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,Lapatinib,PIK3CA
3675,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,Dactolisib,PIK3CA
3676,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,Lapatinib+Trastuzumab,PIK3CA
3677,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,Dactolisib+Lapatinib,PIK3CA
3678,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,Dactolisib+Trastuzumab,PIK3CA
3679,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5290.0,Dactolisib+Trastuzumab+Lapatinib,PIK3CA
3680,Loss,D,Resistance,Her2-receptor Positive Breast Cancer,5728.0,Trastuzumab,PTEN
3681,Loss,D,Resistance,Her2-receptor Positive Breast Cancer,5728.0,Lapatinib,PTEN
3682,Loss,D,Resistance,Her2-receptor Positive Breast Cancer,5728.0,Dactolisib,PTEN
3683,Loss,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5728.0,Lapatinib+Trastuzumab,PTEN
3684,Loss,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5728.0,Trastuzumab+Dactolisib+Lapatinib,PTEN
3685,R248C,B,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,Erdafitinib,FGFR3
3686,Mutation,B,Sensitivity/Response,Pancreatic Cancer,7157.0,Gemcitabine,TP53
3687,Loss,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,5728.0,Trastuzumab+Dactolisib,PTEN
3688,G598V,D,Sensitivity/Response,Glioblastoma,1956.0,Pacritinib+Osimertinib,EGFR
3689,Y693,D,Resistance,Acute Myeloid Leukemia,2322.0,Gilteritinib,FLT3
3690,Expression,B,Sensitivity/Response,Glioblastoma,1956.0,3-Dimensional Conformal Radiation Therapy+Temozolomide+Nimotuzumab,EGFR
3691,PML-RARA,B,Sensitivity/Response,Acute Promyelocytic Leukemia,5371.0,Gemtuzumab Ozogamicin,PML
3692,Mutation,B,Sensitivity/Response,Colorectal Cancer,3845.0,Metformin,KRAS
3693,D103Y,C,Resistance,Chronic Lymphocytic Leukemia,596.0,Venetoclax,BCL2
3694,G101V,C,Resistance,Chronic Lymphocytic Leukemia,596.0,Venetoclax,BCL2
3695,V156D,B,Resistance,Chronic Lymphocytic Leukemia,596.0,Venetoclax,BCL2
3696,R129L,C,Resistance,Chronic Lymphocytic Leukemia,596.0,Venetoclax,BCL2
3697,A113G,C,Resistance,Chronic Lymphocytic Leukemia,596.0,Venetoclax,BCL2
3698,R107_R110dup,B,Resistance,Chronic Lymphocytic Leukemia,596.0,Venetoclax,BCL2
3699,D103V,C,Resistance,Chronic Lymphocytic Leukemia,596.0,Venetoclax,BCL2
3700,D103E,C,Resistance,Chronic Lymphocytic Leukemia,596.0,Venetoclax,BCL2
3701,D103Y,B,Resistance,Chronic Lymphocytic Leukemia,596.0,Venetoclax,BCL2
3702,A393E,C,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,AZD-4547,FGFR3
3703,S249C,C,Sensitivity/Response,Renal Pelvis Transitional Cell Carcinoma,2261.0,AZD-4547,FGFR3
3704,R248C,B,Sensitivity/Response,Bladder Carcinoma,2261.0,Infigratinib,FGFR3
3705,R248C,C,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,Dovitinib,FGFR3
3706,R248C,D,Sensitivity/Response,Solid Tumor,2261.0,R3Mab,FGFR3
3707,LOSS,D,Sensitivity/Response,Malignant Pleural Mesothelioma,8314.0,EPZ011989,BAP1
3708,D835,B,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Gilteritinib,FLT3
3709,G101V,D,Resistance,Chronic Lymphocytic Leukemia,596.0,Venetoclax,BCL2
3710,D103E,D,Resistance,Chronic Lymphocytic Leukemia,596.0,Venetoclax,BCL2
3711,Y842C,D,Resistance,Acute Myeloid Leukemia,2322.0,FLT3/ABL/Aurora Kinase Inhibitor KW-2449,FLT3
3712,Y842C,D,Resistance,Acute Myeloid Leukemia,2322.0,Sorafenib,FLT3
3713,Y842C,D,Resistance,Acute Myeloid Leukemia,2322.0,Sunitinib,FLT3
3714,Y842C,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Lestaurtinib,FLT3
3715,Y842C,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Midostaurin,FLT3
3716,F691L,D,Resistance,Acute Myeloid Leukemia,2322.0,Lestaurtinib,FLT3
3717,F691L,D,Resistance,Acute Myeloid Leukemia,2322.0,Midostaurin,FLT3
3718,D835I,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Gilteritinib,FLT3
3719,D816V,D,Resistance,Chronic Myeloid Leukemia,3815.0,Imatinib,KIT
3720,D816V,D,Sensitivity/Response,Chronic Myeloid Leukemia,3815.0,Dasatinib,KIT
3721,D816V,D,Sensitivity/Response,Chronic Myeloid Leukemia,3815.0,Imatinib,KIT
3722,H1047R,D,Sensitivity/Response,Colorectal Cancer,5290.0,Akt Inhibitor MK2206+Vemurafenib,PIK3CA
3723,Fusion,C,Sensitivity/Response,Melanoma,5894.0,Trametinib+Cobimetinib,RAF1
3724,F104I,C,Resistance,Follicular Lymphoma,596.0,Venetoclax,BCL2
3725,F104I,D,Resistance,Follicular Lymphoma,596.0,Venetoclax,BCL2
3726,TRUNCATING MUTATIONS AND DELETERIOUS SUBSTITUTIONS,D,Resistance,Acute Lymphoblastic Leukemia,1387.0,Therapeutic Glucocorticoid,CREBBP
3727,Oncogenic Mutations (loss of function alterations),A,Sensitivity/Response,Prostate Carcinoma,79728.0,Olaparib,PALB2
3728,Oncogenic Mutations (loss of function alterations),A,Sensitivity/Response,Prostate Carcinoma,472.0,Olaparib,ATM
3729,V600E,D,Sensitivity/Response,Colorectal Cancer,673.0,Irinotecan+Vemurafenib+Cetuximab,BRAF
3730,V600E,D,Sensitivity/Response,Colorectal Cancer,673.0,Vemurafenib+Erlotinib,BRAF
3731,BCR-ABL Y253F,C,Resistance,Chronic Myeloid Leukemia,25.0,Imatinib,ABL1
3732,ITD & TKD MUTATIONS,B,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Midostaurin,FLT3
3733,D835H,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Gilteritinib,FLT3
3734,D835V,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Gilteritinib,FLT3
3735,IGH-CRLF2,D,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",64109.0,Ruxolitinib,CRLF2
3736,E545K,D,Resistance,Her2-receptor Positive Breast Cancer,5290.0,Trastuzumab,PIK3CA
3737,H1047R,D,Resistance,Her2-receptor Positive Breast Cancer,5290.0,Trastuzumab,PIK3CA
3738,C420R,D,Resistance,Her2-receptor Positive Breast Cancer,5290.0,Trastuzumab,PIK3CA
3739,K111N,D,Resistance,Her2-receptor Positive Breast Cancer,5290.0,Trastuzumab,PIK3CA
3740,F691L,D,Resistance,Acute Myeloid Leukemia,2322.0,Gilteritinib,FLT3
3741,MUTATION,B,Sensitivity/Response,Core Binding Factor Acute Myeloid Leukemia,3815.0,Dasatinib,KIT
3742,A203T,D,Sensitivity/Response,Myelofibrosis,4915.0,Entrectinib+Larotrectinib,NTRK2
3743,R458G,C,Sensitivity/Response,Atypical Chronic Myeloid Leukemia,4915.0,Larotrectinib+Entrectinib,NTRK2
3744,V411L,C,Sensitivity/Response,Colorectal Cancer,5426.0,,POLE
3745,S249C,D,Resistance,Transitional Cell Carcinoma,2261.0,Cisplatin,FGFR3
3746,V600E,B,Resistance,Colorectal Cancer,673.0,Bevacizumab+Oxaliplatin+Capecitabine+Cetuximab,BRAF
3747,Y842C,D,Resistance,Acute Myeloid Leukemia,2322.0,Quizartinib,FLT3
3748,Fusion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Alectinib,ALK
3749,F691L,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Pexidartinib,FLT3
3750,M664I,D,Resistance,Acute Myeloid Leukemia,2322.0,Pexidartinib,FLT3
3751,ITD & D839G,D,Resistance,Acute Myeloid Leukemia,2322.0,Pexidartinib,FLT3
3752,K663Q,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sunitinib,FLT3
3753,D839A,D,Resistance,Acute Myeloid Leukemia,2322.0,Pexidartinib,FLT3
3754,D839N,D,Resistance,Acute Myeloid Leukemia,2322.0,Pexidartinib,FLT3
3755,D839H,D,Resistance,Acute Myeloid Leukemia,2322.0,Pexidartinib,FLT3
3756,F691L,B,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Pexidartinib,FLT3
3757,Loss,B,Sensitivity/Response,Prostate Cancer,5728.0,Ipatasertib,PTEN
3758,R201H,C,Sensitivity/Response,Appendix Cancer,2778.0,Trametinib,GNAS
3759,Mutation,B,Resistance,Her2-receptor Positive Breast Cancer,5290.0,Capecitabine+Lapatinib,PIK3CA
3760,Mutation,B,Sensitivity/Response,Ovary Serous Adenocarcinoma,3845.0,Binimetinib,KRAS
3761,S249C,D,Sensitivity/Response,Urinary Bladder Cancer,2261.0,,FGFR3
3762,D594N,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,673.0,Trametinib+Dabrafenib,BRAF
3763,EML4-ALK C1156Y,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
3764,G101V,D,Resistance,Chronic Lymphocytic Leukemia,596.0,Venetoclax,BCL2
3765,Mutation,A,Sensitivity/Response,Prostate Cancer,675.0,Olaparib,BRCA2
3766,F691L,D,Resistance,Acute Myeloid Leukemia,2322.0,Quizartinib,FLT3
3767,F691L,D,Resistance,Acute Myeloid Leukemia,2322.0,Sunitinib,FLT3
3768,F691L,D,Resistance,Acute Myeloid Leukemia,2322.0,Sorafenib,FLT3
3769,F691L,D,Resistance,Acute Myeloid Leukemia,2322.0,FLT3/ABL/Aurora Kinase Inhibitor KW-2449,FLT3
3770,EXON 14 SKIPPING MUTATION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,4233.0,Capmatinib,MET
3771,EXON 14 SKIPPING MUTATION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,4233.0,Tepotinib,MET
3772,Amplification,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,4233.0,Capmatinib,MET
3773,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,5979.0,Selpercatinib,RET
3774,Mutation,B,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,5979.0,Selpercatinib,RET
3775,Fusion,B,Sensitivity/Response,Thyroid Gland Cancer,5979.0,Selpercatinib,RET
3776,Mutation,C,Sensitivity/Response,Acute Myeloid Leukemia,3417.0,Venetoclax,IDH1
3777,Mutation,C,Sensitivity/Response,Acute Myeloid Leukemia,3418.0,Venetoclax,IDH2
3778,N841I,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Midostaurin,FLT3
3779,EML4-ALK C1156Y,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Ensartinib,ALK
3780,EML4-ALK G1269A,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,238.0,Ensartinib,ALK
3781,SQSTM1-NTRK1,C,Sensitivity/Response,Congenital Fibrosarcoma,4914.0,Larotrectinib,NTRK1
3782,LMNA::NTRK1 e2-e10,C,Sensitivity/Response,Congenital Fibrosarcoma,4914.0,Crizotinib,NTRK1
3783,Y373C,B,Sensitivity/Response,Transitional Cell Carcinoma,2261.0,Erlotinib,FGFR3
3784,EML4::ALK e6-e19 G1269A and Amplification,C,Resistance,Lung Non-small Cell Carcinoma,238.0,Crizotinib,ALK
3785,V658A,D,Resistance,Melanoma,5156.0,Imatinib,PDGFRA
3786,V658A,D,Sensitivity/Response,Melanoma,5156.0,Crenolanib,PDGFRA
3787,G12V,C,Resistance,Lung Non-small Cell Carcinoma,3845.0,Crizotinib,KRAS
3788,RBPMS-MET,C,Sensitivity/Response,Congenital Fibrosarcoma,4233.0,Cabozantinib,MET
3789,ITD&F691(I/L),D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Ponatinib,FLT3
3790,ITD & D835(V/Y/F/H),D,Resistance,Acute Myeloid Leukemia,2322.0,Ponatinib,FLT3
3791,ITD & Y842C,D,Resistance,Acute Myeloid Leukemia,2322.0,Sorafenib+Ponatinib,FLT3
3792,ITD & D839G,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Quizartinib,FLT3
3793,ITD & D839G,D,Resistance,Acute Myeloid Leukemia,2322.0,Ponatinib+Sorafenib,FLT3
3794,G697S,D,Resistance,Acute Myeloid Leukemia,2322.0,Gilteritinib,FLT3
3795,LMNA::NTRK1 e11-e10,C,Sensitivity/Response,Colorectal Cancer,4914.0,Entrectinib,NTRK1
3796,LMNA::NTRK1 e2-e10,C,Sensitivity/Response,Sarcomatoid Carcinoma,4914.0,TRK Inhibitor,NTRK1
3797,G636C,D,Sensitivity/Response,Stomach Cancer,2264.0,FGFR Inhibitor ASP5878,FGFR4
3798,N535K,D,Sensitivity/Response,Rhabdomyosarcoma,2264.0,"FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074",FGFR4
3799,V550E,D,Sensitivity/Response,Rhabdomyosarcoma,2264.0,"FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074",FGFR4
3800,ITD and co-mutations,B,Resistance,Acute Myeloid Leukemia,2322.0,Chemotherapy,FLT3
3801,ITD D651G,D,Resistance,Acute Myeloid Leukemia,2322.0,Sorafenib,FLT3
3802,ITD  N676D,D,Resistance,Acute Myeloid Leukemia,2322.0,Sorafenib,FLT3
3803,ITD I687F,D,Resistance,Acute Myeloid Leukemia,2322.0,Sorafenib,FLT3
3804,ITD & Y842C,D,Resistance,Acute Myeloid Leukemia,2322.0,Sorafenib,FLT3
3805,ITD & TKD MUTATIONS,D,Resistance,Acute Myeloid Leukemia,2322.0,Sorafenib,FLT3
3806,Fusion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,6098.0,Crizotinib,ROS1
3807,ETV6-NTRK3,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,4916.0,Methotrexate+Larotrectinib+Etoposide,NTRK3
3808,G810C,C,Resistance,Cancer,5979.0,Pralsetinib+Selpercatinib,RET
3809,G810S,C,Resistance,Thyroid Gland Medullary Carcinoma,5979.0,Pralsetinib+Selpercatinib,RET
3810,Y806C,C,Resistance,Thyroid Gland Medullary Carcinoma,5979.0,Pralsetinib+Selpercatinib,RET
3811,Y806N,C,Resistance,Thyroid Gland Medullary Carcinoma,5979.0,Pralsetinib+Selpercatinib,RET
3812,V738A,D,Resistance,Cancer,5979.0,Selpercatinib+Pralsetinib,RET
3813,ITD,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Gilteritinib,FLT3
3814,ITD,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Gilteritinib,FLT3
3815,ETV6-NTRK3,D,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,4916.0,Larotrectinib,NTRK3
3816,Mutation,C,Sensitivity/Response,Ovary Serous Adenocarcinoma,3845.0,Trametinib,KRAS
3817,Q61K,C,Sensitivity/Response,Ovary Serous Adenocarcinoma,4893.0,Trametinib,NRAS
3818,Y842C,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Midostaurin,FLT3
3819,KIAA1549-BRAF,D,Sensitivity/Response,Childhood Pilocytic Astrocytoma,673.0,Selumetinib,BRAF
3820,KIAA1549-BRAF,D,Sensitivity/Response,Childhood Pilocytic Astrocytoma,673.0,Trametinib,BRAF
3821,R167Q (c.500G>A),C,Sensitivity/Response,Von Hippel-Lindau Disease,7428.0,Pazopanib,VHL
3822,V600E,D,Resistance,Diffuse Large B-cell Lymphoma,673.0,Venetoclax,BRAF
3823,N505I,D,Sensitivity/Response,Skin Melanoma,3815.0,Sorafenib+Imatinib,KIT
3824,Overexpression,D,Resistance,Lung Adenocarcinoma,86.0,Cisplatin,
3825,Overexpression,D,Sensitivity/Response,Lung Adenocarcinoma,86.0,Cisplatin+Panobinostat,
3826,Loss-of-function,D,Sensitivity/Response,Prostate Cancer,675.0,Olaparib+Dasatinib,BRCA2
3827,Loss-of-function,D,Sensitivity/Response,Prostate Cancer,675.0,Talazoparib+Dasatinib,BRCA2
3828,Loss-of-function,D,Sensitivity/Response,Prostate Cancer,675.0,Dasatinib+Cisplatin,BRCA2
3829,Loss-of-function,D,Sensitivity/Response,Prostate Cancer,675.0,Talazoparib+Bosutinib,BRCA2
3830,Overexpression,D,Resistance,Ovarian Cancer,86.0,Cisplatin,
3831,Mutation,B,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,5979.0,Cabozantinib,RET
3832,Overexpression,D,Sensitivity/Response,Neuroblastoma,4613.0,Niraparib+Talazoparib+Veliparib+Olaparib,MYCN
3833,E17K,B,Sensitivity/Response,Cancer,207.0,Capivasertib,AKT1
3834,Expression,B,Sensitivity/Response,Melanoma,29126.0,Nivolumab+Pembrolizumab,CD274
3835,Expression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,29126.0,Atezolizumab,CD274
3836,Expression,B,Sensitivity/Response,Nasopharynx Carcinoma,29126.0,Nivolumab,CD274
3837,V600E,B,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,673.0,Vemurafenib,BRAF
3838,Mutation,B,Sensitivity/Response,Breast Cancer,672.0,Olaparib,BRCA1
3839,Fusion,C,Sensitivity/Response,Melanoma,5894.0,Trametinib,RAF1
3840,G697S,D,Reduced Sensitivity,Acute Myeloid Leukemia,2322.0,Gilteritinib,FLT3
3841,AMPLIFICATION,D,Sensitivity/Response,Glioblastoma,4193.0,MDM2 Inhibitor KRT-232+RG7112,MDM2
3842,Overexpression,D,Sensitivity/Response,Salivary Gland Adenoid Cystic Carcinoma,3480.0,Gefitinib+Linsitinib+Crizotinib,IGF1R
3843,ITD,B,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sorafenib+Hematopoietic Cell Transplantation,FLT3
3844,ITD,B,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Hematopoietic Cell Transplantation+Sorafenib,FLT3
3845,ITD & Y842C,D,Resistance,Acute Myeloid Leukemia,2322.0,Sorafenib+Selinexor,FLT3
3846,ITD & Y842C,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,FLT3 Inhibitor FF-10101 Succinate,FLT3
3847,BCR-ABL G250E,D,Sensitivity/Response,Cancer,25.0,Dasatinib,ABL1
3848,BCR-ABL H396P,D,Sensitivity/Response,Cancer,25.0,Dasatinib,ABL1
3849,Amplification,D,Resistance,Lung Non-small Cell Carcinoma,3845.0,JNJ38877605+PHA-665752,KRAS
3850,G12V,D,Resistance,Head And Neck Squamous Cell Carcinoma,3265.0,Alpelisib,HRAS
3851,K383fs,D,Sensitivity/Response,Colon Carcinoma,4437.0,7-Ethyl-10-Hydroxycamptothecin+Oxaliplatin,MSH3
3852,AMPLIFICATION,D,Sensitivity/Response,Hepatocellular Carcinoma,5894.0,Sorafenib,RAF1
3853,Overexpression,C,Sensitivity/Response,Papillary Renal Cell Carcinoma,22882.0,Sorafenib,
3854,Overexpression,D,Sensitivity/Response,Neuroblastoma,2146.0,Tazemetostat+GSK126,EZH2
3855,Amplification,C,Resistance,Lung Non-small Cell Carcinoma,3845.0,Crizotinib,KRAS
3856,Overexpression,D,Sensitivity/Response,Breast Cancer,3066.0,Mocetinostat,
3857,G12C,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,3845.0,Selumetinib+ERK1/2 Inhibitor ATG-017,KRAS
3858,SFPQ-ABL1,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,25.0,Imatinib+Dasatinib,ABL1
3859,RCSD1-ABL1,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,25.0,Dasatinib,ABL1
3860,RCSD1-ABL1,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,25.0,Dasatinib,ABL1
3861,RCSD1-ABL1,C,Reduced Sensitivity,B-lymphoblastic Leukemia/lymphoma,25.0,Dasatinib,ABL1
3862,RCSD1-ABL1,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,25.0,Dasatinib,ABL1
3863,RCSD1-ABL1,C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",25.0,Tyrosine Kinase Inhibitor,ABL1
3864,ETV6-ABL1,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,25.0,Imatinib,ABL1
3865,RANBP2-ABL1,C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",25.0,Dasatinib,ABL1
3866,RCSD1-ABL1,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,25.0,Ponatinib,ABL1
3867,RCSD1-ABL1,D,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,25.0,Ponatinib,ABL1
3868,ITD,B,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Pacritinib,FLT3
3869,A767_V769dupASV,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Osimertinib,EGFR
3870,N771_P772insL,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Osimertinib,EGFR
3871,Exon 20 Insertion,B,Resistance,Lung Adenocarcinoma,1956.0,Erlotinib,EGFR
3872,D770_N771insG,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Osimertinib,EGFR
3873,S768_D770dup,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Osimertinib,EGFR
3874,A763_Y764insFQEA,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,1956.0,Osimertinib,EGFR
3875,FGFR3-TACC3,C,Sensitivity/Response,Renal Pelvis Transitional Cell Carcinoma,2261.0,FGFR Inhibitor AZD4547,FGFR3
3876,Overexpression,B,Sensitivity/Response,Breast Cancer,7422.0,Bevacizumab,VEGFA
3877,Overexpression,B,Resistance,Breast Cancer,9734.0,Panobinostat+Vorinostat+Trichostatin A,
3878,Overexpression,D,Sensitivity/Response,Esophagus Squamous Cell Carcinoma,7465.0,Adavosertib,WEE1
3879,Overexpression,D,Resistance,Colorectal Cancer,2294.0,Bevacizumab,FOXF1
3880,Deletion,D,Sensitivity/Response,Cancer,546.0,Fluorouracil+Cisplatin,ATRX
3881,FGFR3-TACC3,C,Sensitivity/Response,Cervical Squamous Cell Carcinoma,2261.0,FGFR Inhibitor AZD4547,FGFR3
3882,FGFR3-TACC3,C,Sensitivity/Response,Diffuse Astrocytoma,2261.0,FGFR Inhibitor AZD4547,FGFR3
3883,BAG4-FGFR1,C,Sensitivity/Response,Carcinoma,2260.0,FGFR Inhibitor AZD4547,FGFR1
3884,Loss-of-function,D,Sensitivity/Response,Neuroendocrine Tumor,4221.0,JQ1,MEN1
3885,Expression,D,Sensitivity/Response,B-cell Acute Lymphoblastic Leukemia,695.0,Ibrutinib,BTK
3886,Expression,D,Sensitivity/Response,B-cell Acute Lymphoblastic Leukemia,640.0,Ibrutinib,
3887,overexpression of VEGF165b,D,Adverse Response,Colorectal Cancer,7422.0,Bevacizumab,VEGFA
3888,overexpression of VEGF-Axxxa,B,Sensitivity/Response,Breast Cancer,7422.0,Bevacizumab,VEGFA
3889,Mutation,B,Sensitivity/Response,Pancreatic Cancer,675.0,Rucaparib,BRCA2
3890,Mutation,C,Sensitivity/Response,Pancreatic Cancer,675.0,Rucaparib,BRCA2
3891,Mutation,B,Sensitivity/Response,Pancreatic Cancer,79728.0,Rucaparib,PALB2
3892,low ratio of VEGF165b/VEGFtotal,B,Sensitivity/Response,Colorectal Cancer,7422.0,Bevacizumab,VEGFA
3893,Overexpression of VEGF121,B,Sensitivity/Response,Her2-receptor Negative Breast Cancer,7422.0,Bevacizumab,VEGFA
3894,Overexpression of VEGF121 and VEGF110,B,Sensitivity/Response,Stomach Cancer,7422.0,Bevacizumab,VEGFA
3895,Overexpression of VEGF121 and VEGF110,B,Sensitivity/Response,Breast Cancer,7422.0,Bevacizumab,VEGFA
3896,Overexpression of VEGF121 and VEGF110,B,Sensitivity/Response,Breast Cancer,7422.0,Bevacizumab,VEGFA
3897,Overexpression of VEGF121 and VEGF110,B,Sensitivity/Response,Breast Cancer,7422.0,Bevacizumab,VEGFA
3898,Q575Δ,C,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Gilteritinib,FLT3
3899,Q575Δ,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Tyrphostin AG 1295+Midostaurin+Sorafenib+Lestaurtinib,FLT3
3900,Y572Δ,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Quizartinib+Lestaurtinib+Crenolanib+Midostaurin+Sorafenib+Ponatinib,FLT3
3901,E573Δ,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Sorafenib+Midostaurin+Crenolanib+Ponatinib+Quizartinib+Lestaurtinib,FLT3
3902,S574Δ,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Lestaurtinib+Quizartinib+Crenolanib+Midostaurin+Ponatinib+Sorafenib,FLT3
3903,Overexpression,D,Sensitivity/Response,Esophageal Cancer,1025.0,CAN508+Alvocidib,
3904,Overexpression,D,Sensitivity/Response,Hepatocellular Carcinoma,1025.0,Dinaciclib,
3905,Overexpression,D,Resistance,Lymphoma,596.0,Venetoclax+Dinaciclib,BCL2
3906,EXPRESSION,D,Sensitivity/Response,Melanoma,6941.0,Mirdametinib+Birabresib,
3907,OVEREXPRESSION,D,Sensitivity/Response,Melanoma,23476.0,,BRD4
3908,OVEREXPRESSION,D,Sensitivity/Response,Childhood Medulloblastoma,23476.0,JQ1,BRD4
3909,OVEREXPRESSION,D,Sensitivity/Response,Esophageal Cancer,10413.0,Docetaxel+Verteporfin,YAP1
3910,R1032Q,D,Sensitivity/Response,Colorectal Cancer,3791.0,Axitinib+Dovitinib+Lenvatinib+Cabozantinib,KDR
3911,low ratio of VEGF165b/VEGFtotal,B,Sensitivity/Response,Colorectal Cancer,7422.0,Bevacizumab,VEGFA
3912,MEF2D-CSF1R,D,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,1436.0,Panobinostat,CSF1R
3913,MEF2D-CSF1R,C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",1436.0,Imatinib,CSF1R
3914,Y646H,C,Sensitivity/Response,Diffuse Large B-cell Lymphoma,2146.0,Tazemetostat,EZH2
3915,CD4v8-v10 and CD44v3-v10,B,Resistance,Cancer,960.0,RG7356,
3916,I1171T,C,Sensitivity/Response,Neuroblastoma,238.0,Ceritinib,ALK
3917,CD44v6,D,Resistance,Ovarian Cancer,960.0,Cisplatin,
3918,CD44v6,D,Resistance,Stomach Cancer,960.0,Cisplatin,
3919,G12C,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,3845.0,Sotorasib,KRAS
3920,CD44v8-10,D,Reduced Sensitivity,Prostate Cancer,960.0,Docetaxel,
3921,CD44v6,D,Resistance,Stomach Cancer,960.0,Cisplatin,
3922,CD44v6,B,Resistance,Cervical Cancer,960.0,Cisplatin,
3923,E1799K,D,Sensitivity/Response,Megalencephaly,2475.0,Everolimus,MTOR
3924,E1799K,D,Sensitivity/Response,Focal Cortical Dysplasia,2475.0,Everolimus,MTOR
3925,Overexpression of VEGF121,B,Resistance,Glioblastoma,7422.0,Bevacizumab,VEGFA
3926,Overexpression of AR-V9,B,Resistance,Prostate Cancer,367.0,Abiraterone,AR
3927,G469V,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,673.0,Trametinib+Dabrafenib,BRAF
3928,G596C,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,673.0,Dabrafenib+Trametinib,BRAF
3929,G469S,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,673.0,Dabrafenib+Trametinib,BRAF
3930,V7 EXPRESSION,B,Resistance,Prostate Cancer,367.0,Abiraterone+Enzalutamide,AR
3931,V7 EXPRESSION,B,Sensitivity/Response,Prostate Cancer,367.0,Enzalutamide+Galeterone,AR
3932,V7 EXPRESSION,B,Resistance,Prostate Cancer,367.0,Enzalutamide+Abiraterone,AR
3933,V7 EXPRESSION,B,Resistance,Prostate Cancer,367.0,Enzalutamide,AR
3934,V7 EXPRESSION,B,Resistance,Prostate Cancer,367.0,Abiraterone+Enzalutamide,AR
3935,P447_L455del,C,Sensitivity/Response,Estrogen-receptor Positive Breast Cancer,5290.0,Letrozole+Alpelisib,PIK3CA
3936,V7 EXPRESSION,B,Resistance,Prostate Cancer,367.0,Enzalutamide+Abiraterone,AR
3937,V567es expression,B,Resistance,Prostate Cancer,367.0,Taxane Compound,AR
3938,E114K,D,Sensitivity/Response,Cancer,1956.0,Cetuximab+Panitumumab,EGFR
3939,LMNA-NTRK1,C,Sensitivity/Response,Solid Tumor,4914.0,Larotrectinib,NTRK1
3940,TPR-NTRK1,C,Sensitivity/Response,Solid Tumor,4914.0,Larotrectinib,NTRK1
3941,F617L,C,Resistance,Gastrointestinal Stromal Tumor,4916.0,Larotrectinib,NTRK3
3942,G595R and G667S,C,Resistance,Solid Tumor,4914.0,Larotrectinib,NTRK1
3943,R165Q,D,Sensitivity/Response,Colorectal Cancer,1956.0,Panitumumab+Cetuximab,EGFR
3944,KRAS4A,D,Resistance,Pancreatic Cancer,3845.0,Rigosertib+KG5,KRAS
3945,KRAS4A underexpression,D,Resistance,Pancreatic Cancer,3845.0,Rigosertib+RG5,KRAS
3946,TNC-L,D,Resistance,Pancreatic Cancer,3371.0,Gemcitabine,TNC
3947,underexpression beta-1,B,Sensitivity/Response,Breast Cancer,2100.0,Exemestane+Tamoxifen,
3948,LGR5FL,D,Resistance,Colorectal Cancer,8549.0,Fluorouracil,
3949,EDB,B,Sensitivity/Response,Melanoma,2335.0,Daromun,
3950,EDB,B,Sensitivity/Response,Melanoma,2335.0,Dacarbazine+L19IL2,
3951,EDB,B,Sensitivity/Response,Melanoma,2335.0,L19IL2,
3952,Overexpression,D,Sensitivity/Response,Esophagus Adenocarcinoma,6790.0,Alisertib+Cisplatin,AURKA
3953,A232V,D,Sensitivity/Response,Cancer,2065.0,Trastuzumab+Pertuzumab+Duligotuzumab+Lapatinib,ERBB3
3954,MUTATION,B,Sensitivity/Response,Bladder Urothelial Carcinoma,3265.0,Tipifarnib,HRAS
3955,MUTATION,B,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,3265.0,Tipifarnib,HRAS
3956,TOP2A/90,D,Resistance,Leukemia,7153.0,Etoposide,
3957,TOP2A/90,D,Resistance,Leukemia,7153.0,MVT Regimen+4'-(9-acridinylamino)methanesulfon-m-anisidide+Etoposide+DVP Regmen+Pixantrone,
3958,delta11q,D,Reduced Sensitivity,Breast Cancer,672.0,Cisplatin,BRCA1
3959,R222C,D,Sensitivity/Response,Colorectal Cancer,1956.0,Cetuximab+Panitumumab,EGFR
3960,S492R,D,Sensitivity/Response,Colorectal Cancer,1956.0,Panitumumab,EGFR
3961,P596L,D,Sensitivity/Response,Colorectal Cancer,1956.0,Panitumumab+Cetuximab,EGFR
3962,K708R,D,Sensitivity/Response,Colorectal Cancer,1956.0,Cetuximab+Panitumumab,EGFR
3963,G719S,D,Sensitivity/Response,Colorectal Cancer,1956.0,Panitumumab+Cetuximab,EGFR
3964,V104M,D,Sensitivity/Response,Cancer,2065.0,Lapatinib+Trastuzumab+Pertuzumab+Duligotuzumab,ERBB3
3965,P262H,D,Sensitivity/Response,Cancer,2065.0,Trastuzumab+Pertuzumab+Lapatinib+Duligotuzumab,ERBB3
3966,G1109C,D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,2066.0,Afatinib,ERBB4
3967,L861Q,D,Sensitivity/Response,Esophagus Squamous Cell Carcinoma,1956.0,Afatinib,EGFR
3968,G284R,D,Sensitivity/Response,Cancer,2065.0,Lapatinib+Duligotuzumab+Pertuzumab+Trastuzumab,ERBB3
3969,v242,E,Resistance,Lung Non-small Cell Carcinoma,29126.0,Durvalumab+Avelumab+Atezolizumab,CD274
3970,V777L,D,Sensitivity/Response,Cancer,2064.0,Lapatinib,ERBB2
3971,Alternative splicing,D,Resistance,Chronic Myeloid Leukemia,10018.0,Imatinib,BCL2L11
3972,"delta-ex2, delta-ex5-6",D,Resistance,B-lymphoblastic Leukemia/lymphoma,930.0,Tisagenlecleucel,
3973,DELETION POLYMORPHISM,B,Sensitivity/Response,Chronic Myeloid Leukemia,10018.0,Imatinib,BCL2L11
3974,p61BRAF(V600E),D,Resistance,Melanoma,673.0,Vemurafenib,BRAF
3975,p61BRAF(V600E),C,Resistance,Melanoma,673.0,Vemurafenib,BRAF
3976,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,APITD1
3977,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,BRE
3978,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,C15orf65
3979,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,CARS
3980,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,DUX4L1
3981,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,FAM175A
3982,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,FGFR1OP
3983,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,H2AFX
3984,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,H3F3A
3985,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,H3F3B
3986,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,H3P6
3987,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,HIST1H3B
3988,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,HIST1H4I
3989,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,HMGN2P46
3990,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,MALAT1
3991,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,MDS2
3992,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,MRE11A
3993,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,NBEAP1
3994,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,RNF217-AS1
3995,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,SEPT5
3996,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,SEPT6
3997,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,SEPT9
3998,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,SHFM1
3999,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,STRA13
4000,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,TCEB1
4001,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,TCEB2
4002,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,TCEB3
4003,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,TERC
4004,,B,Sensitivity/Response,Follicular Lymphoma,,Tazemetostat,TMSB4XP8
4005,F691L,A,Resistance,Acute Myeloid Leukemia,2322.0,Quizartinib,FLT3
4006,F691L,D,Sensitivity/Response,Acute Myeloid Leukemia,2322.0,Tirbanibulin,FLT3
4007,Overexpression,A,Resistance,Melanoma,6777.0,Multi-subtype Natural Human Leukocyte Interferon Alpha,STAT5B
4008,Amplification,A,Sensitivity/Response,Childhood Ependymoma,2064.0,Lapatinib,ERBB2
4009,ITD&F691(I/L),D,Resistance,Acute Myeloid Leukemia,2322.0,Quizartinib,FLT3
4010,T599dup,C,Sensitivity/Response,Ganglioglioma,673.0,Trametinib+Dabrafenib,BRAF
4011,ZC3HAV1-ABL2,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,27.0,Imatinib,ABL2
4012,EWSR1-NR4A3,B,Sensitivity/Response,Extraskeletal Myxoid Chondrosarcoma,2130.0,Pazopanib,EWSR1
4013,V600E,A,Sensitivity/Response,Colorectal Cancer,673.0,Encorafenib+Cetuximab,BRAF
4014,EXPRESSION,D,Sensitivity/Response,Ovarian Cancer,4193.0,MDM2 Inhibitor KRT-232,MDM2
4015,High expression,D,Sensitivity/Response,Stomach Cancer,4921.0,Dasatinib,DDR2
4016,Overexpression,D,Sensitivity/Response,Head And Neck Carcinoma,4921.0,Dasatinib,DDR2
4017,Overexpression,D,Sensitivity/Response,Esophageal Cancer,9734.0,HDAC Inhibitor AR-42,
4018,Overexpression,D,Sensitivity/Response,Esophageal Cancer,10013.0,Trichostatin A+Vorinostat+Panobinostat,
4019,V600E and Amplification,B,Sensitivity/Response,Epithelial Ovarian Cancer,673.0,Bevacizumab+Atezolizumab,BRAF
